Medicare Part D: 5 Tier Closed Performance Formulary 2027

Por favor haga clic aquí.

Para Medicare Part D: Criterios de autorización previa

Por favor haga clic aquí.

Para Medicare Part D: Criterios de terapia escalonada

Por favor haga clic aquí.

Planes cubiertos en Pennsylvania
Community Blue Medicare HMO Distinct (HMO)
Community Blue Medicare HMO Signature (HMO)
Community Blue Medicare Plus PPO Signature (HMO)
Community Blue Medicare PPO Merit (PPO)
Community Blue Medicare PPO Signature (HMO)
Complete Blue HMO Distinct (HMO)
Complete Blue Plus PPO Distinct (PPO)
Complete Blue Plus PPO Merit (PPO)
Complete Blue PPO Distinct (PPO)
Complete Blue PPO Merit (PPO)
Complete Blue PPO Signature (PPO)
Freedom Blue PPO ValueRx (PPO)
Security Blue HMO-POS ValueRx (PPO)
Together Blue Medicare HMO Signature (HMO)

Esta lista de medicamentos cubiertos se actualizó el 01 Octubre, 2026.

Para obtener información más reciente o hacer otras preguntas, comuníquese con:

Para obtener información más reciente o hacer otras preguntas, comuníquese con Community Blue Medicare HMO, Community Blue Medicare PPO, Complete Blue HMO, Complete Blue Plus PPO, Complete Blue PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, o Together Blue Medicare HMO with AHN el Servicio de Farmacia al:
(PA) 1-866-675-8637,
(NY) 1-844-845-5501,
(Los usuarios de TTY deben llamar al 711), de hora del este, los siete días de la semana, 8 a. m. a 8 p. m. HE, o visite **medicare.highmark.com/formulary**

ID del formulario: 27204 Versión: 13

Actualizado: 2026/10

Nota a los miembros actuales: Este formulario cambió desde el año pasado.
Revise este documento para asegurarse de que aún contenga los medicamentos que toma.

Cuando esta Lista de medicamentos (formulario) se refiere a “nosotros”, “nos” o “nuestro”, se refiere a Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company, Highmark BCBSD Inc., Highmark Western and Northeastern New York Inc., o Highmark Health Insurance Company.

Cuando se hace referencia a “plan” o “nuestro plan”, se refiere a Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO

Este documento incluye una Lista de medicamentos (formulario) para nuestro plan, que está en vigor al 2027. Para obtener una lista de medicamentos actualizada (formulario), comuníquese con nosotros. Nuestra información de contacto, además de la fecha en que actualizamos por última vez la Lista de medicamentos (formulario), aparece en la portada y en la contraportada.

Generalmente, debe usar las farmacias de la red para recibir el beneficio de los medicamentos con receta. Los beneficios, el formulario, la red de farmacias o los copagos/coseguros pueden cambiar el 1 de enero 2028 y de vez en cuando durante el año.

¿Qué es el formulario de Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO?

En este documento, usamos los términos Lista de medicamentos y formulario para que den a entender lo mismo. Un formulario es una lista de medicamentos cubiertos seleccionados por nuestro plan en consulta con un equipo de proveedores de atención médica, que representa las terapias con receta que se consideran una parte necesaria de un programa de tratamiento de calidad. Nuestro plan generalmente cubrirá los medicamentos que figuran en nuestro formulario, siempre y cuando el medicamento sea médicamente necesario, la receta sea surtida en una farmacia de la red del plan y se cumplan las demás normas del plan. Para obtener más información de cómo surtir sus recetas, consulte su Evidencia de Cobertura.

¿Puede cambiar el formulario?

La mayoría de los cambios en la cobertura de medicamentos ocurren el 1 de enero, pero podemos agregar o eliminar medicamentos del formulario durante el año, trasladarlos a diferentes niveles de costo compartido o agregar nuevas restricciones. Debemos seguir las reglas de Medicare cuando hacemos estos cambios. Las actualizaciones del formulario se publican mensualmente en nuestro sitio web aquí: **medicare.highmark.com/formulary**.

Cambios que pueden afectarlo este año: En los casos que se mencionan abajo, lo afectarán los cambios de cobertura durante el año:

- **Sustituciones inmediatas de ciertas versiones nuevas de medicamentos de marca y productos biológicos originales.** Podemos eliminar inmediatamente un medicamento de nuestro formulario si lo reemplazamos con una nueva versión determinada de ese medicamento que aparecerá en el mismo nivel de costo compartido o en uno más bajo y con las mismas restricciones o menos. Cuando agregamos una nueva versión de un medicamento a nuestro formulario, podemos decidir mantener el medicamento de marca o el producto biológico original en nuestro formulario, pero inmediatamente trasladarlo a un nivel de costo compartido diferente o agregar nuevas restricciones.

  Podemos hacer estos cambios inmediatos solo si estamos agregando una nueva versión genérica de un medicamento de marca, o agregando ciertas nuevas versiones biosimilares de un producto biológico original, que ya estaba en el formulario (por ejemplo, agregando un biosimilar intercambiable que puede sustituirse por un producto biológico original por una farmacia sin una nueva receta).

  Si actualmente está tomando el medicamento de marca o el producto biológico original, es posible que no se lo informemos con antelación antes de hacer un cambio inmediato, pero más adelante le daremos información sobre los cambios específicos que hemos hecho.

  Si hacemos dicho cambio, usted o su médico pueden solicitarnos que hagamos una excepción y continuemos cubriendo el medicamento que se está modificando. Para obtener más información, consulte la sección de abajo "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO Distinct (HMO), Community Blue Medicare HMO Signature (HMO), Community Blue Medicare Plus PPO Signature (PPO), Community Blue Medicare PPO Signature (PPO), Complete Blue HMO Distinct (HMO), Complete Blue Plus PPO Distinct (PPO), Complete Blue Plus PPO Merit (PPO), Complete Blue PPO Distinct (PPO), Complete Blue PPO Merit (PPO), Complete Blue PPO Signature (PPO), Freedom Blue PPO Select (PPO), Freedom Blue PPO Standard (PPO), Freedom Blue PPO ValueRx (PPO), Security Blue HMO-POS ValueRx (HMO-POS), Senior Blue 652 (HMO), Together Blue Medicare HMO with AHN Signature (HMO)?"

  Algunos de estos tipos de medicamentos pueden ser nuevos para usted. Para obtener más información, consulte la sección de abajo titulada "¿Qué son los productos biológicos originales y cómo se relacionan con los biosimilares?"

- **Medicamentos sacados del mercado.** Si el fabricante retira un medicamento de la venta o la Administración de Alimentos y Medicamentos (FDA) determina que debe retirarse por razones de seguridad o eficacia, podemos eliminar inmediatamente el medicamento de nuestro formulario y luego informar a los miembros que toman el medicamento.
- **Otros cambios.** Es posible que hagamos otros cambios que afecten a los miembros que actualmente toman un medicamento. Por ejemplo, podemos eliminar un medicamento de marca del formulario cuando agregamos un equivalente genérico o eliminar un producto biológico original cuando agregamos un biosimilar. También podemos aplicar nuevas restricciones al medicamento de marca o al producto biológico original, o trasladarlo a un nivel diferente de participación en los costos, o ambas cosas. Podemos hacer cambios según nuevas directrices clínicas. Si eliminamos medicamentos de nuestro formulario, agregamos autorización previa, límites de cantidad o restricciones de terapia gradual en un medicamento, o movemos un medicamento a un nivel de costo compartido más alto, debemos informar a los miembros afectados sobre el cambio al menos 31 días antes de

que el cambio entre en vigor. Alternativamente, cuando un miembro solicita una resurtido del medicamento, puede recibir un suministro de 31 días del medicamento y una notificación del cambio.

- Si hacemos estos otros cambios, usted o su médico pueden solicitarnos que hagamos una excepción para usted y continuemos cubriendo el medicamento que ha estado tomando. El aviso que le damos también incluirá información sobre cómo solicitar una excepción, y también puede encontrar información en la sección de abajo titulada "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO?"

Cambios que no lo afectarán si actualmente está tomando el medicamento. Por lo general, si está tomando un medicamento de nuestra lista de medicamentos cubiertos de 2027 que estaba cubierto al inicio del año, no descontinuaremos ni reduciremos la cobertura del medicamento durante el año de cobertura del 2028, excepto como se describe arriba. Esto significa que estos medicamentos seguirán disponibles con el mismo costo compartido y sin nuevas restricciones para los miembros que los estén tomando durante el resto del año de cobertura. No recibirá un aviso directo este año sobre los cambios que no lo afecten. Sin embargo, el 1 de enero del próximo año, dichos cambios lo afectarán y es importante consultar el formulario para el nuevo año de beneficios para conocer si hay cambios en los medicamentos.

La lista de medicamentos cubiertos adjunta está actualizada al 01 de Octubre, 2026. Para recibir información actualizada sobre los medicamentos que cubre nuestro plan, comuníquese con nosotros. Nuestra información de contacto está en la portada y en la contraportada. En el caso de que haya cambios a medio año en la lista de medicamentos cubiertos, que no sean cambios de mantenimiento, se les avisará por correo a los miembros y los miembros potenciales recibirán una actualización de esta lista de medicamentos cubiertos. La Lista de medicamentos cubiertos más actualizada está disponible en nuestro sitio web: **medicare.highmark.com/formulary**.

¿Cómo uso la lista de medicamentos cubiertos?

Hay dos formas de buscar su medicamento en la lista de medicamentos cubiertos:

Condición médica

El formulario comienza en la página 9. Los medicamentos de esta lista de medicamentos cubiertos están agrupados en categorías según el tipo de condiciones para los que se usan. Por ejemplo, los medicamentos que se usan para tratar una condición cardíaca se mencionan en la categoría "Medicamentos cardiovasculares, hipertensión y lípidos". Si sabe para qué se usa su medicamento, busque el nombre de la categoría en la lista que comienza en la página 9. Luego, busque su medicamento abajo del nombre de la categoría.

Lista en orden alfabético

Si no está seguro en qué categoría buscar, debe buscar su medicamento en el Índice que comienza en la página 9. El Índice incluye una lista en orden alfabético de todos los medicamentos incluidos en este documento. Los medicamentos de marca y los genéricos se mencionan en el Índice. Consulte el Índice y busque su medicamento. Junto a su medicamento, verá el número de página donde puede encontrar información de la cobertura. Vaya a la página incluida en el Índice y busque el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Nuestro plan cubre medicamentos de marca y medicamentos genéricos. La FDA aprueba un medicamento genérico siempre que tenga el mismo ingrediente activo que el medicamento de marca. Generalmente, los medicamentos genéricos funcionan igual de bien y suelen costar menos que los de marca. Hay medicamentos genéricos sustitutos disponibles para muchos medicamentos de marca. Los medicamentos genéricos generalmente pueden sustituir al medicamento de marca en la farmacia sin necesidad de una nueva receta, según las leyes estatales.

¿Qué son los productos biológicos originales y cómo se relacionan con los biosimilares?

En el formulario, cuando nos referimos a medicamentos, esto podría significar un fármaco o un producto biológico. Los productos biológicos son medicamentos más complejos que los medicamentos típicos. Ya que los productos biológicos son más complejos que los medicamentos normales, en vez de tener una forma genérica, tienen alternativas llamadas biosimilares. Generalmente, los biosimilares funcionan tan bien como el producto biológico original y pueden costar menos. Hay alternativas biosimilares a algunos productos biológicos originales. Algunos biosimilares son intercambiables y, según las leyes estatales, pueden sustituir al producto biológico original en la farmacia sin necesidad de una nueva receta, al igual que los medicamentos genéricos pueden sustituir a los medicamentos de marca.

Para obtener información sobre los tipos de medicamentos, consulte la Evidencia de cobertura, Capítulo 3, Sección 3.1, “La ‘Lista de medicamentos’ indica qué medicamentos de la Parte D están cubiertos”.

¿Hay alguna restricción en mi cobertura?

Algunos medicamentos cubiertos pueden tener otros requisitos o límites de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Nuestro plan requiere que usted o su médico obtengan una autorización previa para ciertos medicamentos. Esto significa que deberá obtener la aprobación de nuestro plan basado en criterios específicos antes de poder surtir sus recetas. Si no obtiene la aprobación, es posible que nuestro plan no cubra el medicamento.
- **Límites de cantidad:** Para ciertos medicamentos, nuestro plan limita la cantidad la medicamento que cubriremos. Por ejemplo, nuestro plan da 31 tabletas, cada 31 días, 100 mg de Medicamento A. Esto puede ser además del suministro estándar para uno o tres meses.
- **Terapia gradual:** En algunos casos, nuestro plan requiere que primero pruebe con ciertos medicamentos para tratar su estado médico antes de cubrir otro medicamento para dicha condición. Por ejemplo, si el Medicamento A y el Medicamento B están recomendados para su estado médico, es posible que nuestro plan no cubra el Medicamento B, a menos que pruebe primero el Medicamento A. Si el Medicamento A no funciona para usted, entonces nuestro plan cubrirá el Medicamento B.

Puede averiguar si su medicamento tiene más requisitos o límites consultando la lista de medicamentos cubiertos que comienza en la página 9. También puede obtener más información sobre las restricciones aplicadas a medicamentos cubiertos específicos visitando nuestro sitio web. Hemos publicado un documento en línea que explica nuestras restricciones sobre la autorización

previa y la terapia escalonada. También puede pedirnos que le enviemos una copia. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contraportada.

Puede pedir a nuestro plan que hagamos una excepción a estas restricciones o límites, o para una lista de otros medicamentos similares que pudieran servir como tratamiento para su condición. Consulte la sección "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO?" en la página 6 para obtener información sobre cómo solicitar una excepción.

¿Qué pasa si mi medicamento no está en la lista de medicamentos cubiertos?

Si su medicamento no está incluido en esta Lista de medicamentos cubiertos (formulario), primero debe comunicarse con Servicios de Farmacia y preguntar si su medicamento está cubierto.

Si usted se entera que de nuestro plan no cubre su medicamento, tiene dos opciones:

- Puede pedir a Servicios de Farmacia una lista de medicamentos similares que están cubiertos por nuestro plan. Cuando reciba la lista, preséntesela al médico y pídale que le recete algún medicamento similar que cubra nuestro plan.
- Puede solicitar a nuestro plan que haga una excepción y cubra su medicamento. Consulte más abajo para obtener información sobre cómo solicitar una excepción.

¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO?

Puede solicitar a nuestro plan que haga una excepción a nuestras reglas de cobertura. Hay varios tipos de excepciones que puede pedirnos.

- Puede pedirnos que cubramos un medicamento aunque no esté en nuestra Lista de medicamentos cubiertos. Si se aprueba, este medicamento estará cubierto a un nivel de costo compartido predeterminado, y no podrá pedirnos que le demos el medicamento a un nivel de costo compartido más bajo.
- Puede solicitarnos que eliminemos una restricción de cobertura, incluyendo la autorización previa, la terapia gradual o un límite de cantidad en su medicamento. Por ejemplo, para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede pedirnos que no apliquemos el límite y cubramos una cantidad mayor.

Generalmente, nuestro plan solo aprobará su solicitud de excepción si los medicamentos alternativos incluidos en el formulario del plan, el medicamento con menor costo compartido o la aplicación de la restricción no serían tan efectivos para usted o le causarían efectos adversos.

Usted o su médico deben comunicarse con nosotros para solicitar una excepción de formulario, incluyendo una excepción a una restricción de cobertura. ***Cuando solicite una excepción, su médico deberá explicarle las razones médicas por las que necesita la excepción.*** Por lo general, debemos tomar nuestra decisión en un plazo de 72 horas después de recibir la declaración de respaldo de la persona que receta. Puede solicitar una decisión acelerada (rápida) si cree, y estamos de acuerdo, que su salud podría verse gravemente perjudicada si espera hasta 72 horas para recibir una decisión. Si estamos de acuerdo, o si su médico le solicita una decisión rápida, debemos darle una decisión a más tardar 24 horas después de que recibamos la declaración de respaldo de su médico.

¿Qué puedo hacer si mi medicamento no está en el formulario o tiene alguna restricción?

Como miembro nuevo o actual de nuestro plan, es posible que esté tomando medicamentos que no están en nuestra lista de medicamentos cubiertos. O es posible que esté tomando un medicamento que está en nuestro formulario pero tiene una restricción de cobertura, como una autorización previa. Debe hablar con su médico sobre cómo solicitar una decisión de cobertura para mostrar que cumple los criterios de aprobación, cambiar a un medicamento alternativo que cubramos o solicitar una excepción al formulario para que cubramos el medicamento que toma. Mientras usted y su médico determinan el curso de acción adecuado para usted, es posible que cubramos su medicamento en ciertos casos durante los primeros 90 días que sea miembro de nuestro plan.

Para cada uno de sus medicamentos que no esté en nuestro formulario o tenga una restricción de cobertura, cubriremos un suministro temporal para 31 días. Si su receta es para menos días, permitiremos resurtidos para que tenga un suministro máximo de medicamentos para 31 días. Si la cobertura no se aprueba después, de su primer suministro para 31 días, no pagaremos estos medicamentos, incluso si ha sido miembro del plan menos de 90 días.

Si usted es residente de un centro de atención de largo plazo y necesita un medicamento que no está en nuestra lista de medicamentos cubiertos o si su capacidad para obtener sus medicamentos es limitada, pero ya cumplió los primeros 90 días de membresía en nuestro plan, cubriremos un suministro de emergencia para 31 días de ese medicamento mientras pida una excepción a la lista de medicamentos cubiertos.

El proceso de transición de arriba se implementará para acomodarlo si tiene una necesidad inmediata de un medicamento que no está en el formulario o un medicamento que requiere autorización previa por un cambio en su nivel de atención mientras espera que se procese una solicitud de excepción.

Para obtener más información

Para obtener más información detallada sobre la cobertura de medicamentos con receta de su plan, revise su Evidencia de cobertura y otro material del plan.

Si tiene alguna pregunta sobre su plan, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contraportada.

Si tiene preguntas generales sobre la cobertura de medicamentos con receta de Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227), 24/7. Los usuarios de TTY deben llamar al 1-877-486-2048. O visite **http://www.medicare.gov**.

Formulario de Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue HMO, Complete Blue PPO, Complete Blue Plus PPO, Freedom Blue PPO, Security Blue HMO-POS, Senior Blue, y Together Blue Medicare HMO

La Lista de medicamentos cubiertos que empieza en la siguiente página da información de cobertura sobre los medicamentos cubiertos por su plan. Si tiene problemas para buscar su medicamento en la lista, consulte el Índice que comienza en la página 9.

La primera columna de la tabla muestra el nombre del medicamento. Los medicamentos de marca están en mayúsculas (por ejemplo, ABELCET) y los medicamentos genéricos están en cursiva minúscula (por ejemplo, *abacavir*).

La información en la columna Requisitos/Límites le dice si su plan tiene algún requisito especial de cobertura de su medicamento.

El siguiente es solo un ejemplo del formato de la lista de medicamentos cubiertos:

Nombre del medicamento	Rendimiento de nivel del medicamento	Requisitos/Límites
Antiinfecciosos		
MEDICAMENTO XYZ	NF	QL-28

Tabla de contenido

Anti-Infecciosos 3
Cardiovascular, Hipertensión / Lípidos 11
Dermatológicos/Terapia Tópica 16
Diagnósticos / Agentes Varios 20
Endocrino/Diabetes 22
Gastroenterología 26
Inmunología, Vacunas / Biotecnología 28
Medicamentos Antineoplásicos E Inmunosupresores 31
Medicamentos Autonómicos/Snc, Neurología/Psico 39
Medicamentos Para Oídos, Nariz Y Garganta 52
Musculoesquelético / Reumatología 52
Obstetricia / Ginecología 54
Oftalmología 56
Respiratorio Y Alergia 58
Suministros Variados 61
Urológicos 62
Vitaminas, Hematinicos / Electrolitos 63

lowercase italics = Generic drugs
UPPERCASE BOLD = Brand name drugs

Nivel de medicamento
T1 = El Nivel 1 de costo compartido incluye medicamentos genéricos preferidos. Este es el nivel de costo compartido más bajo.
T2 = El Nivel 2 de costo compartido incluye medicamentos genéricos.
T3 = El Nivel 3 de costo compartido incluye medicamentos de marca preferidos y puede incluir algunos medicamentos de fuente única (aquellos medicamentos genéricos fabricados por un solo fabricante).
T4 = El Nivel 4 de costo compartido incluye medicamentos de marca no preferidos y puede incluir algunos medicamentos genéricos de una sola fuente (aquellos medicamentos genéricos fabricados por un solo fabricante).
T5 = El Nivel 5 de costo compartido incluye medicamentos especializados. Este es el nivel de costo compartido más alto.

Requisitos/Límites
LA = Acceso limitado
PA = Se requiere autorización previa
PA-BvD = Este medicamento puede estar cubierto por la parte B o D de Medicare según las circunstancias. Es posible que sea necesario enviar información que describa el uso y la establecimiento del medicamento para tomar la determinación.
PA-NC = Se requiere autorización previa solo para nuevos inicios
QL = Se aplica límite de cantidad. El límite de cantidad se anota para cada medicamento. Por ejemplo, si el límite de cantidad es LC (90 c/u por 180 días), el límite de cantidad sería 90 unidades por suministro de 180 días.
ST = Se aplica la terapia escalonada
ST-NC = La terapia escalonada se aplica únicamente a los nuevos comienzos.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
Anti-Infecciosos		
abacavir	T4	
abacavir-lamivudine	T4	
acyclovir oral capsule	T2	
acyclovir oral suspension 200 mg/5 ml	T4	
acyclovir oral tablet	T2	
acyclovir sodium intravenous solution	T4	PA-BvD
adefovir	T4	
albendazole	T4	
amantadine hcl oral capsule	T3	QL (124 EA per 31 days)
amantadine hcl oral solution	T3	
amikacin injection solution 500 mg/2 ml	T4	
amoxicillin oral capsule	T1	
amoxicillin oral suspension for reconstitution	T1	
amoxicillin oral tablet	T1	
amoxicillin oral tablet,chewable 125 mg, 250 mg	T1	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
amoxicillin-pot clavulanate oral suspension for reconstitution	T2	
amoxicillin-pot clavulanate oral tablet 250-125 mg	T2	
amoxicillin-pot clavulanate oral tablet 500-125 mg, 875-125 mg	T1	
amoxicillin-pot clavulanate oral tablet,chewable	T2	
amphotericin b	T4	PA-BvD
amphotericin b liposome	T5	PA-BvD
ampicillin oral capsule 500 mg	T1	
ampicillin sodium injection recon soln 1 gram, 10 gram, 2 gram	T4	
ampicillin-sulbactam injection	T4	
APTIVUS	T5	
ARIKAYCE	T5	PA
atazanavir	T4	
atovaquone	T4	
atovaquone-proguanil	T3	
azithromycin intravenous	T2	
azithromycin oral tablet	T2	
aztreonam	T4	
BICILLIN C-R	T3	
BICILLIN L-A INTRAMUSCULAR SYRINGE 600,000 UNIT/ML	T3	
BIKTARVY	T5	QL (31 EA per 31 days)
BLUJEPA	T4	QL (20 EA per 5 days)
caspofungin	T4	
CAYSTON	T5	PA
cefaclor oral capsule	T2	
cefadroxil oral capsule	T2	
cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml	T2	
cefadroxil oral tablet	T3	
cefazolin injection recon soln 1 gram, 500 mg	T2	
cefazolin intravenous recon soln 10 gram	T2	
cefdinir oral capsule	T2	
cefepime injection	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
cefixime oral capsule	T2	
cefoxitin	T4	
cefpodoxime	T3	
cefprozil	T2	
ceftaroline fosamil	T5	
ceftazidime	T4	
ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg	T2	
cefuroxime axetil oral tablet	T2	
cefuroxime sodium injection recon soln 750 mg	T4	
cefuroxime sodium intravenous recon soln 1.5 gram	T4	
cephalexin oral capsule 250 mg, 500 mg	T2	
cephalexin oral suspension for reconstitution	T2	
chloroquine phosphate oral tablet 250 mg	T3	QL (50 EA per 30 days)
chloroquine phosphate oral tablet 500 mg	T3	QL (25 EA per 30 days)
CIMDUO	T5	QL (31 EA per 31 days)
ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg	T1	
ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml	T2	
clarithromycin oral tablet	T2	
clarithromycin oral tablet extended release 24 hr	T3	
clindamycin hcl	T2	
clindamycin in 5 % dextrose	T2	
CLINDAMYCIN PEDIATRIC	T4	
clindamycin phosphate injection	T2	
clotrimazole mucous membrane	T2	
COARTEM	T4	
colistin (colistimethate na)	T4	
CRESEMBA ORAL	T5	
dapsone oral	T3	
daptomycin	T4	
darunavir oral tablet 600 mg	T4	
darunavir oral tablet 800 mg	T5	
DELSTRIGO	T5	QL (31 EA per 31 days)
DESCOVY	T5	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
dicloxacillin	T2	
DOVATO	T5	QL (31 EA per 31 days)
doxycycline hyclate intravenous	T4	
doxycycline hyclate oral capsule 100 mg, 50 mg	T2	
doxycycline hyclate oral tablet 100 mg	T2	
doxycycline hyclate oral tablet 20 mg	T1	
doxycycline monohydrate oral capsule 100 mg, 50 mg	T2	
doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg	T2	
EDURANT PED	T5	
efavirenz oral tablet	T4	
efavirenz-emtricitabin-tenofov	T4	
efavirenz-lamivu-tenofov disop	T5	QL (31 EA per 31 days)
emtricitabine	T4	
emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 167-250 mg, 200-300 mg	T4	
emtricitabine-tenofovir (tdf) oral tablet 133-200 mg	T5	
emtricita-rilpivirine-tenof df	T5	
EMTRIVA ORAL SOLUTION	T4	
entecavir	T4	
ertapenem	T4	
erythromycin oral tablet	T4	
ethambutol	T2	
etravirine	T5	
EVOTAZ	T5	
famciclovir	T3	
fidaxomicin	T5	QL (20 EA per 10 days)
fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml	T2	
fluconazole oral suspension for reconstitution	T3	
fluconazole oral tablet	T2	
flucytosine	T5	
fosamprenavir	T5	
fosfomycin tromethamine	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml	T2	
gentamicin injection	T3	
GENVOYA	T5	
griseofulvin microsize	T4	
griseofulvin ultramicrosize oral tablet 125 mg, 250 mg	T4	
HEPCLUDEX	T5	PA; QL (31 EA per 31 days)
hydroxychloroquine oral tablet 200 mg	T2	QL (93 EA per 31 days)
IDVYNSO	T5	QL (31 EA per 31 days)
imipenem-cilastatin	T4	
INTELENCE ORAL TABLET 25 MG	T4	
ISENTRESS HD	T5	
ISENTRESS ORAL POWDER IN PACKET	T5	
ISENTRESS ORAL TABLET	T5	
ISENTRESS ORAL TABLET,CHEWABLE 100 MG	T5	
ISENTRESS ORAL TABLET,CHEWABLE 25 MG	T3	
isoniazid oral	T2	
itraconazole oral capsule	T4	PA
ivermectin oral	T3	PA
JULUCA	T5	
ketoconazole oral	T2	
lamivudine oral solution	T2	
lamivudine oral tablet 100 mg	T3	
lamivudine oral tablet 150 mg, 300 mg	T2	
lamivudine-zidovudine	T2	
levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml	T2	
levofloxacin oral solution	T4	
levofloxacin oral tablet	T1	
linezolid in dextrose 5%	T4	
linezolid oral tablet	T4	
LIVTENCITY	T5	PA; QL (372 EA per 31 days)
lopinavir-ritonavir oral tablet	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
maraviroc oral tablet 150 mg	T5	
maraviroc oral tablet 300 mg	T3	
MAVYRET ORAL PELLETS IN PACKET	T5	PA; QL (140 EA per 28 days)
MAVYRET ORAL TABLET	T5	PA; QL (84 EA per 28 days)
mefloquine	T2	
meropenem intravenous recon soln 1 gram, 500 mg	T3	
methenamine hippurate	T2	
metronidazole in nacl (iso-os)	T2	
metronidazole oral tablet 250 mg, 500 mg	T2	
micafungin	T4	
minocycline oral capsule	T2	
moxifloxacin oral	T3	
moxifloxacin-sod.chloride(iso)	T4	
nafcillin injection recon soln 1 gram, 2 gram	T4	
nafcillin injection recon soln 10 gram	T5	
neomycin	T2	
nevirapine oral suspension	T2	
nevirapine oral tablet	T2	
nevirapine oral tablet extended release 24 hr	T4	
nitazoxanide	T5	
nitrofurantoin macrocrystal oral capsule 50 mg	T2	
nitrofurantoin monohyd/m-cryst	T2	
nystatin oral suspension	T2	
nystatin oral tablet	T2	
ODEFSEY	T5	QL (31 EA per 31 days)
ofloxacin oral tablet 400 mg	T2	
ORLYNVAH	T5	QL (10 EA per 5 days)
oseltamivir oral capsule 30 mg	T2	QL (170 EA per 365 days)
oseltamivir oral capsule 45 mg, 75 mg	T2	QL (90 EA per 365 days)
oseltamivir oral suspension for reconstitution	T3	QL (1080 ML per 365 days)
oxacillin	T4	
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10)	T2	QL (180 EA per 365 days)
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5)	T2	QL (99 EA per 365 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG	T2	QL (270 EA per 365 days)
penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml	T4	
penicillin g potassium injection recon soln 20 million unit	T4	
penicillin v potassium oral tablet	T1	
pentamidine inhalation	T4	PA-BvD
pentamidine injection	T4	
PIFELTRO	T5	QL (62 EA per 31 days)
piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram	T4	
posaconazole oral tablet,delayed release (dr/ec)	T5	PA
praziquantel	T4	
pretomanid	T4	PA; QL (31 EA per 31 days)
PREVYMIS ORAL PELLETS IN PACKET	T5	PA; QL (124 EA per 31 days)
PREVYMIS ORAL TABLET	T5	QL (31 EA per 31 days)
PREZCOBIX	T5	
PREZISTA ORAL SUSPENSION	T5	
PREZISTA ORAL TABLET 150 MG	T5	
PREZISTA ORAL TABLET 75 MG	T4	
primaquine	T3	
pyrazinamide	T4	
pyrimethamine	T5	PA
RELENZA DISKHALER	T3	
REYATAZ ORAL POWDER IN PACKET	T5	
ribavirin oral capsule	T2	
ribavirin oral tablet 200 mg	T2	
rifabutin	T4	
rifampin	T4	
rifapentine	T3	
rilpivirine hcl	T5	
rimantadine	T4	
ritonavir	T3	
RUKOBIA	T5	QL (62 EA per 31 days)
SIRTURO	T5	PA
sofosbuvir-velpatasvir	T5	PA; QL (28 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
streptomycin	T5	
STRIBILD	T5	
sulfadiazine	T5	
sulfamethoxazole-trimethoprim oral suspension	T2	
sulfamethoxazole-trimethoprim oral tablet	T1	
SUNLENCA ORAL	T5	
SYMTUZA	T5	QL (31 EA per 31 days)
tenofovir disoproxil fumarate	T3	
terbinafine hcl oral	T1	QL (90 EA per 180 days)
tetracycline oral capsule	T4	
tigecycline	T4	
tinidazole	T2	
TIVICAY ORAL TABLET 50 MG	T5	
TIVICAY PD	T5	
TOBI PODHALER	T5	PA; QL (224 EA per 56 days)
tobramycin in 0.225 % nacl	T5	PA
tobramycin inhalation	T5	PA
tobramycin sulfate injection solution	T4	
trimethoprim	T2	
TRIUMEQ	T5	
TRIUMEQ PD	T4	QL (186 EA per 31 days)
valacyclovir	T2	
valganciclovir oral recon soln	T5	
valganciclovir oral tablet	T3	
vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg	T4	
vancomycin oral capsule 125 mg	T4	QL (124 EA per 31 days)
vancomycin oral capsule 250 mg	T4	QL (248 EA per 31 days)
VEMLIDY	T5	QL (31 EA per 31 days)
VIRACEPT ORAL TABLET	T5	
VIREAD ORAL POWDER	T5	
VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG	T5	
VIVJOA	T4	PA; QL (18 EA per 84 days)
voriconazole intravenous recon soln	T4	PA
voriconazole oral	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
VOSEVI	T5	PA; QL (28 EA per 28 days)
XIFAXAN ORAL TABLET 200 MG	T3	QL (27 EA per 365 days)
XIFAXAN ORAL TABLET 550 MG	T3	PA; QL (62 EA per 31 days)
XOCOVA	T5	QL (63 EA per 365 days)
XOFLUZA ORAL TABLET 40 MG, 80 MG	T3	QL (9 EA per 365 days)
zidovudine	T2	
Cardiovascular, Hipertensión / Lípidos		
acebutolol	T2	
aliskiren	T4	
amiloride	T2	
amiloride-hydrochlorothiazide	T2	
amiodarone oral	T2	
amlodipine	T1	
amlodipine-benazepril	T1	
amlodipine-olmesartan	T2	QL (31 EA per 31 days)
amlodipine-valsartan	T2	
aspirin-dipyridamole	T4	
atenolol	T1	
atenolol-chlorthalidone	T2	
atorvastatin	T1	
benazepril	T1	
benazepril-hydrochlorothiazide	T1	
bisoprolol fumarate oral tablet 10 mg	T2	
bisoprolol fumarate oral tablet 5 mg	T1	
bisoprolol-hydrochlorothiazide	T1	
bumetanide oral	T2	
candesartan	T2	
candesartan-hydrochlorothiazid	T2	
captopril	T1	
CARTIA XT	T2	
carvedilol	T1	
chlorthalidone oral tablet 25 mg, 50 mg	T1	
cholestyramine (with sugar) oral powder in packet	T2	
CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
cilostazol	T2	
clonidine	T4	
clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg	T1	
clopidogrel	T1	
colesevelam	T4	
colestipol oral packet	T3	
colestipol oral tablet	T3	
dabigatran etexilate oral capsule 110 mg	T4	QL (124 EA per 31 days)
dabigatran etexilate oral capsule 150 mg, 75 mg	T4	QL (62 EA per 31 days)
digoxin oral solution	T3	QL (155 ML per 31 days)
digoxin oral tablet 125 mcg (0.125 mg)	T1	QL (62 EA per 31 days)
digoxin oral tablet 250 mcg (0.25 mg)	T2	QL (31 EA per 31 days)
diltiazem hcl oral capsule,extended release 24 hr 360 mg	T1	
diltiazem hcl oral capsule,extended release 24 hr 420 mg	T2	
diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg	T1	
diltiazem hcl oral capsule,extended release 24hr 300 mg	T2	
diltiazem hcl oral tablet	T2	
DILT-XR	T2	
dofetilide	T4	
doxazosin	T2	
ELIQUIS DVT-PE TREAT 30D START	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET 2.5 MG	T3	QL (60 EA per 30 days)
ELIQUIS ORAL TABLET 5 MG	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG	T3	QL (112 EA per 28 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 1.5 MG (0.5 MG X 3)	T3	QL (336 EA per 28 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 2 MG (0.5 MG X 4)	T3	QL (560 EA per 28 days)
ELIQUIS SPRINKLE	T3	QL (70 EA per 28 days)
eltrombopag olamine oral powder in packet 12.5 mg	T5	PA; QL (372 EA per 31 days)
eltrombopag olamine oral powder in packet 25 mg	T5	PA; QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
eltrombopag olamine oral tablet 12.5 mg, 25 mg	T5	PA; QL (31 EA per 31 days)
eltrombopag olamine oral tablet 50 mg, 75 mg	T5	PA; QL (62 EA per 31 days)
enalapril maleate oral tablet	T1	
enalapril-hydrochlorothiazide	T1	
enoxaparin subcutaneous syringe	T4	
ENTRESTO SPRINKLE	T4	PA; QL (248 EA per 31 days)
eplerenone	T4	
ethacrynic acid	T4	
ezetimibe	T2	
ezetimibe-simvastatin	T3	QL (31 EA per 31 days)
felodipine	T2	
fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg	T2	
fenofibrate nanocrystallized	T2	
fenofibrate oral tablet 160 mg, 54 mg	T2	
FILSPARI ORAL TABLET 200 MG	T5	PA; QL (31 EA per 31 days)
FILSPARI ORAL TABLET 400 MG	T5	PA; QL (62 EA per 31 days)
flecainide	T2	
fluvastatin oral capsule	T1	
fluvastatin oral tablet extended release 24 hr	T2	
fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml	T5	
fondaparinux subcutaneous syringe 2.5 mg/0.5 ml	T4	
fosinopril	T1	
fosinopril-hydrochlorothiazide	T1	
furosemide injection	T2	
furosemide oral solution	T2	
furosemide oral tablet	T1	
gemfibrozil	T1	
heparin (porcine) injection solution	T3	PA-BvD
hydralazine oral	T1	
hydrochlorothiazide	T1	
icosapent ethyl oral capsule 0.5 gram	T4	QL (248 EA per 31 days)
icosapent ethyl oral capsule 1 gram	T4	QL (124 EA per 31 days)
indapamide	T1	
irbesartan	T1	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
irbesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg	T2	
isosorbide mononitrate	T2	
isradipine	T4	
ivabradine oral tablet 5 mg	T4	PA; QL (93 EA per 31 days)
ivabradine oral tablet 7.5 mg	T4	PA; QL (62 EA per 31 days)
JANTOVEN	T1	
KERENDIA	T4	PA; QL (31 EA per 31 days)
labetalol oral tablet 100 mg, 200 mg, 300 mg	T1	
lisinopril	T1	
lisinopril-hydrochlorothiazide	T1	
losartan oral tablet 100 mg	T1	QL (31 EA per 31 days)
losartan oral tablet 25 mg	T1	QL (93 EA per 31 days)
losartan oral tablet 50 mg	T1	QL (62 EA per 31 days)
losartan-hydrochlorothiazide	T1	
lovastatin	T1	
metolazone	T2	
metoprolol succinate	T1	
metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg	T1	
metyrosine	T5	PA
mexiletine	T3	
minoxidil oral	T2	
moexipril	T1	
MULPLETA	T5	PA
nadolol	T4	
nebivolol oral tablet 10 mg, 2.5 mg	T2	QL (93 EA per 31 days)
nebivolol oral tablet 20 mg	T2	QL (62 EA per 31 days)
nebivolol oral tablet 5 mg	T2	QL (217 EA per 31 days)
NEXLETOL	T4	PA; QL (31 EA per 31 days)
NEXLIZET	T4	PA; QL (31 EA per 31 days)
nicardipine oral capsule 30 mg	T4	
nifedipine oral tablet extended release	T2	
nifedipine oral tablet extended release 24hr	T2	
NITRO-BID	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
nitroglycerin sublingual	T2	
nitroglycerin transdermal patch 24 hour	T2	
nitroglycerin translingual	T4	
olmesartan oral tablet 20 mg, 40 mg	T1	QL (31 EA per 31 days)
olmesartan oral tablet 5 mg	T1	QL (93 EA per 31 days)
olmesartan-amlodipin-hcthiazid	T3	
olmesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
omega-3 acid ethyl esters	T3	QL (124 EA per 31 days)
PACERONE ORAL TABLET 100 MG, 200 MG	T2	
pentoxifylline	T2	
perindopril erbumine	T1	
pindolol	T4	
pitavastatin calcium	T3	
prasugrel hcl	T2	
pravastatin	T1	
prazosin	T2	
propafenone oral capsule,extended release 12 hr	T4	
propafenone oral tablet	T2	
propranolol oral capsule,extended release 24 hr	T2	
propranolol oral tablet	T2	
quinapril	T1	
quinapril-hydrochlorothiazide	T1	
quinidine sulfate oral tablet 200 mg	T2	
ramipril	T1	
ranolazine	T4	QL (62 EA per 31 days)
REDEMPLO	T5	PA; QL (0.5 ML per 90 days)
REPATHA SURECLICK	T3	PA; QL (3 ML per 28 days)
REPATHA SYRINGE	T3	PA; QL (3 ML per 28 days)
rivaroxaban oral suspension for reconstitution	T3	QL (930 ML per 31 days)
rivaroxaban oral tablet	T3	QL (62 EA per 31 days)
rosuvastatin	T1	
sacubitril-valsartan oral tablet 24-26 mg	T2	QL (186 EA per 31 days)
sacubitril-valsartan oral tablet 49-51 mg	T2	QL (93 EA per 31 days)
sacubitril-valsartan oral tablet 97-103 mg	T2	QL (62 EA per 31 days)
simvastatin	T1	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
SOTALOL AF	T2	
sotalol oral tablet 120 mg, 160 mg, 240 mg	T2	
sotalol oral tablet 80 mg	T1	
spironolactone oral tablet	T1	
spironolacton-hydrochlorothiaz	T2	
telmisartan	T1	
telmisartan-amlodipine	T2	
telmisartan-hydrochlorothiazid	T1	
terazosin	T1	
TIADYLT ER	T2	
ticagrelor	T3	
timolol maleate oral	T3	
torsemide oral	T1	
trandolapril	T1	
triamterene-hydrochlorothiazid	T1	
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG	T5	PA; QL (62 EA per 31 days)
UPTRAVI ORAL TABLET 200 MCG	T5	PA; QL (224 EA per 28 days)
UPTRAVI ORAL TABLETS,DOSE PACK	T5	PA; QL (400 EA per 365 days)
valsartan oral tablet 160 mg, 40 mg, 80 mg	T1	QL (62 EA per 31 days)
valsartan oral tablet 320 mg	T1	QL (31 EA per 31 days)
valsartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
verapamil oral tablet	T2	
verapamil oral tablet extended release	T2	
VERQUVO	T4	PA; QL (31 EA per 31 days)
warfarin	T1	
Dermatológicos/Terapia Tópica		
acitretin	T4	PA
acyclovir topical ointment	T3	QL (30 GM per 30 days)
ALA-CORT TOPICAL CREAM	T1	
alclometasone	T2	
ammonium lactate	T2	
AMNESTEEM	T4	
ANZUPGO	T5	PA; QL (60 GM per 30 days)
betamethasone dipropionate topical cream	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
betamethasone dipropionate topical lotion	T1	
betamethasone valerate topical cream	T2	
betamethasone valerate topical lotion	T3	
betamethasone valerate topical ointment	T2	
betamethasone, augmented topical cream	T2	
betamethasone, augmented topical gel	T4	
betamethasone, augmented topical lotion	T3	
betamethasone, augmented topical ointment	T3	
calcipotriene scalp	T3	QL (60 ML per 28 days)
calcipotriene topical cream	T3	QL (60 GM per 28 days)
calcipotriene topical ointment	T3	QL (60 GM per 28 days)
ciclopirox topical cream	T2	QL (90 GM per 28 days)
ciclopirox topical suspension	T3	QL (60 ML per 28 days)
CLARAVIS	T4	
clindamycin phosphate topical swab	T2	
clindamycin-benzoyl peroxide topical gel 1.2 %(1 % base) -5 %	T2	
clotrimazole topical cream	T2	QL (45 GM per 28 days)
clotrimazole topical solution	T2	QL (30 ML per 28 days)
clotrimazole-betamethasone topical cream	T2	QL (45 GM per 28 days)
clotrimazole-betamethasone topical lotion	T3	QL (60 ML per 28 days)
COSENTYX (2 SYRINGES)	T5	PA; QL (2 ML per 28 days)
COSENTYX PEN (2 PENS)	T5	PA; QL (2 ML per 28 days)
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
COSENTYX UNOREADY PEN	T5	PA; QL (2 ML per 28 days)
desoximetasone topical cream	T4	QL (100 GM per 28 days)
desoximetasone topical gel	T4	QL (60 GM per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
ERY PADS	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
erythromycin with ethanol topical gel	T2	QL (60 GM per 28 days)
erythromycin with ethanol topical solution	T2	QL (60 ML per 28 days)
erythromycin-benzoyl peroxide	T3	
FILSUVEZ	T5	PA
fluocinolone and shower cap	T3	QL (118.28 ML per 28 days)
fluocinolone topical cream 0.01 %	T4	QL (60 GM per 28 days)
fluocinolone topical cream 0.025 %	T3	QL (120 GM per 28 days)
fluocinolone topical ointment	T3	QL (120 GM per 28 days)
fluocinolone topical solution	T3	QL (90 ML per 28 days)
fluocinonide topical cream 0.05 %	T2	QL (60 GM per 28 days)
fluocinonide topical gel	T4	QL (60 GM per 28 days)
fluocinonide topical ointment	T2	QL (60 GM per 28 days)
fluocinonide topical solution	T2	QL (60 ML per 28 days)
fluocinonide-emollient	T4	QL (60 GM per 28 days)
fluorouracil topical cream 5 %	T3	
fluorouracil topical solution 2 %	T2	
fluorouracil topical solution 5 %	T3	
fluticasone propionate topical cream	T2	
gentamicin topical	T3	QL (60 GM per 28 days)
halobetasol propionate topical cream	T4	QL (50 GM per 28 days)
halobetasol propionate topical ointment	T4	QL (50 GM per 28 days)
hydrocortisone topical cream 1 %	T1	
hydrocortisone topical lotion 2.5 %	T2	QL (118 ML per 28 days)
hydrocortisone topical ointment 1 %, 2.5 %	T1	
imiquimod topical cream in packet 5 %	T2	
ketoconazole topical cream	T2	QL (60 GM per 28 days)
ketoconazole topical shampoo	T2	QL (120 ML per 28 days)
lidocaine hcl mucous membrane solution 2 %	T2	
lidocaine hcl mucous membrane solution 4 % (40 mg/ml)	T2	PA; QL (50 ML per 28 days)
lidocaine topical adhesive patch,medicated 5 %	T4	PA; QL (93 EA per 31 days)
lidocaine topical ointment	T4	PA; QL (50 GM per 28 days)
lidocaine-prilocaine topical cream	T2	PA; QL (30 GM per 28 days)
malathion	T4	
metronidazole topical cream	T3	
metronidazole topical gel 0.75 %	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
metronidazole topical gel 1 %	T4	
metronidazole topical lotion	T4	
mometasone topical	T2	
mupirocin	T2	
NYAMYC	T2	QL (60 GM per 28 days)
nystatin topical cream	T2	QL (30 GM per 28 days)
nystatin topical ointment	T2	QL (30 GM per 28 days)
nystatin topical powder	T2	QL (60 GM per 28 days)
nystatin-triamcinolone	T2	
NYSTOP	T2	QL (60 GM per 28 days)
PANRETIN	T5	PA-NC
penciclovir	T4	QL (5 GM per 28 days)
permethrin	T2	
podofilox topical solution	T4	
selenium sulfide topical lotion	T1	
SILIQ	T5	PA; QL (6 ML per 28 days)
silver sulfadiazine	T1	
SKYRIZI SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE 55 MG/0.37 ML	T5	PA; QL (0.37 ML per 84 days)
SSD	T4	
STEQEYMA SUBCUTANEOUS SOLUTION	T3	PA; QL (0.5 ML per 84 days)
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
STEQEYMA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
SULFAMYLON TOPICAL CREAM	T4	
tacrolimus topical	T4	QL (100 GM per 28 days)
tazarotene topical cream	T4	PA; QL (60 GM per 28 days)
tretinoin topical cream	T2	PA; QL (45 GM per 28 days)
tretinoin topical gel 0.01 %, 0.025 %	T4	PA; QL (45 GM per 28 days)
triamcinolone acetonide topical cream	T1	
triamcinolone acetonide topical lotion	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
triamcinolone acetonide topical ointment 0.025 %, 0.5 %	T2	
triamcinolone acetonide topical ointment 0.1 %	T1	
VALCHLOR	T5	PA-NC
VTAMA	T5	PA; QL (60 GM per 28 days)
YESINTEK SUBCUTANEOUS SOLUTION	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
ZELSUVMI	T5	PA; QL (31 GM per 28 days)
Diagnósticos / Agentes Varios		
acamprosate	T4	
anagrelide	T4	
bupropion hcl (smoking deter)	T2	QL (62 EA per 31 days)
carglumic acid	T5	PA
CHEMET	T4	
CLINIMIX 4.25%/D5W SULFIT FREE	T4	PA-BvD
d10 %-0.45 % sodium chloride	T2	
d2.5 %-0.45 % sodium chloride	T2	
d5 % and 0.9 % sodium chloride	T2	
d5 %-0.45 % sodium chloride	T2	
deferasirox oral tablet, dispersible 125 mg	T4	PA
deferasirox oral tablet, dispersible 250 mg, 500 mg	T5	PA
dextrose 10 % in water (d10w)	T2	
dextrose 5 % in water (d5w) intravenous parenteral solution	T2	
disulfiram	T3	
droxidopa oral capsule 100 mg	T4	PA; QL (465 EA per 31 days)
droxidopa oral capsule 200 mg, 300 mg	T5	PA; QL (186 EA per 31 days)
DUVYZAT	T5	PA; QL (420 ML per 35 days)
glycerol phenylbutyrate	T5	PA
INCRELEX	T5	PA
JOENJA ORAL TABLET 70 MG	T5	PA; QL (60 EA per 30 days)
KIONEX ORAL SUSPENSION	T2	
KYGEVVI	T5	PA; QL (496 EA per 30 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
levocarnitine (with sugar)	T4	PA-BvD
levocarnitine oral tablet	T4	PA-BvD
LITFULO	T5	PA; QL (28 EA per 28 days)
LOARGYS	T5	PA
LOKELMA	T3	QL (93 EA per 31 days)
midodrine	T2	
NICOTROL NS	T4	
nitisinone	T5	PA
PHEBURANE	T5	PA; QL (620 GM per 31 days)
pilocarpine hcl oral	T3	
PROLASTIN-C INTRAVENOUS SOLUTION	T5	PA
REVCOVI	T5	
REZDIFFRA	T5	PA; QL (31 EA per 31 days)
riluzole	T4	
risedronate oral tablet 30 mg	T5	
sevelamer carbonate oral powder in packet	T4	PA-BvD
sevelamer carbonate oral tablet	T3	PA-BvD
sodium chloride 0.9 % intravenous parenteral solution	T2	
sodium chloride irrigation	T2	
sodium phenylbutyrate	T5	PA
sodium polystyrene sulfonate	T2	
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 5 MG	T5	PA; QL (31 EA per 31 days)
SOHONOS ORAL CAPSULE 10 MG	T5	PA; QL (62 EA per 31 days)
SPS (WITH SORBITOL) ORAL	T2	
trientine oral capsule 250 mg	T5	QL (248 EA per 31 days)
varenicline tartrate oral tablet	T4	QL (60 EA per 30 days)
varenicline tartrate oral tablets,dose pack	T4	QL (106 EA per 365 days)
WEGOVY ORAL	T3	PA; QL (31 EA per 31 days)
WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML	T3	PA; QL (2 ML per 28 days)
WEGOVY SUBCUTANEOUS PEN INJECTOR 1.7 MG/0.75 ML, 2.4 MG/0.75 ML	T3	PA; QL (3 ML per 28 days)
ZOKINVY	T5	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
Endocrino/Diabetes		
acarbose	T2	QL (93 EA per 31 days)
ALCOHOL PADS	T2	PA
cabergoline	T3	
calcitonin (salmon) nasal	T3	PA-BvD
calcitriol oral capsule	T2	PA-BvD
calcitriol oral solution	T4	PA-BvD
cinacalcet oral tablet 30 mg, 60 mg	T4	PA-BvD; QL (62 EA per 31 days)
cinacalcet oral tablet 90 mg	T4	PA-BvD; QL (124 EA per 31 days)
danazol	T4	
dapagliflozin	T3	QL (31 EA per 31 days)
desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)	T4	
desmopressin oral	T2	
dexamethasone oral solution	T2	
dexamethasone oral tablet	T1	
diazoxide	T5	
doxercalciferol oral	T4	PA-BvD
FARXIGA	T3	ST; QL (31 EA per 31 days)
FIASP FLEXTOUCH U-100 INSULIN	T3	
FIASP PENFILL U-100 INSULIN	T3	
FIASP U-100 INSULIN	T3	
fludrocortisone	T1	
glimepiride oral tablet 1 mg, 2 mg, 4 mg	T1	
glipizide oral tablet 10 mg, 5 mg	T1	
glipizide oral tablet extended release 24hr	T1	
glipizide-metformin	T1	
GLUCAGON EMERGENCY KIT (HUMAN)	T3	
glyburide	T2	
glyburide-metformin	T2	
GLYXAMBI	T3	QL (31 EA per 31 days)
GVOKE	T3	
GVOKE HYPOPEN 2-PACK	T3	
GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
HUMALOG JUNIOR KWIKPEN U-100	T3	
HUMALOG KWIKPEN INSULIN	T3	
HUMALOG MIX 50-50 KWIKPEN	T3	
HUMALOG MIX 75-25 KWIKPEN	T3	
HUMALOG MIX 75-25(U-100)INSULN	T3	
HUMALOG U-100 INSULIN	T3	
HUMULIN 70/30 U-100 INSULIN	T3	
HUMULIN 70/30 U-100 KWIKPEN	T3	
HUMULIN N NPH INSULIN KWIKPEN	T3	
HUMULIN N NPH U-100 INSULIN	T3	
HUMULIN R REGULAR U-100 INSULN	T3	
HUMULIN R U-500 (CONC) KWIKPEN	T3	
hydrocortisone oral	T1	
insulin glargine-yfgn	T3	
insulin lispro	T3	
insulin lispro protamin-lispro	T3	
JANUMET	T3	ST; QL (62 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG	T3	ST; QL (31 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG	T3	ST; QL (62 EA per 31 days)
JANUVIA ORAL TABLET 100 MG, 50 MG	T3	ST; QL (31 EA per 31 days)
JANUVIA ORAL TABLET 25 MG	T3	ST; QL (93 EA per 31 days)
JARDIANCE ORAL TABLET 10 MG	T3	ST; QL (62 EA per 31 days)
JARDIANCE ORAL TABLET 25 MG	T3	ST; QL (31 EA per 31 days)
JAVYGTOR	T5	PA
JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG	T3	ST; QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG	T3	ST; QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG	T3	ST; QL (31 EA per 31 days)
KIRSTY	T3	
KIRSTY PEN	T3	
LANTUS SOLOSTAR U-100 INSULIN	T3	
LANTUS U-100 INSULIN	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
levothyroxine oral tablet	T1	
liothyronine oral	T2	
liraglutide	T4	PA; QL (9 ML per 30 days)
metformin oral tablet 1,000 mg, 500 mg, 850 mg	T1	
metformin oral tablet extended release 24 hr	T1	
methimazole oral tablet 10 mg, 5 mg	T1	
methylprednisolone	T2	
mifepristone oral tablet 300 mg	T5	PA; QL (124 EA per 31 days)
miglustat	T5	PA; QL (93 EA per 31 days)
MOUNJARO	T3	PA; QL (2 ML per 28 days)
nateglinide	T1	QL (93 EA per 31 days)
NOVOLIN 70/30 U-100 INSULIN	T3	
NOVOLIN 70-30 FLEXPEN U-100	T3	
NOVOLIN N FLEXPEN	T3	
NOVOLIN N NPH U-100 INSULIN	T3	
NOVOLIN R FLEXPEN	T3	
NOVOLIN R REGULAR U100 INSULIN	T3	
NOVOLOG MIX 70-30 U-100 INSULN	T3	
NOVOLOG MIX 70-30FLEXPEN U-100	T3	
OZEMPIC ORAL	T3	PA; QL (31 EA per 31 days)
OZEMPIC SUBCUTANEOUS	T3	PA; QL (3 ML per 28 days)
paricalcitol oral	T4	PA-BvD
pioglitazone	T1	QL (31 EA per 31 days)
pioglitazone-metformin	T2	QL (93 EA per 31 days)
prednisolone oral solution	T2	
prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)	T2	
prednisone oral solution	T3	
prednisone oral tablet	T1	
prednisone oral tablets,dose pack	T2	
propylthiouracil	T2	
repaglinide oral tablet 0.5 mg, 1 mg	T1	QL (124 EA per 31 days)
repaglinide oral tablet 2 mg	T1	QL (248 EA per 31 days)
REZVOGLAR KWIKPEN	T3	
sapropterin	T5	PA
saxagliptin	T3	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg	T3	QL (62 EA per 31 days)
saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg	T3	QL (31 EA per 31 days)
sitagliptin oral tablet 100 mg, 50 mg	T3	QL (31 EA per 31 days)
sitagliptin oral tablet 25 mg	T3	QL (93 EA per 31 days)
sitagliptin phos-metformin oral tablet	T3	QL (62 EA per 31 days)
sitagliptin phos-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-500 mg	T3	QL (31 EA per 31 days)
sitagliptin phos-metformin oral tablet, er multiphase 24 hr 50-1,000 mg	T3	QL (62 EA per 31 days)
sitagliptin phosphate oral tablet 100 mg, 50 mg	T3	QL (31 EA per 31 days)
sitagliptin phosphate oral tablet 25 mg	T3	QL (93 EA per 31 days)
sitagliptin-metformin oral tablet	T3	QL (62 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-500 mg	T3	QL (31 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 50-1,000 mg	T3	QL (62 EA per 31 days)
SOLIQUA 100/33	T3	QL (18 ML per 30 days)
SOMAVERT	T5	PA
SYNAREL	T5	PA
SYNJARDY	T3	QL (62 EA per 31 days)
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 12.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 25-1,000 MG	T3	QL (31 EA per 31 days)
SYNTHROID	T3	
TARPEYO	T5	PA; QL (124 EA per 31 days)
testosterone cypionate	T2	PA
testosterone enanthate	T2	PA
testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)	T4	PA
tolvaptan	T5	PA
tolvaptan (polycys kidney dis) oral tablet	T5	PA; QL (112 EA per 28 days)
tolvaptan (polycys kidney dis) oral tablets, sequential	T5	PA; QL (56 EA per 28 days)
TOUJEO MAX U-300 SOLOSTAR	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
TOUJEO SOLOSTAR U-300 INSULIN	T3	
TRADJENTA	T3	ST; QL (31 EA per 31 days)
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG	T3	QL (31 EA per 31 days)
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG	T3	QL (62 EA per 31 days)
TRULICITY	T3	PA; QL (2 ML per 28 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG	T3	QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
XULTOPHY 100/3.6	T3	QL (15 ML per 30 days)
YARGESA	T5	PA; QL (93 EA per 31 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML	T5	PA; QL (1.12 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 294 MCG/0.98 ML	T5	PA; QL (1.96 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 420 MCG/1.4 ML	T5	PA; QL (2.8 ML per 28 days)
ZELVYSIA	T5	PA
Gastroenterología		
alosetron oral tablet 0.5 mg	T4	PA; QL (93 EA per 31 days)
alosetron oral tablet 1 mg	T5	PA; QL (62 EA per 31 days)
aprepitant oral capsule 125 mg	T5	PA-BvD
aprepitant oral capsule 40 mg, 80 mg	T4	PA-BvD
aprepitant oral capsule,dose pack	T4	PA-BvD
balsalazide	T4	
betaine	T5	
bismuth subcit k-metronidz-tcn	T4	
budesonide oral capsule,delayed,extend.release	T4	
budesonide oral tablet,delayed and ext.release	T5	
COMPRO	T4	
CONSTULOSE	T2	
CREON	T3	
cromolyn oral	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
dicyclomine oral capsule	T2	
dicyclomine oral solution	T2	
dicyclomine oral tablet 20 mg	T2	
diphenoxylate-atropine oral liquid	T4	
diphenoxylate-atropine oral tablet	T2	
dronabinol oral capsule	T4	PA-BvD
ENTYVIO PEN	T5	PA; QL (1.36 ML per 28 days)
ENULOSE	T2	
EOHILIA	T5	PA; QL (1800 ML per 365 days)
famotidine oral suspension for reconstitution	T2	
famotidine oral tablet 20 mg, 40 mg	T1	
GATTEX 30-VIAL	T5	PA
GAVILYTE-C	T1	
GAVILYTE-G	T1	
GAVILYTE-N	T1	
GENERLAC	T2	
glycopyrrolate oral tablet 1 mg, 2 mg	T2	
granisetron hcl oral	T4	PA-BvD
hydrocortisone rectal	T4	
hydrocortisone topical cream with perineal applicator 2.5 %	T1	
lactulose oral solution	T1	
LINZESS	T3	QL (31 EA per 31 days)
loperamide oral capsule	T2	
lubiprostone	T4	QL (62 EA per 31 days)
meclizine oral tablet 12.5 mg, 25 mg	T4	
mesalamine oral capsule (with del rel tablets)	T4	QL (186 EA per 31 days)
mesalamine oral capsule,extended release 24hr	T4	QL (124 EA per 31 days)
mesalamine oral tablet,delayed release (dr/ec) 1.2 gram	T4	QL (124 EA per 31 days)
mesalamine rectal enema	T4	QL (1860 ML per 31 days)
metoclopramide hcl oral solution	T2	
metoclopramide hcl oral tablet	T2	
misoprostol	T2	
MOVANTIK	T3	QL (31 EA per 31 days)
nitroglycerin rectal	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
omeprazole oral capsule,delayed release(dr/ec)	T1	
ondansetron hcl oral solution	T3	PA-BvD
ondansetron hcl oral tablet 4 mg, 8 mg	T2	PA-BvD
ondansetron oral tablet,disintegrating 4 mg, 8 mg	T2	PA-BvD
pantoprazole oral tablet,delayed release (dr/ec)	T1	
peg 3350-electrolytes	T1	
peg3350-sod sul-nacl-kcl-asb-c	T4	
peg-electrolyte soln	T1	
prochlorperazine	T4	
prochlorperazine maleate	T2	
PROCTO-MED HC	T2	
PROCTOSOL HC TOPICAL	T2	
PROCTOZONE-HC	T2	
rabeprazole oral tablet,delayed release (dr/ec)	T2	QL (62 EA per 31 days)
scopolamine base	T3	QL (10 EA per 30 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)	T5	PA; QL (1.2 ML per 56 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)	T5	PA; QL (2.4 ML per 56 days)
sodium,potassium,mag sulfates	T4	
sucralfate oral tablet	T2	
sulfasalazine	T2	
ursodiol oral capsule 300 mg	T3	
ursodiol oral tablet	T3	
VOWST	T5	PA; QL (12 EA per 14 days)
ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT	T3	
ZYMFENTRA	T5	PA; QL (1 EA per 28 days)
Inmunología, Vacunas / Biotecnología		
ABRYSVO (PF)	T3	QL (1 EA per 365 days)
ACTHIB (PF)	T3	
ACTIMMUNE	T5	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ADACEL(TDAP ADOLESN/ADULT)(PF)	T3	
AREXVY (PF)	T3	QL (1 EA per 365 days)
AVONEX INTRAMUSCULAR PEN INJECTOR KIT	T5	PA; QL (1 EA per 28 days)
AVONEX INTRAMUSCULAR SYRINGE KIT	T5	PA; QL (1 EA per 28 days)
bcg vaccine, live (pf)	T3	
BESREMI	T5	PA-NC; QL (2 ML per 28 days)
BESREMI PEN	T5	PA-NC; QL (1 ML per 28 days)
BETASERON SUBCUTANEOUS KIT	T5	PA; QL (14 EA per 28 days)
BEXSERO	T3	
BOOSTRIX TDAP INTRAMUSCULAR SYRINGE	T3	
DAPTACEL (DTAP PEDIATRIC) (PF)	T3	
ENGERIX-B (PF)	T3	PA-BvD
ENGERIX-B PEDIATRIC (PF)	T3	PA-BvD
GAMMAGARD LIQUID	T5	PA
GAMMAGARD LIQUID ERC	T5	PA
GAMMAGARD S-D (IGA < 1 MCG/ML)	T5	PA
GARDASIL 9 (PF)	T3	
HAVRIX (PF)	T3	
HEPLISAV-B (PF)	T3	PA-BvD
HIBERIX (PF)	T3	
IMOVAX RABIES VACCINE (PF)	T3	PA-BvD
INFANRIX (DTAP) (PF)	T3	
IPOL	T3	
IXIARO (PF)	T3	
JYNNEOS (PF)	T3	PA-BvD
KINRIX (PF)	T3	
LEUKINE INJECTION RECON SOLN	T5	PA
MENQUADFI (PF)	T3	
MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT	T3	
M-M-R II (PF)	T3	
MRESVIA (PF)	T3	QL (1 ML per 365 days)
NIVESTYM	T5	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML)	T5	PA
PEDIARIX (PF)	T3	
PEDVAX HIB (PF)	T3	
PEGASYS	T5	PA
PENBRAYA (PF)	T3	
PENMENVY MEN A-B-C-W-Y (PF)	T3	
PENTACEL (PF)	T3	
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PRIORIX (PF)	T3	
PRIVIGEN	T5	PA
PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T3	PA-BvD
PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML	T5	PA-BvD
PROQUAD (PF)	T3	
QUADRACEL (PF)	T3	
RABAVERT (PF)	T3	PA-BvD
RECOMBIVAX HB (PF)	T3	PA-BvD
RETACRIT	T3	PA-BvD
ROTARIX	T3	
ROTATEQ VACCINE	T3	
SHINGRIX (PF)	T3	QL (2 EA per 999 days)
TENIVAC (PF)	T3	
TICOVAC	T3	
TRUMENBA	T3	
TWINRIX (PF)	T3	
TYPHIM VI INTRAMUSCULAR SYRINGE	T3	
VAQTA (PF)	T3	
VARIVAX (PF)	T3	
VAXCHORA VACCINE	T3	QL (200 ML per 365 days)
VIMKUNYA (PF)	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
VIVOTIF	T3	
XOLREMDI	T5	PA; QL (124 EA per 31 days)
YF-VAX (PF)	T3	
ZARXIO	T5	
Medicamentos Antineoplásicos E Inmunosupresores		
abiraterone oral tablet 250 mg	T5	PA-NC; QL (124 EA per 31 days)
abiraterone oral tablet 500 mg	T5	PA-NC; QL (62 EA per 31 days)
ABIRTEGA	T3	PA-NC; QL (124 EA per 31 days)
AKEEGA	T5	PA-NC; QL (62 EA per 31 days)
ALECENSA	T5	PA-NC; QL (248 EA per 31 days)
ALUNBRIG ORAL TABLET 180 MG, 90 MG	T5	PA-NC; QL (31 EA per 31 days)
ALUNBRIG ORAL TABLET 30 MG	T5	PA-NC; QL (186 EA per 31 days)
ALUNBRIG ORAL TABLETS,DOSE PACK	T5	PA-NC; QL (60 EA per 365 days)
anastrozole	T2	
AUGTYRO ORAL CAPSULE 160 MG	T5	PA-NC; QL (62 EA per 31 days)
AUGTYRO ORAL CAPSULE 40 MG	T5	PA-NC; QL (186 EA per 31 days)
AVMAPKI-FAKZYNJA	T5	PA-NC; QL (66 EA per 28 days)
AYVAKIT	T5	PA-NC; QL (31 EA per 31 days)
azathioprine oral tablet 50 mg	T2	PA-BvD
BALVERSA	T5	PA-NC
bexarotene oral	T5	PA-NC
bexarotene topical	T5	PA-NC; QL (60 GM per 28 days)
bicalutamide	T2	
BILPREVDA	T3	PA-NC
BOSULIF ORAL CAPSULE 100 MG	T5	PA-NC; QL (186 EA per 31 days)
BOSULIF ORAL CAPSULE 50 MG	T5	PA-NC; QL (341 EA per 31 days)
BOSULIF ORAL TABLET 100 MG	T5	PA-NC; QL (93 EA per 31 days)
BOSULIF ORAL TABLET 400 MG, 500 MG	T5	PA-NC; QL (31 EA per 31 days)
bosutinib oral tablet 400 mg	T5	PA-NC; QL (31 EA per 31 days)
BRAFTOVI	T5	PA-NC; QL (186 EA per 31 days)
BRUKINSA ORAL TABLET	T5	PA-NC; QL (62 EA per 31 days)
CABOMETYX	T5	PA-NC; QL (31 EA per 31 days)
CALQUENCE (ACALABRUTINIB MAL)	T5	PA-NC; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 100 MG	T5	PA-NC; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 300 MG	T5	PA-NC; QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)	T5	PA-NC; QL (56 EA per 28 days)
COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)	T5	PA-NC; QL (112 EA per 28 days)
COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)	T5	PA-NC; QL (84 EA per 28 days)
COPIKTRA	T5	PA-NC; QL (62 EA per 31 days)
COTELLIC	T5	PA-NC; LA; QL (63 EA per 28 days)
cyclophosphamide oral capsule	T3	PA-BvD
cyclophosphamide oral tablet 50 mg	T3	PA-BvD
cyclosporine modified oral capsule	T2	PA-BvD
cyclosporine modified oral solution	T5	PA-BvD
cyclosporine oral capsule	T3	PA-BvD
DANZITEN	T5	PA-NC; QL (124 EA per 31 days)
dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg	T5	PA-NC; QL (31 EA per 31 days)
dasatinib oral tablet 20 mg	T5	PA-NC; QL (93 EA per 31 days)
DAURISMO ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
DAURISMO ORAL TABLET 25 MG	T5	PA-NC; QL (62 EA per 31 days)
ELIGARD	T4	QL (1 EA per 30 days)
ELIGARD (3 MONTH)	T4	QL (1 EA per 90 days)
ELIGARD (4 MONTH)	T4	QL (1 EA per 120 days)
ELIGARD (6 MONTH)	T4	QL (1 EA per 180 days)
ENSACOVE	T5	PA-NC; QL (62 EA per 31 days)
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG	T4	PA-BvD
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 4 MG	T5	PA-BvD
ERIVEDGE	T5	PA-NC; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 240 MG	T5	PA-NC; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 60 MG	T5	PA-NC; QL (93 EA per 31 days)
erlotinib	T5	PA-NC; QL (31 EA per 31 days)
EULEXIN	T4	
everolimus (antineoplastic) oral tablet	T5	PA-NC; QL (31 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg	T5	PA-NC; QL (62 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
everolimus (antineoplastic) oral tablet for suspension 3 mg	T5	PA-NC; QL (93 EA per 31 days)
everolimus (immunosuppressive) oral tablet 0.25 mg	T4	PA-BvD
everolimus (immunosuppressive) oral tablet 0.5 mg, 0.75 mg, 1 mg	T5	PA-BvD
exemestane	T4	
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG	T5	PA-NC
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG	T4	PA-NC
FOTIVDA	T5	PA-NC; QL (21 EA per 28 days)
FRUZAQLA ORAL CAPSULE 1 MG	T5	PA-NC; QL (84 EA per 28 days)
FRUZAQLA ORAL CAPSULE 5 MG	T5	PA-NC; QL (21 EA per 28 days)
GAVRETO	T5	PA-NC; QL (124 EA per 31 days)
gefitinib	T5	PA-NC; QL (31 EA per 31 days)
GENGRAF ORAL CAPSULE	T2	PA-BvD
GILOTRIF	T5	PA-NC; QL (31 EA per 31 days)
GOMEKLI ORAL CAPSULE 1 MG	T5	PA-NC; QL (126 EA per 28 days)
GOMEKLI ORAL CAPSULE 2 MG	T5	PA-NC; QL (84 EA per 28 days)
GOMEKLI ORAL TABLET FOR SUSPENSION	T5	PA-NC; QL (168 EA per 28 days)
HERNEXEOS	T5	PA-NC; QL (93 EA per 31 days)
hydroxyurea	T2	
HYRNUO	T5	PA-NC; QL (124 EA per 31 days)
IBRANCE ORAL CAPSULE 125 MG	T5	PA-NC; QL (21 EA per 28 days)
IBRANCE ORAL TABLET	T5	PA-NC; QL (21 EA per 28 days)
IBTROZI	T5	PA-NC; QL (93 EA per 31 days)
ICLUSIG	T5	PA-NC; QL (31 EA per 31 days)
IDHIFA	T5	PA-NC; QL (31 EA per 31 days)
imatinib oral tablet 100 mg	T5	PA-NC; QL (93 EA per 31 days)
imatinib oral tablet 400 mg	T5	PA-NC; QL (62 EA per 31 days)
IMBRUVICA ORAL CAPSULE 140 MG	T5	PA-NC; QL (124 EA per 31 days)
IMBRUVICA ORAL CAPSULE 70 MG	T5	PA-NC; QL (31 EA per 31 days)
IMBRUVICA ORAL SUSPENSION	T5	PA-NC; QL (216 ML per 25 days)
IMBRUVICA ORAL TABLET	T5	PA-NC; QL (31 EA per 31 days)
IMKELDI	T5	PA-NC; QL (280 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INLURIYO	T5	PA-NC; QL (62 EA per 31 days)
INLYTA	T5	PA-NC; QL (124 EA per 31 days)
INQOVI	T5	PA-NC; QL (5 EA per 28 days)
INREBIC	T5	PA-NC; QL (124 EA per 31 days)
ITOVEBI ORAL TABLET 3 MG	T5	PA-NC; QL (62 EA per 31 days)
ITOVEBI ORAL TABLET 9 MG	T5	PA-NC; QL (31 EA per 31 days)
IWILFIN	T5	PA-NC; QL (248 EA per 31 days)
JAKAFI	T5	PA-NC; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 100 MG	T5	PA-NC; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 50 MG	T5	PA-NC; QL (31 EA per 31 days)
JIDEYTRO ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
JIDEYTRO ORAL TABLET 25 MG	T5	PA-NC; QL (93 EA per 31 days)
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NC; QL (21 EA per 28 days)
KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)	T5	PA-NC; QL (42 EA per 28 days)
KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)	T5	PA-NC; QL (63 EA per 28 days)
KOMZIFTI	T5	PA-NC; QL (90 EA per 30 days)
KOSELUGO ORAL CAPSULE 10 MG	T5	PA-NC; QL (279 EA per 31 days)
KOSELUGO ORAL CAPSULE 25 MG	T5	PA-NC; QL (124 EA per 31 days)
KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG	T5	PA-NC; QL (600 EA per 30 days)
KOSELUGO ORAL CAPSULE, SPRINKLE 7.5 MG	T5	PA-NC; QL (360 EA per 30 days)
KRAZATI	T5	PA-NC; QL (186 EA per 31 days)
lapatinib	T5	PA-NC; QL (186 EA per 31 days)
LAZCLUZE ORAL TABLET 240 MG	T5	PA-NC; QL (30 EA per 30 days)
LAZCLUZE ORAL TABLET 80 MG	T5	PA-NC; QL (60 EA per 30 days)
lenalidomide	T5	PA-NC; QL (21 EA per 28 days)
LENVIMA	T5	PA-NC
letrozole	T2	
leucovorin calcium oral tablet 10 mg, 5 mg	T2	
leucovorin calcium oral tablet 15 mg, 25 mg	T3	
LEUKERAN	T5	
leuprolide subcutaneous kit	T4	QL (2 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9)	T5	PA-NC; QL (18 EA per 28 days)
LIFYORLI ORAL CAPSULE 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9)	T5	PA-NC; QL (27 EA per 28 days)
lomustine oral capsule 10 mg, 40 mg	T4	PA-NC
lomustine oral capsule 100 mg	T5	PA-NC
LONSURF	T5	PA-NC
LORBRENA ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
LORBRENA ORAL TABLET 25 MG	T5	PA-NC; QL (93 EA per 31 days)
LUMAKRAS ORAL TABLET 120 MG, 240 MG	T5	PA-NC; QL (62 EA per 31 days)
LUMAKRAS ORAL TABLET 320 MG	T5	PA-NC; QL (93 EA per 31 days)
LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG	T5	QL (1 EA per 90 days)
LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG	T5	QL (1 EA per 30 days)
LYNPARZA	T5	PA-NC; QL (124 EA per 31 days)
LYSODREN	T5	
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3)	T5	PA-NC; QL (93 EA per 31 days)
LYTGOBI ORAL TABLET 16 MG/DAY (4 MG X 4)	T5	PA-NC; QL (124 EA per 31 days)
LYTGOBI ORAL TABLET 20 MG/DAY (4 MG X 5)	T5	PA-NC; QL (155 EA per 31 days)
MATULANE	T5	
megestrol oral suspension 400 mg/10 ml (40 mg/ml)	T2	PA
megestrol oral suspension 625 mg/5 ml (125 mg/ml)	T4	PA
megestrol oral tablet	T2	PA-NC
MEKINIST ORAL RECON SOLN	T5	PA-NC; QL (1260 ML per 31 days)
MEKINIST ORAL TABLET 0.5 MG	T5	PA-NC; QL (93 EA per 31 days)
MEKINIST ORAL TABLET 2 MG	T5	PA-NC; QL (31 EA per 31 days)
MEKTOVI	T5	PA-NC; QL (186 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
mercaptopurine oral suspension	T5	
mercaptopurine oral tablet	T2	
mesna oral	T4	
methotrexate sodium (pf) injection solution	T2	
methotrexate sodium injection	T2	
methotrexate sodium oral	T1	PA-BvD
MODEYSO	T5	PA-NC; QL (20 EA per 28 days)
mycophenolate mofetil oral capsule	T2	PA-BvD
mycophenolate mofetil oral suspension for reconstitution	T5	PA-BvD
mycophenolate mofetil oral tablet	T2	PA-BvD
mycophenolate sodium	T4	PA-BvD
NEMLUVIO	T5	PA; QL (2 EA per 28 days)
NERLYNX	T5	PA-NC; QL (186 EA per 31 days)
nilotinib hcl	T5	PA-NC; QL (124 EA per 31 days)
nilutamide	T5	
NINLARO	T5	PA-NC; QL (3 EA per 28 days)
NUBEQA	T5	PA-NC; QL (124 EA per 31 days)
octreotide acetate injection solution	T4	PA
ODOMZO	T5	PA-NC; LA; QL (31 EA per 31 days)
OGSIVEO ORAL TABLET 100 MG, 150 MG	T5	PA-NC; QL (62 EA per 31 days)
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION	T5	PA-NC; QL (96 ML per 28 days)
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4)	T5	PA-NC; QL (16 EA per 28 days)
OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5)	T5	PA-NC; QL (20 EA per 28 days)
OJEMDA ORAL TABLET 600 MG/WEEK (100 MG X 6)	T5	PA-NC; QL (24 EA per 28 days)
OJJAARA	T5	PA-NC; QL (31 EA per 31 days)
ONUREG	T5	PA-NC; QL (14 EA per 28 days)
ORGOVYX	T5	PA-NC; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 345 MG	T5	PA-NC; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 86 MG	T5	PA-NC; QL (93 EA per 31 days)
pazopanib oral tablet 200 mg	T5	PA-NC; QL (124 EA per 31 days)
PEMAZYRE	T5	PA-NC; QL (14 EA per 21 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NC; QL (28 EA per 28 days)
PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)	T5	PA-NC; QL (56 EA per 28 days)
pomalidomide	T5	PA-NC; QL (21 EA per 28 days)
POMALYST	T5	PA-NC; QL (21 EA per 28 days)
PROGRAF ORAL GRANULES IN PACKET	T4	PA-BvD
QINLOCK	T5	PA-NC; QL (93 EA per 31 days)
RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG	T5	PA-NC; QL (62 EA per 31 days)
RETEVMO ORAL TABLET 40 MG	T5	PA-NC; QL (93 EA per 31 days)
REVUFORJ ORAL TABLET 110 MG	T5	PA-NC; QL (124 EA per 31 days)
REVUFORJ ORAL TABLET 160 MG	T5	PA-NC; QL (62 EA per 31 days)
REVUFORJ ORAL TABLET 25 MG	T5	PA-NC; QL (248 EA per 31 days)
REZLIDHIA	T5	PA-NC; QL (62 EA per 31 days)
ROMVIMZA	T5	PA-NC; QL (8 EA per 28 days)
ROZLYTREK ORAL CAPSULE 100 MG	T5	PA-NC; QL (155 EA per 31 days)
ROZLYTREK ORAL CAPSULE 200 MG	T5	PA-NC; QL (93 EA per 31 days)
ROZLYTREK ORAL PELLETS IN PACKET	T5	PA-NC; QL (372 EA per 31 days)
RUBRACA	T5	PA-NC; QL (124 EA per 31 days)
RYDAPT	T5	PA-NC; QL (248 EA per 31 days)
SCEMBLIX ORAL TABLET 100 MG	T5	PA-NC; QL (124 EA per 31 days)
SCEMBLIX ORAL TABLET 20 MG	T5	PA-NC; QL (62 EA per 31 days)
SCEMBLIX ORAL TABLET 40 MG	T5	PA-NC; QL (248 EA per 31 days)
SIGNIFOR	T5	PA
sirolimus	T4	PA-BvD
SOLTAMOX	T4	
sorafenib	T5	PA-NC; QL (124 EA per 31 days)
STIVARGA	T5	PA-NC; QL (84 EA per 28 days)
sunitinib malate	T5	PA-NC; QL (31 EA per 31 days)
TABLOID	T4	
TABRECTA	T5	PA-NC; QL (124 EA per 31 days)
tacrolimus oral capsule 0.5 mg, 1 mg	T2	PA-BvD
tacrolimus oral capsule 5 mg	T4	PA-BvD
TAFINLAR ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
TAFINLAR ORAL TABLET FOR SUSPENSION	T5	PA-NC; QL (930 EA per 31 days)
TAGRISSO	T5	PA-NC; LA; QL (31 EA per 31 days)
TALZENNA	T5	PA-NC; QL (31 EA per 31 days)
tamoxifen	T1	
TEPMETKO	T5	PA-NC; QL (62 EA per 31 days)
THALOMID ORAL CAPSULE 100 MG	T5	PA-NC; QL (112 EA per 28 days)
THALOMID ORAL CAPSULE 50 MG	T5	PA-NC; QL (28 EA per 28 days)
TIBSOVO	T5	PA-NC; QL (62 EA per 31 days)
toremifene	T5	
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG	T4	QL (1 EA per 84 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG	T4	QL (1 EA per 168 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG	T4	QL (1 EA per 28 days)
tretinoin (antineoplastic)	T5	
TRUQAP	T5	PA-NC; QL (64 EA per 28 days)
TUKYSA ORAL TABLET 150 MG	T5	PA-NC; QL (124 EA per 31 days)
TUKYSA ORAL TABLET 50 MG	T5	PA-NC; QL (248 EA per 31 days)
TURALIO	T5	PA-NC; QL (124 EA per 31 days)
VANFLYTA	T5	PA-NC; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 10 MG	T3	PA-NC; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 100 MG	T5	PA-NC; QL (186 EA per 31 days)
VENCLEXTA ORAL TABLET 50 MG	T5	PA-NC; QL (31 EA per 31 days)
VENCLEXTA STARTING PACK	T5	PA-NC; QL (84 EA per 365 days)
VERZENIO	T5	PA-NC; QL (62 EA per 31 days)
VITRAKVI ORAL CAPSULE 100 MG	T5	PA-NC; QL (62 EA per 31 days)
VITRAKVI ORAL CAPSULE 25 MG	T5	PA-NC; QL (186 EA per 31 days)
VITRAKVI ORAL SOLUTION	T5	PA-NC; QL (310 ML per 31 days)
VONJO	T5	PA-NC; QL (124 EA per 31 days)
VORANIGO ORAL TABLET 10 MG	T5	PA-NC; QL (62 EA per 31 days)
VORANIGO ORAL TABLET 40 MG	T5	PA-NC; QL (31 EA per 31 days)
WELIREG	T5	PA-NC; QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
WYOST	T3	PA-NC
XALKORI ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)
XALKORI ORAL PELLET 150 MG	T5	PA-NC; QL (186 EA per 31 days)
XALKORI ORAL PELLET 20 MG, 50 MG	T5	PA-NC; QL (124 EA per 31 days)
XATMEP	T4	PA-BvD
XERMELO	T5	PA; QL (93 EA per 31 days)
XOSPATA	T5	PA-NC; QL (124 EA per 31 days)
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2)	T5	PA-NC; QL (8 EA per 28 days)
XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4)	T5	PA-NC; QL (16 EA per 28 days)
XPOVIO ORAL TABLET 60 MG/WEEK (60 MG X 1), 80 MG/WEEK (80 MG X 1)	T5	PA-NC; QL (4 EA per 28 days)
XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)	T5	PA-NC; QL (24 EA per 28 days)
XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)	T5	PA-NC; QL (32 EA per 28 days)
XTANDI ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)
XTANDI ORAL TABLET 40 MG	T5	PA-NC; QL (124 EA per 31 days)
XTANDI ORAL TABLET 80 MG	T5	PA-NC; QL (62 EA per 31 days)
XTRENBO	T3	PA-NC
YONSA	T5	PA-NC; QL (124 EA per 31 days)
YULITHIRA	T3	PA-NC; QL (31 EA per 31 days)
ZEJULA	T5	PA-NC; QL (31 EA per 31 days)
ZELBORAF	T5	PA-NC; QL (248 EA per 31 days)
ZENBEXUS	T5	PA-NC; QL (21 EA per 28 days)
ZOLINZA	T5	PA-NC
ZYKADIA	T5	PA-NC; QL (93 EA per 31 days)
Medicamentos Autonómicos/Snc, Neurología/Psico		
ABILIFY MAINTENA	T5	QL (1 EA per 28 days)
acetaminophen-codeine oral solution 120-12 mg/5 ml	T2	PA; QL (5167 ML per 31 days)
acetaminophen-codeine oral tablet	T2	PA; QL (403 EA per 31 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML	T3	PA; QL (1 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML	T3	PA; QL (2 ML per 28 days)
alprazolam oral tablet 0.25 mg, 0.5 mg	T2	PA; QL (93 EA per 31 days)
alprazolam oral tablet 1 mg, 2 mg	T2	PA; QL (155 EA per 31 days)
amitriptyline	T2	PA-NC
amoxapine	T3	
aripiprazole oral solution	T4	PA-NC
aripiprazole oral tablet	T2	
aripiprazole oral tablet,disintegrating	T4	PA-NC
armodafinil	T3	PA; QL (31 EA per 31 days)
asenapine maleate	T4	PA-NC; QL (62 EA per 31 days)
atomoxetine oral capsule 10 mg, 25 mg, 40 mg	T3	QL (62 EA per 31 days)
atomoxetine oral capsule 100 mg, 60 mg, 80 mg	T3	QL (31 EA per 31 days)
atomoxetine oral capsule 18 mg	T3	QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 12 MG, 6 MG	T5	PA; QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 9 MG	T5	PA; QL (155 EA per 31 days)
AUSTEDO XR	T5	PA; QL (31 EA per 31 days)
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG	T5	PA; QL (56 EA per 365 days)
AUVELITY ORAL TABLET, IR AND ER, BIPHASIC	T5	PA-NC; QL (62 EA per 31 days)
baclofen oral tablet 10 mg	T1	
baclofen oral tablet 20 mg	T2	
BAFIERTAM	T5	PA; QL (124 EA per 31 days)
benztropine oral	T2	PA
brivaracetam oral solution	T5	QL (620 ML per 31 days)
brivaracetam oral tablet	T5	QL (62 EA per 31 days)
bromocriptine	T4	
buprenorphine	T4	PA; QL (4 EA per 28 days)
buprenorphine hcl sublingual	T3	
buprenorphine-naloxone sublingual film	T2	
buprenorphine-naloxone sublingual tablet	T4	
bupropion hcl oral tablet	T2	
bupropion hcl oral tablet extended release 24 hr 150 mg	T2	QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
bupropion hcl oral tablet extended release 24 hr 300 mg	T2	QL (31 EA per 31 days)
bupropion hcl oral tablet sustained-release 12 hr	T2	QL (62 EA per 31 days)
buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T2	
butorphanol nasal	T4	QL (5 ML per 28 days)
CAPLYTA	T5	PA-NC; QL (31 EA per 31 days)
carbamazepine oral capsule, er multiphase 12 hr	T3	
carbamazepine oral suspension 100 mg/5 ml	T3	
carbamazepine oral tablet	T2	
carbamazepine oral tablet extended release 12 hr	T3	
carbamazepine oral tablet,chewable 100 mg	T2	
carbidopa-levodopa oral tablet	T2	
carbidopa-levodopa oral tablet extended release	T2	
carbidopa-levodopa oral tablet,disintegrating	T2	
carbidopa-levodopa-entacapone	T4	
celecoxib oral capsule 100 mg, 200 mg, 50 mg	T2	QL (62 EA per 31 days)
celecoxib oral capsule 400 mg	T3	QL (62 EA per 31 days)
chlorpromazine oral	T4	
citalopram oral solution	T3	
citalopram oral tablet	T1	
clobazam oral suspension	T4	PA-NC; QL (496 ML per 31 days)
clobazam oral tablet	T3	PA-NC; QL (62 EA per 31 days)
clomipramine	T4	PA-NC
clonazepam oral tablet 0.5 mg	T2	PA-NC; QL (93 EA per 31 days)
clonazepam oral tablet 1 mg	T2	PA-NC; QL (124 EA per 31 days)
clonazepam oral tablet 2 mg	T2	PA-NC; QL (310 EA per 31 days)
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg	T2	PA-NC; QL (93 EA per 31 days)
clonazepam oral tablet,disintegrating 1 mg	T2	PA-NC; QL (124 EA per 31 days)
clonazepam oral tablet,disintegrating 2 mg	T2	PA-NC; QL (310 EA per 31 days)
clorazepate dipotassium oral tablet 15 mg	T3	PA-NC; QL (186 EA per 31 days)
clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg	T3	PA-NC; QL (93 EA per 31 days)
clozapine oral tablet 100 mg	T3	QL (279 EA per 31 days)
clozapine oral tablet 200 mg	T3	QL (124 EA per 31 days)
clozapine oral tablet 25 mg	T2	QL (279 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
clozapine oral tablet 50 mg	T2	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 100 mg, 25 mg	T4	QL (279 EA per 31 days)
clozapine oral tablet,disintegrating 12.5 mg	T4	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 150 mg	T4	QL (186 EA per 31 days)
clozapine oral tablet,disintegrating 200 mg	T4	QL (124 EA per 31 days)
COBENFY	T5	PA-NC; QL (62 EA per 31 days)
COBENFY STARTER PACK	T5	PA-NC; QL (112 EA per 365 days)
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
cyclobenzaprine oral tablet 10 mg, 5 mg	T4	PA
dalfampridine	T3	PA; QL (62 EA per 31 days)
desipramine	T4	
desvenlafaxine succinate	T3	QL (31 EA per 31 days)
dexmethylphenidate oral tablet 10 mg	T2	QL (62 EA per 31 days)
dexmethylphenidate oral tablet 2.5 mg, 5 mg	T2	QL (93 EA per 31 days)
dextroamphetamine-amphetamine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T1	QL (62 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 12.5 mg	T1	
dextroamphetamine-amphetamine oral tablet 20 mg	T1	QL (93 EA per 31 days)
dextromethorphan-quinidine	T5	PA; QL (62 EA per 31 days)
DIACOMIT ORAL CAPSULE 250 MG	T5	PA-NC; QL (341 EA per 31 days)
DIACOMIT ORAL CAPSULE 500 MG	T5	PA-NC; QL (186 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 250 MG	T5	PA-NC; QL (341 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 500 MG	T5	PA-NC; QL (186 EA per 31 days)
DIAZEPAM INTENSOL	T2	PA-NC; QL (248 ML per 31 days)
diazepam oral solution 5 mg/5 ml (1 mg/ml)	T2	PA-NC; QL (1500 ML per 31 days)
diazepam oral tablet	T2	PA-NC; QL (124 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
diazepam rectal	T4	
diclofenac sodium topical drops	T2	QL (450 ML per 28 days)
dihydroergotamine nasal	T4	PA; QL (8 ML per 28 days)
DILANTIN	T3	
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg	T4	PA; QL (62 EA per 31 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)	T4	PA; QL (120 EA per 365 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 240 mg	T5	PA; QL (62 EA per 31 days)
divalproex oral capsule, delayed rel sprinkle	T2	
divalproex oral tablet extended release 24 hr 250 mg	T2	
divalproex oral tablet extended release 24 hr 500 mg	T3	
divalproex oral tablet,delayed release (dr/ec)	T2	
donepezil oral tablet 10 mg, 5 mg	T1	
donepezil oral tablet,disintegrating	T2	
doxepin oral capsule	T2	PA-NC
doxepin oral concentrate	T2	PA-NC
doxepin oral tablet	T3	PA
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG	T3	PA-NC; QL (93 EA per 31 days)
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 30 MG, 60 MG	T3	PA-NC; QL (62 EA per 31 days)
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG	T3	PA-NC; QL (31 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 20 mg, 60 mg	T2	QL (62 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 30 mg	T2	QL (31 EA per 31 days)
EMGALITY PEN	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3)	T5	PA; QL (3 ML per 28 days)
EMSAM	T5	QL (30 EA per 30 days)
entacapone	T3	
EPIDIOLEX	T5	PA-NC

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ergotamine-caffeine	T3	PA
escitalopram oxalate oral capsule	T4	PA-NC; QL (31 EA per 31 days)
escitalopram oxalate oral solution	T4	QL (620 ML per 31 days)
escitalopram oxalate oral tablet 10 mg	T1	QL (45 EA per 30 days)
escitalopram oxalate oral tablet 20 mg, 5 mg	T1	QL (30 EA per 30 days)
eslicarbazepine oral tablet 200 mg	T4	QL (186 EA per 31 days)
eslicarbazepine oral tablet 400 mg	T4	QL (93 EA per 31 days)
eslicarbazepine oral tablet 600 mg, 800 mg	T5	QL (62 EA per 31 days)
ethosuximide	T3	
EXXUA ORAL TABLET EXTENDED RELEASE 24 HR	T4	PA-NC; QL (31 EA per 31 days)
EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK	T4	PA-NC; QL (64 EA per 365 days)
FANAPT	T5	PA-NC; QL (62 EA per 31 days)
FANAPT TITRATION PACK A	T4	PA-NC; QL (16 EA per 365 days)
FANAPT TITRATION PACK B	T4	PA-NC; QL (24 EA per 365 days)
FANAPT TITRATION PACK C	T4	PA-NC; QL (16 EA per 365 days)
felbamate	T4	
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 75 mcg/hr	T4	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 25 mcg/hr, 50 mcg/hr	T3	PA; QL (10 EA per 30 days)
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)	T4	PA-NC; QL (56 EA per 365 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG	T4	PA-NC; QL (31 EA per 31 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG	T4	PA-NC; QL (93 EA per 31 days)
fingolimod	T5	PA; QL (31 EA per 31 days)
FINTEPLA	T5	PA-NC; QL (360 ML per 30 days)
fluoxetine oral capsule	T1	
fluoxetine oral solution	T3	
fluphenazine decanoate	T3	
fluphenazine hcl injection	T4	
fluphenazine hcl oral concentrate	T4	
fluphenazine hcl oral elixir	T4	
fluphenazine hcl oral tablet 1 mg, 2.5 mg, 5 mg	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
fluphenazine hcl oral tablet 10 mg	T4	
fluvoxamine oral tablet	T2	
gabapentin oral capsule 100 mg, 400 mg	T2	QL (270 EA per 30 days)
gabapentin oral capsule 300 mg	T2	QL (360 EA per 30 days)
gabapentin oral solution 250 mg/5 ml	T4	QL (2160 ML per 30 days)
gabapentin oral tablet 600 mg	T2	QL (180 EA per 30 days)
gabapentin oral tablet 800 mg	T2	QL (120 EA per 30 days)
galantamine oral capsule,ext rel. pellets 24 hr	T3	
galantamine oral solution	T4	
galantamine oral tablet	T3	
glatiramer subcutaneous syringe 20 mg/ml	T5	PA; QL (31 ML per 31 days)
glatiramer subcutaneous syringe 40 mg/ml	T5	PA; QL (12 ML per 28 days)
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
guanfacine oral tablet extended release 24 hr	T2	PA
haloperidol	T2	
haloperidol decanoate	T2	
haloperidol lactate injection	T1	
haloperidol lactate oral	T2	
hydromorphone oral liquid	T4	PA; QL (1240 ML per 31 days)
hydromorphone oral tablet 2 mg, 4 mg	T2	PA; QL (186 EA per 31 days)
hydromorphone oral tablet 8 mg	T3	PA; QL (155 EA per 31 days)
IBU ORAL TABLET 600 MG, 800 MG	T1	
ibuprofen oral tablet 400 mg, 600 mg, 800 mg	T1	
imipramine hcl	T2	PA-NC
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML	T5	QL (3.5 ML per 180 days)
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML	T5	QL (5 ML per 180 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML	T5	QL (0.75 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML	T5	QL (1 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML	T5	QL (1.5 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML	T4	QL (0.25 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML	T5	QL (0.5 ML per 28 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML	T5	QL (0.88 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML	T5	QL (1.32 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML	T5	QL (1.75 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML	T5	QL (2.63 ML per 84 days)
KESIMPTA PEN	T5	PA; QL (0.4 ML per 28 days)
ketorolac oral	T2	
KLOXXADO	T3	
lacosamide oral	T4	
lamotrigine oral tablet	T2	
lamotrigine oral tablet extended release 24hr	T4	
lamotrigine oral tablet, chewable dispersible	T2	
LEQEMBI IQLIK SUBCUTANEOUS AUTO-INJECTOR 360 MG/1.8 ML	T5	PA; QL (7.2 ML per 28 days)
levetiracetam oral solution 100 mg/ml	T2	
levetiracetam oral tablet	T2	
levetiracetam oral tablet extended release 24 hr	T2	
lithium carbonate oral capsule	T1	
lithium carbonate oral tablet	T1	
lithium carbonate oral tablet extended release	T2	
lithium citrate oral solution	T2	
lofexidine	T5	
LORAZEPAM INTENSOL	T2	PA; QL (155 ML per 31 days)
lorazepam oral tablet 0.5 mg	T2	PA; QL (124 EA per 31 days)
lorazepam oral tablet 1 mg	T2	PA; QL (186 EA per 31 days)
lorazepam oral tablet 2 mg	T2	PA; QL (155 EA per 31 days)
loxapine succinate	T2	
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg	T4	PA-NC; QL (31 EA per 31 days)
lurasidone oral tablet 80 mg	T4	PA-NC; QL (62 EA per 31 days)
LYBALVI	T5	PA-NC; QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
MARPLAN	T4	
meloxicam oral tablet	T1	
memantine oral tablet	T2	
memantine-donepezil	T4	PA
methadone oral solution 10 mg/5 ml	T2	PA; QL (620 ML per 31 days)
methadone oral solution 5 mg/5 ml	T2	PA; QL (1240 ML per 31 days)
methadone oral tablet 10 mg	T2	PA; QL (124 EA per 31 days)
methadone oral tablet 5 mg	T2	PA; QL (248 EA per 31 days)
methocarbamol oral tablet 500 mg, 750 mg	T2	
methsuximide	T4	
methylphenidate hcl oral tablet	T2	QL (93 EA per 31 days)
mirtazapine oral tablet 15 mg, 30 mg, 45 mg	T2	
mirtazapine oral tablet 7.5 mg	T3	
mirtazapine oral tablet,disintegrating	T3	
modafinil	T2	PA; QL (31 EA per 31 days)
molindone	T4	
morphine concentrate oral solution	T2	PA; QL (310 ML per 31 days)
morphine oral solution 10 mg/5 ml (2 mg/ml)	T2	PA; QL (2800 ML per 31 days)
morphine oral solution 20 mg/5 ml (4 mg/ml)	T2	PA; QL (1400 ML per 31 days)
morphine oral tablet	T2	PA; QL (186 EA per 31 days)
morphine oral tablet extended release 100 mg	T3	PA; QL (62 EA per 31 days)
morphine oral tablet extended release 15 mg, 30 mg, 60 mg	T3	PA; QL (100 EA per 31 days)
morphine oral tablet extended release 200 mg	T3	PA; QL (31 EA per 31 days)
naloxone injection solution	T2	
naloxone injection syringe	T2	
naltrexone	T2	
naproxen oral tablet	T1	
naproxen sodium oral tablet 550 mg	T2	
naratriptan oral tablet 1 mg	T4	QL (20 EA per 28 days)
naratriptan oral tablet 2.5 mg	T4	QL (9 EA per 28 days)
NAYZILAM	T4	PA-NC; QL (10 EA per 30 days)
nefazodone	T4	
nortriptyline	T2	PA-NC
NUPLAZID	T5	PA-NC; QL (31 EA per 31 days)
NURTEC ODT	T3	PA; QL (18 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
olanzapine intramuscular	T4	
olanzapine oral tablet	T2	QL (31 EA per 31 days)
olanzapine oral tablet,disintegrating	T4	QL (31 EA per 31 days)
OPIPZA	T5	PA-NC
oxcarbazepine oral suspension	T4	
oxcarbazepine oral tablet	T2	
oxycodone oral concentrate	T4	PA; QL (180 ML per 31 days)
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg	T3	PA; QL (186 EA per 31 days)
oxycodone oral tablet 30 mg	T3	PA; QL (138 EA per 31 days)
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg	T3	PA; QL (372 EA per 31 days)
oxycodone-acetaminophen oral tablet 5-325 mg, 7.5-325 mg	T2	PA; QL (372 EA per 31 days)
paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg	T4	QL (31 EA per 31 days)
paliperidone oral tablet extended release 24hr 6 mg	T4	QL (62 EA per 31 days)
paroxetine hcl oral suspension	T4	PA-NC
paroxetine hcl oral tablet	T1	PA-NC
perampanel oral suspension	T5	QL (744 ML per 31 days)
perampanel oral tablet	T4	QL (31 EA per 31 days)
perphenazine	T4	
phenelzine	T2	
phenobarbital	T2	
PHENYTEK	T3	
phenytoin oral suspension 125 mg/5 ml	T2	
phenytoin oral tablet,chewable	T2	
phenytoin sodium extended oral capsule 100 mg	T2	
pimozide	T4	
pramipexole oral tablet	T2	
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg	T2	PA-NC; QL (93 EA per 31 days)
pregabalin oral capsule 225 mg, 300 mg	T2	PA-NC; QL (62 EA per 31 days)
pregabalin oral solution	T2	PA-NC; QL (930 ML per 31 days)
primidone oral tablet 125 mg	T3	
primidone oral tablet 250 mg, 50 mg	T2	
protriptyline	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
pyridostigmine bromide oral tablet 60 mg	T3	
pyridostigmine bromide oral tablet extended release 180 mg	T4	
quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg	T2	QL (62 EA per 31 days)
quetiapine oral tablet 150 mg	T3	QL (62 EA per 31 days)
quetiapine oral tablet 25 mg	T1	QL (62 EA per 31 days)
quetiapine oral tablet extended release 24 hr	T3	QL (62 EA per 31 days)
QULIPTA	T3	PA; QL (31 EA per 31 days)
RALDESY	T5	
ramelteon	T4	QL (31 EA per 31 days)
rasagiline	T4	
RELGAABI ORAL CAPSULE 300 MG	T2	QL (360 EA per 30 days)
RELGAABI ORAL CAPSULE 400 MG	T2	QL (270 EA per 30 days)
REXULTI ORAL TABLET	T5	PA-NC; QL (31 EA per 31 days)
REZENOPY	T3	
risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml	T4	QL (2 EA per 28 days)
risperidone microspheres intramuscular suspension,extended rel recon 25 mg/2 ml, 37.5 mg/2 ml, 50 mg/2 ml	T5	QL (2 EA per 28 days)
risperidone oral solution	T2	QL (496 ML per 31 days)
risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg	T2	QL (31 EA per 31 days)
risperidone oral tablet 3 mg	T2	QL (93 EA per 31 days)
risperidone oral tablet 4 mg	T2	QL (124 EA per 31 days)
risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg	T4	QL (31 EA per 31 days)
risperidone oral tablet,disintegrating 3 mg	T4	QL (93 EA per 31 days)
risperidone oral tablet,disintegrating 4 mg	T4	QL (124 EA per 31 days)
rivastigmine	T4	QL (30 EA per 30 days)
rivastigmine tartrate	T3	
rizatriptan oral tablet 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet 5 mg	T2	QL (24 EA per 28 days)
rizatriptan oral tablet,disintegrating 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet,disintegrating 5 mg	T2	QL (24 EA per 28 days)
ropinirole oral tablet	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ROWEEPRA	T2	
rufinamide oral suspension	T5	PA-NC
rufinamide oral tablet 200 mg	T4	PA-NC
rufinamide oral tablet 400 mg	T5	PA-NC
RYTARY	T3	ST
SECUADO	T5	PA-NC; QL (31 EA per 31 days)
selegiline hcl	T2	
sertraline oral concentrate	T2	
sertraline oral tablet	T1	
sodium oxybate	T5	PA; QL (540 ML per 30 days)
SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG	T4	
SUBVENITE ORAL SUSPENSION	T5	
SUBVENITE ORAL TABLET	T2	
sumatriptan nasal spray,non-aerosol 20 mg/actuation	T4	QL (8 EA per 28 days)
sumatriptan nasal spray,non-aerosol 5 mg/actuation	T4	QL (32 EA per 28 days)
sumatriptan succinate oral tablet 100 mg	T2	QL (9 EA per 28 days)
sumatriptan succinate oral tablet 25 mg	T2	QL (36 EA per 28 days)
sumatriptan succinate oral tablet 50 mg	T2	QL (18 EA per 28 days)
sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous solution	T4	QL (4 ML per 28 days)
SYMPAZAN ORAL FILM 10 MG, 20 MG	T5	PA-NC; QL (62 EA per 31 days)
SYMPAZAN ORAL FILM 5 MG	T4	PA-NC; QL (62 EA per 31 days)
TASCENSO ODT	T5	PA; QL (31 EA per 31 days)
tasimelteon	T5	PA; QL (31 EA per 31 days)
teriflunomide	T5	PA; QL (31 EA per 31 days)
tetrabenazine oral tablet 12.5 mg	T4	PA; QL (93 EA per 31 days)
tetrabenazine oral tablet 25 mg	T5	PA; QL (124 EA per 31 days)
thioridazine	T2	
thiothixene oral capsule 1 mg	T2	
thiothixene oral capsule 10 mg, 2 mg, 5 mg	T3	
tiagabine	T4	
tizanidine oral tablet	T2	
topiramate oral capsule, sprinkle 15 mg, 25 mg	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
topiramate oral solution	T4	PA-NC; QL (496 ML per 31 days)
topiramate oral tablet	T2	
tramadol oral tablet 50 mg	T1	PA; QL (240 EA per 30 days)
tranylcypromine	T4	
trazodone oral tablet 100 mg, 150 mg, 50 mg	T1	
trifluoperazine	T2	
trimipramine	T4	
TRINTELLIX	T4	PA-NC
valproic acid	T2	
valproic acid (as sodium salt) oral solution 250 mg/5 ml	T2	
VALTOCO	T5	PA-NC; QL (10 EA per 30 days)
venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg	T2	QL (31 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 75 mg	T2	QL (93 EA per 31 days)
venlafaxine oral tablet	T2	
VERSACLOZ	T5	QL (558 ML per 31 days)
vigabatrin	T5	PA-NC
VIGADRONE	T5	PA-NC
vilazodone	T3	PA-NC; QL (31 EA per 31 days)
VIVITROL	T5	
VRAYLAR	T3	PA-NC; QL (31 EA per 31 days)
VUMERITY	T5	PA; QL (124 EA per 31 days)
XCOPRI	T5	PA-NC
XCOPRI MAINTENANCE PACK	T5	PA-NC
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)	T4	PA-NC
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)	T5	PA-NC
ZEPOSIA	T5	PA; QL (31 EA per 31 days)
ZEPOSIA STARTER KIT (28-DAY)	T5	PA; QL (56 EA per 365 days)
ZEPOSIA STARTER PACK (7-DAY)	T5	PA; QL (14 EA per 365 days)
ziprasidone hcl	T3	QL (62 EA per 31 days)
ziprasidone mesylate	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
zolpidem oral tablet	T2	PA; QL (31 EA per 31 days)
ZONISADE	T5	PA-NC; QL (930 ML per 31 days)
zonisamide	T2	
ZTALMY	T5	PA-NC; QL (1100 ML per 30 days)
ZUBSOLV	T3	
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG	T5	PA-NC; QL (28 EA per 180 days)
ZURZUVAE ORAL CAPSULE 30 MG	T5	PA-NC; QL (14 EA per 180 days)
Medicamentos Para Oídos, Nariz Y Garganta		
acetic acid otic (ear)	T2	
azelastine nasal spray,non-aerosol 137 mcg (0.1 %)	T2	QL (30 ML per 25 days)
chlorhexidine gluconate mucous membrane	T1	
ciprofloxacin-dexamethasone	T4	
fluocinolone acetonide oil	T2	
ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)	T1	QL (30 ML per 28 days)
ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)	T1	QL (15 ML per 28 days)
KOURZEQ	T2	
neomycin-polymyxin-hc otic (ear)	T3	
ofloxacin otic (ear)	T2	
olopatadine nasal	T3	QL (30.5 GM per 30 days)
PERIOGARD	T1	
triamcinolone acetonide dental	T2	
Musculoesquelético / Reumatología		
ACTEMRA ACTPEN	T5	PA; QL (3.6 ML per 28 days)
ACTEMRA SUBCUTANEOUS	T5	PA; QL (3.6 ML per 28 days)
alendronate oral tablet 10 mg, 35 mg, 70 mg	T1	
allopurinol oral tablet 100 mg, 300 mg	T1	
BENLYSTA SUBCUTANEOUS	T5	PA; QL (4 ML per 28 days)
BILDYOS	T3	PA; QL (1 ML per 180 days)
colchicine oral tablet	T2	QL (62 EA per 31 days)
ENBREL MINI	T5	PA; QL (8 ML per 28 days)
ENBREL SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)	T5	PA; QL (8 ML per 28 days)
ENBREL SURECLICK	T5	PA; QL (8 ML per 28 days)
ENOBY	T3	PA; QL (1 ML per 180 days)
HADLIMA	T5	PA; QL (3.2 ML per 28 days)
HADLIMA PUSHTOUCH	T5	PA; QL (3.2 ML per 28 days)
HADLIMA(CF)	T5	PA; QL (1.6 ML per 28 days)
HADLIMA(CF) PUSHTOUCH	T5	PA; QL (1.6 ML per 28 days)
ibandronate oral	T2	
JUBBONTI	T3	PA; QL (1 ML per 180 days)
KINERET	T5	PA; QL (18.76 ML per 28 days)
leflunomide	T3	
ORENCIA CLICKJECT	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML	T5	PA; QL (1.6 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML	T5	PA; QL (2.8 ML per 28 days)
OTEZLA	T5	PA; QL (62 EA per 31 days)
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47)	T5	PA; QL (110 EA per 365 days)
OTEZLA XR	T5	PA; QL (30 EA per 30 days)
OTEZLA XR INITIATION	T5	PA; QL (82 EA per 365 days)
penicillamine oral tablet	T5	
probenecid	T2	
probenecid-colchicine	T2	
raloxifene	T3	
RINVOQ LQ	T5	PA; QL (372 ML per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG	T5	PA; QL (31 EA per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG	T5	PA; QL (168 EA per 365 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML	T5	PA; QL (4 EA per 28 days)
SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 80 MG/0.8 ML	T5	PA; QL (2 EA per 28 days)
SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML	T5	PA; QL (2 EA per 28 days)
SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML	T5	PA; QL (4 EA per 28 days)
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)	T5	PA; QL (2.48 ML per 28 days)
tofacitinib oral solution	T5	PA; QL (310 ML per 31 days)
tofacitinib oral tablet	T3	PA; QL (62 EA per 31 days)
tofacitinib oral tablet extended release 24 hr 11 mg	T3	PA; QL (31 EA per 31 days)
tofacitinib oral tablet extended release 24 hr 22 mg	T5	PA; QL (31 EA per 31 days)
TYMLOS	T5	PA; QL (1.56 ML per 30 days)
Obstetricia / Ginecología		
ABIGALE	T2	
ALTAVERA (28)	T2	
ALYACEN 1/35 (28)	T2	
APRI	T2	
AVIANE	T2	
CAMILA	T2	
clindamycin phosphate vaginal	T2	
CRYSELLE (28)	T2	
CYRED EQ	T2	
DEPO-SUBQ PROVERA 104	T3	
drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4)	T2	
drospirenone-ethinyl estradiol	T2	
ERRIN	T2	
ESTARYLLA	T2	
estradiol oral tablet 0.5 mg	T1	
estradiol oral tablet 1 mg, 2 mg	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
estradiol transdermal patch weekly 0.025 mg/24 hr	T3	
estradiol transdermal patch weekly 0.05 mg/24 hr, 0.075 mg/24 hr	T2	
estradiol vaginal cream	T2	
estradiol vaginal tablet	T4	
estradiol-norethindrone acet	T2	
etonogestrel-ethinyl estradiol	T3	
GALLIFREY	T2	
HEATHER	T2	
IMVEXXY MAINTENANCE PACK	T3	
IMVEXXY STARTER PACK	T3	
INCASSIA	T2	
ISIBLOOM	T2	
JINTELI	T4	
JUNEL 1.5/30 (21)	T2	
JUNEL 1/20 (21)	T2	
JUNEL FE 1.5/30 (28)	T2	
JUNEL FE 1/20 (28)	T2	
JUNEL FE 24	T2	
KARIVA (28)	T2	
KURVELO (28)	T2	
l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)	T2	
LESSINA	T2	
levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg	T2	
levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month	T2	
levonorg-eth estrad triphasic	T2	
LILETTA	T3	
LYLEQ	T2	
LYZA	T2	
medroxyprogesterone	T2	
metronidazole vaginal gel 0.75 % (37.5mg/5 gram)	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
MICONAZOLE-3 VAGINAL SUPPOSITORY	T2	
MICROGESTIN 1.5/30 (21)	T2	
MICROGESTIN 1/20 (21)	T2	
MICROGESTIN FE 1.5/30 (28)	T2	
MICROGESTIN FE 1/20 (28)	T2	
MILI	T2	
NEXPLANON	T3	
norethindrone (contraceptive)	T2	
norethindrone acetate	T2	
norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg	T3	
norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg	T2	
norethindrone-e.estradiol-iron oral tablet,chewable	T2	
norgestimate-ethinyl estradiol	T2	
NORTREL 7/7/7 (28)	T2	
NYLIA 1/35 (28)	T2	
NYLIA 7/7/7 (28)	T2	
PREMARIN VAGINAL	T3	
SETLAKIN	T2	
SPRINTEC (28)	T2	
terconazole	T2	
tranexamic acid oral	T3	
TRI-LO-SPRINTEC	T2	
TRI-MILI	T2	
TRI-SPRINTEC (28)	T2	
VESTURA (28)	T2	
VIENVA	T2	
YUVAFEM	T4	
ZAFEMY	T3	
Oftalmología		
acetazolamide	T3	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 %	T3	
apraclonidine	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
azelastine ophthalmic (eye)	T2	
bacitracin-polymyxin b	T2	
BESIVANCE	T4	
betaxolol ophthalmic (eye)	T2	
bimatoprost ophthalmic (eye) drops 0.03 %	T2	
brimonidine ophthalmic (eye) drops 0.1 %	T3	
brimonidine ophthalmic (eye) drops 0.15 %	T4	
brimonidine ophthalmic (eye) drops 0.2 %	T2	
brimonidine-timolol	T3	
brinzolamide	T4	
carteolol	T2	
ciprofloxacin hcl ophthalmic (eye)	T1	
COMBIGAN	T3	
cromolyn ophthalmic (eye)	T2	
cyclosporine ophthalmic (eye)	T3	QL (60 EA per 30 days)
CYSTARAN	T5	PA; QL (60 ML per 28 days)
dexamethasone sodium phosphate ophthalmic (eye)	T2	
diclofenac sodium ophthalmic (eye)	T1	
difluprednate	T4	
dorzolamide	T2	
dorzolamide-timolol	T2	
erythromycin ophthalmic (eye)	T2	
fluorometholone	T3	
flurbiprofen sodium	T2	
gatifloxacin	T3	
gentamicin ophthalmic (eye) drops	T1	
ketorolac ophthalmic (eye) drops 0.4 %	T3	
ketorolac ophthalmic (eye) drops 0.5 %	T2	
latanoprost	T1	
levobunolol ophthalmic (eye) drops 0.5 %	T1	
LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %	T3	QL (5 ML per 31 days)
methazolamide	T4	
MIEBO (PF)	T4	
moxifloxacin ophthalmic (eye) drops	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
neomycin-bacitracin-poly-hc	T3	
neomycin-bacitracin-polymyxin	T2	
neomycin-polymyxin b-dexameth	T2	
neomycin-polymyxin-gramicidin	T2	
neomycin-polymyxin-hc ophthalmic (eye)	T3	
ofloxacin ophthalmic (eye)	T2	
pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %	T3	
polymyxin b sulf-trimethoprim	T1	
prednisolone acetate	T1	
prednisolone sodium phosphate ophthalmic (eye)	T2	
RESTASIS	T3	QL (60 EA per 30 days)
RESTASIS MULTIDOSE	T3	QL (5.5 ML per 27 days)
RHOPRESSA	T4	ST
ROCKLATAN	T4	ST
SIMBRINZA	T4	
sulfacetamide sodium ophthalmic (eye) drops	T2	
sulfacetamide-prednisolone	T2	
timolol maleate ophthalmic (eye) drops	T1	
timolol maleate ophthalmic (eye) gel forming solution	T3	
tobramycin ophthalmic (eye)	T1	
tobramycin-dexamethasone	T3	
travoprost	T3	
trifluridine	T3	
XDEMVY	T5	PA; QL (10 ML per 42 days)
XIIDRA	T3	QL (60 EA per 30 days)
ZIRGAN	T4	ST
Respiratorio Y Alergia		
acetylcysteine	T2	PA-BvD
ADEMPAS	T5	PA; QL (93 EA per 31 days)
ADVAIR HFA	T3	QL (12 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation	T3	QL (17 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)	T3	QL (13.4 GM per 30 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml	T2	PA-BvD
albuterol sulfate oral syrup	T1	
ambrisentan	T5	PA; QL (31 EA per 31 days)
ANORO ELLIPTA	T3	QL (60 EA per 30 days)
ASMANEX HFA	T3	QL (13 GM per 30 days)
ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)	T3	QL (1 EA per 30 days)
azelastine-fluticasone	T4	QL (23 GM per 30 days)
BREO ELLIPTA	T3	QL (60 EA per 30 days)
BREZTRI AEROSPHERE	T3	QL (10.7 GM per 30 days)
BRINSUPRI	T5	PA; QL (31 EA per 31 days)
budesonide inhalation	T4	PA-BvD
budesonide-formoterol	T3	QL (10.2 GM per 30 days)
cetirizine oral solution 1 mg/ml	T1	
CINRYZE	T5	PA; QL (20 EA per 28 days)
COMBIVENT RESPIMAT	T3	QL (4 GM per 30 days)
cromolyn inhalation	T4	PA-BvD
cyproheptadine oral tablet	T2	PA
desloratadine oral tablet	T1	QL (31 EA per 31 days)
DULERA	T3	QL (13 GM per 30 days)
epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml	T3	
FASENRA PEN	T5	PA; QL (1 ML per 28 days)
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML	T5	PA; QL (0.5 ML per 56 days)
FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML	T5	PA; QL (1 ML per 28 days)
fluticasone furoate-vilanterol	T3	QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 100 mcg/actuation, 50 mcg/actuation	T4	ST; QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 250 mcg/actuation	T4	ST; QL (240 EA per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation	T4	ST; QL (12 GM per 30 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation	T4	ST; QL (24 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation	T4	ST; QL (10.6 GM per 30 days)
fluticasone propionate nasal	T1	QL (16 GM per 30 days)
hydroxyzine hcl oral tablet	T4	PA
icatibant	T5	PA; QL (18 ML per 30 days)
ipratropium bromide inhalation hfa aerosol inhaler	T4	QL (25.8 GM per 30 days)
ipratropium bromide inhalation solution	T2	PA-BvD
ipratropium-albuterol	T2	PA-BvD
JASCAYD	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 5.8 MG, 50 MG, 75 MG	T5	PA; QL (56 EA per 28 days)
KALYDECO ORAL GRANULES IN PACKET 25 MG	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL TABLET	T5	PA; QL (62 EA per 31 days)
levalbuterol hcl inhalation solution for nebulization 1.25 mg/3 ml	T3	PA-BvD
levalbuterol tartrate	T3	QL (30 GM per 30 days)
levocetirizine oral solution	T4	QL (310 ML per 31 days)
levocetirizine oral tablet	T1	QL (31 EA per 31 days)
montelukast oral tablet	T1	QL (31 EA per 31 days)
montelukast oral tablet,chewable	T1	QL (31 EA per 31 days)
nintedanib	T5	PA; QL (62 EA per 31 days)
NUCALA SUBCUTANEOUS AUTO-INJECTOR	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS RECON SOLN	T5	PA; QL (3 EA per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.4 ML per 28 days)
OFEV	T5	PA; QL (62 EA per 31 days)
OPSUMIT	T5	PA; QL (31 EA per 31 days)
OPSYNVI	T5	PA; QL (31 EA per 31 days)
ORKAMBI ORAL GRANULES IN PACKET	T5	PA; QL (62 EA per 31 days)
ORKAMBI ORAL TABLET	T5	PA; QL (124 EA per 31 days)
pirfenidone oral capsule	T5	PA; QL (279 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
pirfenidone oral tablet	T5	PA; QL (93 EA per 31 days)
promethazine oral tablet	T4	PA
PULMOZYME	T5	PA
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION	T3	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION	T3	QL (21.2 GM per 30 days)
roflumilast	T4	QL (31 EA per 31 days)
SAJAZIR	T5	PA; QL (18 ML per 30 days)
SEREVENT DISKUS	T3	QL (60 EA per 30 days)
sildenafil (pulm.hypertension) oral tablet	T3	PA; QL (372 EA per 31 days)
SPIRIVA RESPIMAT	T3	QL (4 GM per 30 days)
STIOLTO RESPIMAT	T3	QL (4 GM per 30 days)
STRIVERDI RESPIMAT	T4	QL (4 GM per 30 days)
tadalafil (pulm. hypertension)	T4	PA; QL (62 EA per 31 days)
terbutaline oral	T4	
TEZSPIRE SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1.91 ML per 28 days)
THEO-24	T3	
theophylline oral solution	T2	
theophylline oral tablet extended release 12 hr	T2	
theophylline oral tablet extended release 24 hr	T2	
TRELEGY ELLIPTA	T3	QL (60 EA per 30 days)
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)
TRIKAFTA ORAL TABLETS, SEQUENTIAL	T5	PA; QL (84 EA per 28 days)
VENTOLIN HFA	T3	QL (36 GM per 30 days)
WINREVAIR	T5	PA
XOLAIR	T5	PA
zafirlukast	T2	
Suministros Variados		
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"	T4	
GAUZE PAD TOPICAL BANDAGE 2 X 2 "	T2	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge	T3	
pen needle, diabetic needle 29 gauge x 1/2"	T4	
Urológicos		
alfuzosin	T2	QL (31 EA per 31 days)
bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg	T2	
bethanechol chloride oral tablet 50 mg	T3	
CYSTAGON	T4	
dutasteride	T2	QL (31 EA per 31 days)
ELMIRON	T5	
finasteride oral tablet 5 mg	T2	
GEMTESA	T4	QL (31 EA per 31 days)
MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON	T3	QL (300 ML per 30 days)
MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR	T3	QL (31 EA per 31 days)
oxybutynin chloride oral syrup	T2	
oxybutynin chloride oral tablet	T2	
oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg	T2	QL (31 EA per 31 days)
oxybutynin chloride oral tablet extended release 24hr 15 mg	T3	QL (62 EA per 31 days)
potassium citrate oral tablet extended release	T3	
RIVFLOZA SUBCUTANEOUS SOLUTION	T5	PA; QL (1 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML	T5	PA; QL (0.8 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 160 MG/ML	T5	PA; QL (1 ML per 28 days)
solifenacin	T4	QL (31 EA per 31 days)
tadalafil oral tablet 2.5 mg	T4	PA; QL (62 EA per 31 days)
tadalafil oral tablet 5 mg	T4	PA; QL (31 EA per 31 days)
tamsulosin	T1	
tolterodine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
tolterodine oral tablet	T3	QL (62 EA per 31 days)
trospium oral tablet	T2	QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
Vitaminas, Hematinicos / Electrolitos		
calcium acetate(phosphat bind)	T2	PA-BvD
CLINIMIX 5%/D15W SULFITE FREE	T4	PA-BvD
CLINIMIX 4.25%/D10W SULF FREE	T4	PA-BvD
CLINIMIX 5%-D20W(SULFITE-FREE)	T4	PA-BvD
fluoride (sodium) oral tablet	T2	
INTRALIPID INTRAVENOUS EMULSION 20 %	T4	PA-BvD
ISOLYTE S PH 7.4	T3	PA-BvD
ISOLYTE-P IN 5 % DEXTROSE	T4	PA-BvD
KLOR-CON	T4	
KLOR-CON 10	T2	
KLOR-CON 8	T2	
KLOR-CON M10	T2	
KLOR-CON M15	T2	
KLOR-CON M20	T1	
magnesium sulfate injection	T2	
PLENAMINE	T4	PA-BvD
potassium chlorid-d5-0.45%nacl intravenous parenteral solution 10 meq/l, 20 meq/l, 40 meq/l	T2	
potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l	T2	
potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml	T2	
potassium chloride intravenous	T2	
potassium chloride oral capsule, extended release 10 meq	T1	
potassium chloride oral capsule, extended release 8 meq	T2	
potassium chloride oral liquid	T2	
potassium chloride oral tablet extended release 10 meq, 20 meq	T1	
potassium chloride oral tablet extended release 8 meq	T2	
potassium chloride oral tablet,er particles/crystals 10 meq, 20 meq	T1	
potassium chloride oral tablet,er particles/crystals 15 meq	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
potassium chloride-0.45 % nacl	T2	
PRENATAL VITAMIN PLUS LOW IRON	T2	PA
PROSOL 20 %	T4	PA-BvD
sodium chloride 0.45 % intravenous	T2	
sodium chloride 3 % hypertonic	T2	
sodium chloride 5 % hypertonic	T2	
TRAVASOL 10 %	T4	PA-BvD
TROPHAMINE 10 %	T4	PA-BvD

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Índice de drogas

abacavir 3
abacavir-lamivudine 3
ABIGALE 54
ABILIFY MAINTENA 39
abiraterone 31
ABIRTEGA 31
ABRYSVO (PF) 28
acamprosate 20
acarbose 22
acebutolol 11
acetaminophen-codeine 39
acetazolamide 56
acetic acid 52
acetylcysteine 58
acitretin 16
ACTEMRA 52
ACTEMRA ACTPEN 52
ACTHIB (PF) 28
ACTIMMUNE 28
acyclovir 3, 16
acyclovir sodium 3
ADACEL(TDAP ADOLESN/ADULT)(PF) 29
adefovir 3
ADEMPAS 58
ADVAIR HFA 58
AIMOVIG AUTOINJECTOR 39, 40
AKEEGA 31
ALA-CORT 16
albendazole 3
albuterol sulfate 58, 59
alclometasone 16
ALCOHOL PADS 22
ALECENSA 31
alendronate 52
alfuzosin 62
aliskiren 11
allopurinol 52
alosetron 26
ALPHAGAN P 56
alprazolam 40
ALTAVERA (28) 54
ALUNBRIG 31
ALYACEN 1/35 (28) 54
amantadine hcl 3
ambrisentan 59
amikacin 3
amiloride 11
amiloride-hydrochlorothiazide 11
amiodarone 11
amitriptyline 40
amlodipine 11
amlodipine-benazepril 11
amlodipine-olmesartan 11
amlodipine-valsartan 11
ammonium lactate 16
AMNESTEEM 16
amoxapine 40
amoxicillin 3
amoxicillin-pot clavulanate 4
amphotericin b 4
amphotericin b liposome 4
ampicillin 4
ampicillin sodium 4
ampicillin-sulbactam 4
anagrelide 20
anastrozole 31
ANORO ELLIPTA 59
ANZUPGO 16
apraclonidine 56
aprepitant 26
APRI 54
APTIVUS 4
AREXVY (PF) 29
ARIKAYCE 4
aripiprazole 40
armodafinil 40
asenapine maleate 40
ASMANEX HFA 59
ASMANEX TWISTHALER 59
aspirin-dipyridamole 11
ASSURE ID INSULIN SAFETY 61
atazanavir 4
atenolol 11
atenolol-chlorthalidone 11
atomoxetine 40
atorvastatin 11
atovaquone 4
atovaquone-proguanil 4
AUGTYRO 31
AUSTEDO 40
AUSTEDO XR 40
AUSTEDO XR TITRATION KT(WK1-4) 40
AUVELITY 40
AVIANE 54
AVMAPKI-FAKZYNJA 31
AVONEX 29
AYVAKIT 31
azathioprine 31
azelastine 52, 57
azelastine-fluticasone 59
azithromycin 4
aztreonam 4
bacitracin-polymyxin b 57
baclofen 40
BAFIERTAM 40
balsalazide 26
BALVERSA 31
bcg vaccine, live (pf) 29
benazepril 11
benazepril-hydrochlorothiazide 11
BENLYSTA 52
benztropine 40
BESIVANCE 57
BESREMI 29
BESREMI PEN 29
betaine 26
betamethasone dipropionate 16, 17
betamethasone valerate 17
betamethasone, augmented 17
BETASERON 29
betaxolol 57
bethanechol chloride 62
bexarotene 31
BEXSERO 29
bicalutamide 31
BICILLIN C-R 4
BICILLIN L-A 4
BIKTARVY 4
BILDYOS 52
BILPREVDA 31
bimatoprost 57
bismuth subcit k-metronidz-tcn 26
bisoprolol fumarate 11
bisoprolol-hydrochlorothiazide 11
BLUJEPA 4
BOOSTRIX TDAP 29
BOSULIF 31
bosutinib 31
BRAFTOVI 31
BREO ELLIPTA 59
BREZTRI AEROSPHERE 59
brimonidine 57
brimonidine-timolol 57
BRINSUPRI 59
brinzolamide 57
brivaracetam 40
bromocriptine 40
BRUKINSA 31
budesonide 26, 59

budesonide-formoterol 59
bumetanide 11
buprenorphine 40
buprenorphine hcl 40
buprenorphine-naloxone 40
bupropion hcl 40, 41
bupropion hcl (smoking deter) 20
buspirone 41
butorphanol 41
cabergoline 22
CABOMETYX 31
calcipotriene 17
calcitonin (salmon) 22
calcitriol 22
calcium acetate(phosphat bind) 63
CALQUENCE (ACALABRUTINIB MAL) 31
CAMILA 54
candesartan 11
candesartan-hydrochlorothiazid 11
CAPLYTA 41
CAPRELSA 31
captopril 11
carbamazepine 41
carbidopa-levodopa 41
carbidopa-levodopa-entacapone 41
carglumic acid 20
carteolol 57
CARTIA XT 11
carvedilol 11
caspofungin 4
CAYSTON 4
cefaclor 4
cefadroxil 4
cefazolin 4
cefdinir 4
cefepime 4
cefixime 5
cefoxitin 5
cefpodoxime 5
cefprozil 5
ceftaroline fosamil 5
ceftazidime 5
ceftriaxone 5
cefuroxime axetil 5
cefuroxime sodium 5
celecoxib 41
cephalexin 5
cetirizine 59
CHEMET 20
chlorhexidine gluconate 52
chloroquine phosphate 5
chlorpromazine 41
chlorthalidone 11
cholestyramine (with sugar) 11
CHOLESTYRAMINE LIGHT 11
ciclopirox 17
cilostazol 12
CIMDUO 5
cinacalcet 22
CINRYZE 59
ciprofloxacin hcl 5, 57
ciprofloxacin in 5 % dextrose 5
ciprofloxacin-dexamethasone 52
citalopram 41
CLARAVIS 17
clarithromycin 5
clindamycin hcl 5
clindamycin in 5 % dextrose 5
CLINDAMYCIN PEDIATRIC 5
clindamycin phosphate 5, 17, 54
clindamycin-benzoyl peroxide 17
CLINIMIX 5%/D15W SULFITE FREE 63
CLINIMIX 4.25%/D10W SULF FREE 63
CLINIMIX 4.25%/D5W SULFIT FREE 20
CLINIMIX 5%-D20W(SULFITE-FREE) 63
clobazam 41
clomipramine 41
clonazepam 41
clonidine 12
clonidine hcl 12
clopidogrel 12
clorazepate dipotassium 41
clotrimazole 5, 17
clotrimazole-betamethasone 17
clozapine 41, 42
COARTEM 5
COBENFY 42
COBENFY STARTER PACK 42
colchicine 52
colesevelam 12
colestipol 12
colistin (colistimethate na) 5
COMBIGAN 57
COMBIVENT RESPIMAT 59
COMETRIQ 32
COMPRO 26
CONSTULOSE 26
COPAXONE 42
COPIKTRA 32
COSENTYX 17
COSENTYX (2 SYRINGES) 17
COSENTYX PEN (2 PENS) 17
COSENTYX UNOREADY PEN 17
COTELLIC 32
CREON 26
CRESEMBA 5
cromolyn 26, 57, 59
CRYSELLE (28) 54
cyclobenzaprine 42
cyclophosphamide 32
cyclosporine 32, 57
cyclosporine modified 32
cyproheptadine 59
CYRED EQ 54
CYSTAGON 62
CYSTARAN 57
d10 %-0.45 % sodium chloride 20
d2.5 %-0.45 % sodium chloride 20
d5 % and 0.9 % sodium chloride 20
d5 %-0.45 % sodium chloride 20
dabigatran etexilate 12
dalfampridine 42
danazol 22
DANZITEN 32
dapagliflozin 22
dapsone 5
DAPTACEL (DTAP PEDIATRIC) (PF) 29
daptomycin 5
darunavir 5
dasatinib 32
DAURISMO 32
deferasirox 20
DELSTRIGO 5
DEPO-SUBQ PROVERA 104 54
DESCOVY 5
desipramine 42
desloratadine 59
desmopressin 22
desoximetasone 17
desvenlafaxine succinate 42
dexamethasone 22
dexamethasone sodium phosphate 57
dexmethylphenidate 42
dextroamphetamine-amphetamine 42

dextromethorphan-quinidine 42
dextrose 10 % in water (d10w) ... 20
dextrose 5 % in water (d5w) 20
DIACOMIT 42
diazepam 42, 43
DIAZEPAM INTENSOL 42
diazoxide 22
diclofenac sodium 43, 57
dicloxacillin 6
dicyclomine 27
difluprednate 57
digoxin 12
dihydroergotamine 43
DILANTIN 43
diltiazem hcl 12
DILT-XR 12
dimethyl fumarate 43
diphenoxylate-atropine 27
disulfiram 20
divalproex 43
dofetilide 12
donepezil 43
dorzolamide 57
dorzolamide-timolol 57
DOVATO 6
doxazosin 12
doxepin 43
doxercalciferol 22
doxycycline hyclate 6
doxycycline monohydrate 6
DRIZALMA SPRINKLE 43
dronabinol 27
drospirenone-e.estradiol-lm.fa ... 54
drospirenone-ethinyl estradiol 54
droxidopa 20
DULERA 59
duloxetine 43
DUPIXENT PEN 17
DUPIXENT SYRINGE 17
dutasteride 62
DUVYZAT 20
EDURANT PED 6
efavirenz 6
efavirenz-emtricitabin-tenofov 6
efavirenz-lamivu-tenofov disop 6
ELIGARD 32
ELIGARD (3 MONTH) 32
ELIGARD (4 MONTH) 32
ELIGARD (6 MONTH) 32
ELIQUIS 12
ELIQUIS DVT-PE TREAT 30D START 12
ELIQUIS SPRINKLE 12
ELMIRON 62
eltrombopag olamine 12, 13
EMGALITY PEN 43
EMGALITY SYRINGE 43
EMSAM 43
emtricitabine 6
emtricitabine-tenofovir (tdf) 6
emtricita-rilpivirine-tenof df 6
EMTRIVA 6
enalapril maleate 13
enalapril-hydrochlorothiazide 13
ENBREL 52, 53
ENBREL MINI 52
ENBREL SURECLICK 53
ENGERIX-B (PF) 29
ENGERIX-B PEDIATRIC (PF) 29
ENOBY 53
enoxaparin 13
ENSACOVE 32
entacapone 43
entecavir 6
ENTRESTO SPRINKLE 13
ENTYVIO PEN 27
ENULOSE 27
ENVARSUS XR 32
EOHILIA 27
EPIDIOLEX 43
epinephrine 59
eplerenone 13
ergotamine-caffeine 44
ERIVEDGE 32
ERLEADA 32
erlotinib 32
ERRIN 54
ertapenem 6
ERY PADS 17
erythromycin 6, 57
erythromycin with ethanol 18
erythromycin-benzoyl peroxide ... 18
escitalopram oxalate 44
eslicarbazepine 44
ESTARYLLA 54
estradiol 54, 55
estradiol-norethindrone acet 55
ethacrynic acid 13
ethambutol 6
ethosuximide 44
etonogestrel-ethinyl estradiol 55
etravirine 6
EULEXIN 32
everolimus (antineoplastic) ... 32, 33
everolimus (immunosuppressive) 33
EVOTAZ 6
exemestane 33
EXXUA 44
ezetimibe 13
ezetimibe-simvastatin 13
famciclovir 6
famotidine 27
FANAPT 44
FANAPT TITRATION PACK A 44
FANAPT TITRATION PACK B 44
FANAPT TITRATION PACK C 44
FARXIGA 22
FASENRA 59
FASENRA PEN 59
felbamate 44
felodipine 13
fenofibrate 13
fenofibrate micronized 13
fenofibrate nanocrystallized 13
fentanyl 44
FETZIMA 44
FIASP FLEXTOUCH U-100 INSULIN 22
FIASP PENFILL U-100 INSULIN 22
FIASP U-100 INSULIN 22
fidaxomicin 6
FILSPARI 13
FILSUVEZ 18
finasteride 62
fingolimod 44
FINTEPLA 44
FIRMAGON KIT W DILUENT SYRINGE 33
flecainide 13
fluconazole 6
fluconazole in nacl (iso-osm) 6
flucytosine 6
fludrocortisone 22
fluocinolone 18
fluocinolone acetonide oil 52
fluocinolone and shower cap 18
fluocinonide 18
fluocinonide-emollient 18
fluoride (sodium) 63
fluorometholone 57

fluorouracil 18
fluoxetine 44
fluphenazine decanoate 44
fluphenazine hcl 44, 45
flurbiprofen sodium 57
fluticasone furoate-vilanterol 59
fluticasone propionate 18, 59, 60
fluvastatin 13
fluvoxamine 45
fondaparinux 13
fosamprenavir 6
fosfomycin tromethamine 6
fosinopril 13
fosinopril-hydrochlorothiazide ... 13
FOTIVDA 33
FRUZAQLA 33
furosemide 13
gabapentin 45
galantamine 45
GALLIFREY 55
GAMMAGARD LIQUID 29
GAMMAGARD LIQUID ERC 29
GAMMAGARD S-D (IGA < 1 MCG/ML) 29
GARDASIL 9 (PF) 29
gatifloxacin 57
GATTEX 30-VIAL 27
GAUZE PAD 61
GAVILYTE-C 27
GAVILYTE-G 27
GAVILYTE-N 27
GAVRETO 33
gefitinib 33
gemfibrozil 13
GEMTESA 62
GENERLAC 27
GENGRAF 33
gentamicin 7, 18, 57
gentamicin in nacl (iso-osm) 7
GENVOYA 7
GILOTRIF 33
glatiramer 45
GLATOPA 45
glimepiride 22
glipizide 22
glipizide-metformin 22
GLUCAGON EMERGENCY KIT (HUMAN) 22
glyburide 22
glyburide-metformin 22
glycerol phenylbutyrate 20
glycopyrrolate 27
GLYXAMBI 22
GOMEKLI 33
granisetron hcl 27
griseofulvin microsize 7
griseofulvin ultramicrosize 7
guanfacine 45
GVOKE 22
GVOKE HYPOPEN 2-PACK 22
GVOKE PFS 1-PACK SYRINGE 22
HADLIMA 53
HADLIMA PUSHTOUCH 53
HADLIMA(CF) 53
HADLIMA(CF) PUSHTOUCH 53
halobetasol propionate 18
haloperidol 45
haloperidol decanoate 45
haloperidol lactate 45
HAVRIX (PF) 29
HEATHER 55
heparin (porcine) 13
HEPCLUDEX 7
HEPLISAV-B (PF) 29
HERNEXEOS 33
HIBERIX (PF) 29
HUMALOG JUNIOR KWIKPEN U-100 23
HUMALOG KWIKPEN INSULIN 23
HUMALOG MIX 50-50 KWIKPEN 23
HUMALOG MIX 75-25 KWIKPEN 23
HUMALOG MIX 75-25(U-100)INSULN 23
HUMALOG U-100 INSULIN 23
HUMULIN 70/30 U-100 INSULIN 23
HUMULIN 70/30 U-100 KWIKPEN 23
HUMULIN N NPH INSULIN KWIKPEN 23
HUMULIN N NPH U-100 INSULIN 23
HUMULIN R REGULAR U-100 INSULN 23
HUMULIN R U-500 (CONC) KWIKPEN 23
hydralazine 13
hydrochlorothiazide 13
hydrocortisone 18, 23, 27
hydromorphone 45
hydroxychloroquine 7
hydroxyurea 33
hydroxyzine hcl 60
HYRNUO 33
ibandronate 53
IBRANCE 33
IBTROZI 33
IBU 45
ibuprofen 45
icatibant 60
ICLUSIG 33
icosapent ethyl 13
IDHIFA 33
IDVYNSO 7
imatinib 33
IMBRUVICA 33
imipenem-cilastatin 7
imipramine hcl 45
imiquimod 18
IMKELDI 33
IMOVAX RABIES VACCINE (PF) 29
IMVEXXY MAINTENANCE PACK 55
IMVEXXY STARTER PACK 55
INCASSIA 55
INCRELEX 20
indapamide 13
INFANRIX (DTAP) (PF) 29
INLURIYO 34
INLYTA 34
INQOVI 34
INREBIC 34
insulin glargine-yfgn 23
insulin lispro 23
insulin lispro protamin-lispro 23
insulin syringe-needle u-100 62
INTELENCE 7
INTRALIPID 63
INVEGA HAFYERA 45
INVEGA SUSTENNA 45, 46
INVEGA TRINZA 46
IPOL 29
ipratropium bromide 52, 60
ipratropium-albuterol 60
irbesartan 13
irbesartan-hydrochlorothiazide 14
ISENTRESS 7
ISENTRESS HD 7
ISIBLOOM 55

ISOLYTE S PH 7.4 63
ISOLYTE-P IN 5 % DEXTROSE 63
isoniazid 7
isosorbide dinitrate 14
isosorbide mononitrate 14
isradipine 14
ITOVEBI 34
itraconazole 7
ivabradine 14
ivermectin 7
IWILFIN 34
IXIARO (PF) 29
JAKAFI 34
JANTOVEN 14
JANUMET 23
JANUMET XR 23
JANUVIA 23
JARDIANCE 23
JASCAYD 60
JAVYGTOR 23
JAYPIRCA 34
JENTADUETO 23
JENTADUETO XR 23
JIDEYTRO 34
JINTELI 55
JOENJA 20
JUBBONTI 53
JULUCA 7
JUNEL 1.5/30 (21) 55
JUNEL 1/20 (21) 55
JUNEL FE 1.5/30 (28) 55
JUNEL FE 1/20 (28) 55
JUNEL FE 24 55
JYNNEOS (PF) 29
KALYDECO 60
KARIVA (28) 55
KERENDIA 14
KESIMPTA PEN 46
ketoconazole 7, 18
ketorolac 46, 57
KINERET 53
KINRIX (PF) 29
KIONEX 20
KIRSTY 23
KIRSTY PEN 23
KISQALI 34
KLOR-CON 63
KLOR-CON 10 63
KLOR-CON 8 63
KLOR-CON M10 63
KLOR-CON M15 63
KLOR-CON M20 63
KLOXXADO 46
KOMZIFTI 34
KOSELUGO 34
KOURZEQ 52
KRAZATI 34
KURVELO (28) 55
KYGEVVI 20
l norgest/e.estradiol-e.estrad 55
labetalol 14
lacosamide 46
lactulose 27
lamivudine 7
lamivudine-zidovudine 7
lamotrigine 46
LANTUS SOLOSTAR U-100 INSULIN 23
LANTUS U-100 INSULIN 23
lapatinib 34
latanoprost 57
LAZCLUZE 34
leflunomide 53
lenalidomide 34
LENVIMA 34
LEQEMBI IQLIK 46
LESSINA 55
letrozole 34
leucovorin calcium 34
LEUKERAN 34
LEUKINE 29
leuprolide 34
levalbuterol hcl 60
levalbuterol tartrate 60
levetiracetam 46
levobunolol 57
levocarnitine 21
levocarnitine (with sugar) 21
levocetirizine 60
levofloxacin 7
levofloxacin in d5w 7
levonorgestrel-ethinyl estrad 55
levonorg-eth estrad triphasic 55
levothyroxine 24
lidocaine 18
lidocaine hcl 18
lidocaine-prilocaine 18
LIFYORLI 35
LILETTA 55
linezolid 7
linezolid in dextrose 5% 7
LINZESS 27
liothyronine 24
liraglutide 24
lisinopril 14
lisinopril-hydrochlorothiazide 14
LITFULO 21
lithium carbonate 46
lithium citrate 46
LIVTENCITY 7
LOARGYS 21
lofexidine 46
LOKELMA 21
lomustine 35
LONSURF 35
loperamide 27
lopinavir-ritonavir 7
lorazepam 46
LORAZEPAM INTENSOL 46
LORBRENA 35
losartan 14
losartan-hydrochlorothiazide 14
lovastatin 14
loxapine succinate 46
lubiprostone 27
LUMAKRAS 35
LUMIGAN 57
LUPRON DEPOT 35
LUPRON DEPOT (3 MONTH) 35
lurasidone 46
LYBALVI 46
LYLEQ 55
LYNPARZA 35
LYSODREN 35
LYTGOBI 35
LYZA 55
magnesium sulfate 63
malathion 18
maraviroc 8
MARPLAN 47
MATULANE 35
MAVYRET 8
meclizine 27
medroxyprogesterone 55
mefloquine 8
megestrol 35
MEKINIST 35
MEKTOVI 35
meloxicam 47
memantine 47
memantine-donepezil 47
MENQUADFI (PF) 29
MENVEO A-C-Y-W-135-DIP (PF) 29

mercaptopurine 36
meropenem 8
mesalamine 27
mesna 36
metformin 24
methadone 47
methazolamide 57
methenamine hippurate 8
methimazole 24
methocarbamol 47
methotrexate sodium 36
methotrexate sodium (pf) 36
methsuximide 47
methylphenidate hcl 47
methylprednisolone 24
metoclopramide hcl 27
metolazone 14
metoprolol succinate 14
metoprolol tartrate 14
metronidazole 8, 18, 19, 55
metronidazole in nacl (iso-os) 8
metyrosine 14
mexiletine 14
micafungin 8
MICONAZOLE-3 56
MICROGESTIN 1.5/30 (21) 56
MICROGESTIN 1/20 (21) 56
MICROGESTIN FE 1.5/30 (28) 56
MICROGESTIN FE 1/20 (28) 56
midodrine 21
MIEBO (PF) 57
mifepristone 24
miglustat 24
MILI 56
minocycline 8
minoxidil 14
mirtazapine 47
misoprostol 27
M-M-R II (PF) 29
modafinil 47
MODEYSO 36
moexipril 14
molindone 47
mometasone 19
montelukast 60
morphine 47
morphine concentrate 47
MOUNJARO 24
MOVANTIK 27
moxifloxacin 8, 57
moxifloxacin-sod.chloride(iso) 8
MRESVIA (PF) 29
MULPLETA 14
mupirocin 19
mycophenolate mofetil 36
mycophenolate sodium 36
MYRBETRIQ 62
nadolol 14
nafcillin 8
naloxone 47
naltrexone 47
naproxen 47
naproxen sodium 47
naratriptan 47
nateglinide 24
NAYZILAM 47
nebivolol 14
nefazodone 47
NEMLUVIO 36
neomycin 8
neomycin-bacitracin-poly-hc 58
neomycin-bacitracin-polymyxin 58
neomycin-polymyxin b-dexameth 58
neomycin-polymyxin-gramicidin 58
neomycin-polymyxin-hc 52, 58
NERLYNX 36
nevirapine 8
NEXLETOL 14
NEXLIZET 14
NEXPLANON 56
nicardipine 14
NICOTROL NS 21
nifedipine 14
nilotinib hcl 36
nilutamide 36
NINLARO 36
nintedanib 60
nitazoxanide 8
nitisinone 21
NITRO-BID 14
nitrofurantoin macrocrystal 8
nitrofurantoin monohyd/m-cryst 8
nitroglycerin 15, 27
NIVESTYM 29
NORDITROPIN FLEXPRO 30
norethindrone (contraceptive) 56
norethindrone acetate 56
norethindrone ac-eth estradiol 56
norethindrone-e.estradiol-iron 56
norgestimate-ethinyl estradiol 56
NORTREL 7/7/7 (28) 56
nortriptyline 47
NOVOLIN 70/30 U-100 INSULIN 24
NOVOLIN 70-30 FLEXPEN U-100 24
NOVOLIN N FLEXPEN 24
NOVOLIN N NPH U-100 INSULIN 24
NOVOLIN R FLEXPEN 24
NOVOLIN R REGULAR U100 INSULIN 24
NOVOLOG MIX 70-30 U-100 INSULN 24
NOVOLOG MIX 70-30FLEXPEN U-100 24
NUBEQA 36
NUCALA 60
NUPLAZID 47
NURTEC ODT 47
NYAMYC 19
NYLIA 1/35 (28) 56
NYLIA 7/7/7 (28) 56
nystatin 8, 19
nystatin-triamcinolone 19
NYSTOP 19
octreotide acetate 36
ODEFSEY 8
ODOMZO 36
OFEV 60
ofloxacin 8, 52, 58
OGSIVEO 36
OJEMDA 36
OJJAARA 36
olanzapine 48
olmesartan 15
olmesartan-amlodipin-hcthiazid 15
olmesartan-hydrochlorothiazide 15
olopatadine 52
omega-3 acid ethyl esters 15
omeprazole 28
ondansetron 28
ondansetron hcl 28
ONUREG 36
OPIPZA 48
OPSUMIT 60
OPSYNVI 60
ORENCIA 53
ORENCIA CLICKJECT 53
ORGOVYX 36
ORKAMBI 60
ORLYNVAH 8
ORSERDU 36
oseltamivir 8

OTEZLA 53
OTEZLA STARTER 53
OTEZLA XR 53
OTEZLA XR INITIATION 53
oxacillin 8
oxcarbazepine 48
oxybutynin chloride 62
oxycodone 48
oxycodone-acetaminophen 48
OZEMPIC 24
PACERONE 15
paliperidone 48
PANRETIN 19
pantoprazole 28
paricalcitol 24
paroxetine hcl 48
PAXLOVID 8, 9
pazopanib 36
PEDIARIX (PF) 30
PEDVAX HIB (PF) 30
peg 3350-electrolytes 28
peg3350-sod sul-nacl-kcl-asb-c 28
PEGASYS 30
peg-electrolyte soln 28
PEMAZYRE 36
pen needle, diabetic 62
PENBRAYA (PF) 30
penciclovir 19
penicillamine 53
penicillin g pot in dextrose 9
penicillin g potassium 9
penicillin v potassium 9
PENMENVY MEN A-B-C-W-Y (PF) 30
PENTACEL (PF) 30
pentamidine 9
pentoxifylline 15
perampanel 48
perindopril erbumine 15
PERIOGARD 52
permethrin 19
perphenazine 48
PHEBURANE 21
phenelzine 48
phenobarbital 48
PHENYTEK 48
phenytoin 48
phenytoin sodium extended 48
PIFELTRO 9
pilocarpine hcl 21, 58
pimozide 48
pindolol 15
pioglitazone 24
pioglitazone-metformin 24
piperacillin-tazobactam 9
PIQRAY 37
pirfenidone 60, 61
pitavastatin calcium 15
PLEGRIDY 30
PLENAMINE 63
podofilox 19
polymyxin b sulf-trimethoprim 58
pomalidomide 37
POMALYST 37
posaconazole 9
potassium chlorid-d5-0.45%nacl 63
potassium chloride 63
potassium chloride in 0.9%nacl 63
potassium chloride in water 63
potassium chloride-0.45 % nacl 64
potassium citrate 62
pramipexole 48
prasugrel hcl 15
pravastatin 15
praziquantel 9
prazosin 15
prednisolone 24
prednisolone acetate 58
prednisolone sodium phosphate 24, 58
prednisone 24
pregabalin 48
PREMARIN 56
PRENATAL VITAMIN PLUS LOW IRON 64
pretomanid 9
PREVYMIS 9
PREZCOBIX 9
PREZISTA 9
primaquine 9
primidone 48
PRIORIX (PF) 30
PRIVIGEN 30
probenecid 53
probenecid-colchicine 53
prochlorperazine 28
prochlorperazine maleate 28
PROCRIT 30
PROCTO-MED HC 28
PROCTOSOL HC 28
PROCTOZONE-HC 28
PROGRAF 37
PROLASTIN-C 21
promethazine 61
propafenone 15
propranolol 15
propylthiouracil 24
PROQUAD (PF) 30
PROSOL 20 % 64
protriptyline 48
PULMOZYME 61
pyrazinamide 9
pyridostigmine bromide 49
pyrimethamine 9
QINLOCK 37
QUADRACEL (PF) 30
quetiapine 49
quinapril 15
quinapril-hydrochlorothiazide 15
quinidine sulfate 15
QULIPTA 49
QVAR REDIHALER 61
RABAVERT (PF) 30
rabeprazole 28
RALDESY 49
raloxifene 53
ramelteon 49
ramipril 15
ranolazine 15
rasagiline 49
RECOMBIVAX HB (PF) 30
REDEMPLO 15
RELENZA DISKHALER 9
RELGAABI 49
repaglinide 24
REPATHA SURECLICK 15
REPATHA SYRINGE 15
RESTASIS 58
RESTASIS MULTIDOSE 58
RETACRIT 30
RETEVMO 37
REVCOVI 21
REVUFORJ 37
REXULTI 49
REYATAZ 9
REZDIFFRA 21
REZENOPY 49
REZLIDHIA 37
REZVOGLAR KWIKPEN 24
RHOPRESSA 58
ribavirin 9
rifabutin 9
rifampin 9
rifapentine 9
rilpivirine hcl 9

riluzole 21
rimantadine 9
RINVOQ 53
RINVOQ LQ 53
risedronate 21
risperidone 49
risperidone microspheres 49
ritonavir 9
rivaroxaban 15
rivastigmine 49
rivastigmine tartrate 49
RIVFLOZA 62
rizatriptan 49
ROCKLATAN 58
roflumilast 61
ROMVIMZA 37
ropinirole 49
rosuvastatin 15
ROTARIX 30
ROTATEQ VACCINE 30
ROWEEPRA 50
ROZLYTREK 37
RUBRACA 37
rufinamide 50
RUKOBIA 9
RYDAPT 37
RYTARY 50
sacubitril-valsartan 15
SAJAZIR 61
sapropterin 24
saxagliptin 24
saxagliptin-metformin 25
SCEMBLIX 37
scopolamine base 28
SECUADO 50
selegiline hcl 50
selenium sulfide 19
SEREVENT DISKUS 61
sertraline 50
SETLAKIN 56
sevelamer carbonate 21
SHINGRIX (PF) 30
SIGNIFOR 37
sildenafil (pulm.hypertension) 61
SILIQ 19
silver sulfadiazine 19
SIMBRINZA 58
SIMLANDI(CF) 54
SIMLANDI(CF) AUTOINJECTOR 54
simvastatin 15
sirolimus 37
SIRTURO 9
sitagliptin 25
sitagliptin phos-metformin 25
sitagliptin phosphate 25
sitagliptin-metformin 25
SKYRIZI 19, 28
sodium chloride 21
sodium chloride 0.45 % 64
sodium chloride 0.9 % 21
sodium chloride 3 % hypertonic 64
sodium chloride 5 % hypertonic 64
sodium oxybate 50
sodium phenylbutyrate 21
sodium polystyrene sulfonate 21
sodium,potassium,mag sulfates 28
sofosbuvir-velpatasvir 9
SOHONOS 21
solifenacin 62
SOLIQUA 100/33 25
SOLTAMOX 37
SOMAVERT 25
sorafenib 37
sotalol 16
SOTALOL AF 16
SPIRIVA RESPIMAT 61
spironolactone 16
spironolacton-hydrochlorothiaz 16
SPRINTEC (28) 56
SPRITAM 50
SPS (WITH SORBITOL) 21
SSD 19
STEQEYMA 19
STIOLTO RESPIMAT 61
STIVARGA 37
streptomycin 10
STRIBILD 10
STRIVERDI RESPIMAT 61
SUBVENITE 50
sucralfate 28
sulfacetamide sodium 58
sulfacetamide-prednisolone 58
sulfadiazine 10
sulfamethoxazole-trimethoprim 10
SULFAMYLON 19
sulfasalazine 28
sumatriptan 50
sumatriptan succinate 50
sunitinib malate 37
SUNLENCA 10
SYMPAZAN 50
SYMTUZA 10
SYNAREL 25
SYNJARDY 25
SYNJARDY XR 25
SYNTHROID 25
TABLOID 37
TABRECTA 37
tacrolimus 19, 37
tadalafil 62
tadalafil (pulm. hypertension) 61
TAFINLAR 37, 38
TAGRISSO 38
TALZENNA 38
tamoxifen 38
tamsulosin 62
TARPEYO 25
TASCENSO ODT 50
tasimelteon 50
tazarotene 19
telmisartan 16
telmisartan-amlodipine 16
telmisartan-hydrochlorothiazid 16
TENIVAC (PF) 30
tenofovir disoproxil fumarate 10
TEPMETKO 38
terazosin 16
terbinafine hcl 10
terbutaline 61
terconazole 56
teriflunomide 50
teriparatide 54
testosterone 25
testosterone cypionate 25
testosterone enanthate 25
tetrabenazine 50
tetracycline 10
TEZSPIRE 61
THALOMID 38
THEO-24 61
theophylline 61
thioridazine 50
thiothixene 50
TIADYLT ER 16
tiagabine 50
TIBSOVO 38
ticagrelor 16
TICOVAC 30
tigecycline 10
timolol maleate 16, 58
tinidazole 10
TIVICAY 10
TIVICAY PD 10
tizanidine 50
TOBI PODHALER 10

tobramycin 10, 58
tobramycin in 0.225 % nacl 10
tobramycin sulfate 10
tobramycin-dexamethasone 58
tofacitinib 54
tolterodine 62
tolvaptan 25
tolvaptan (polycys kidney dis) 25
topiramate 50, 51
toremifene 38
torsemide 16
TOUJEO MAX U-300 SOLOSTAR 25
TOUJEO SOLOSTAR U-300 INSULIN 26
TRADJENTA 26
tramadol 51
trandolapril 16
tranexamic acid 56
tranylcypromine 51
TRAVASOL 10 % 64
travoprost 58
trazodone 51
TRELEGY ELLIPTA 61
TRELSTAR 38
tretinoin 19
tretinoin (antineoplastic) 38
triamcinolone acetonide . 19, 20, 52
triamterene-hydrochlorothiazid .. 16
trientine 21
trifluoperazine 51
trifluridine 58
TRIJARDY XR 26
TRIKAFTA 61
TRI-LO-SPRINTEC 56
trimethoprim 10
TRI-MILI 56
trimipramine 51
TRINTELLIX 51
TRI-SPRINTEC (28) 56
TRIUMEQ 10
TRIUMEQ PD 10
TROPHAMINE 10 % 64
trospium 62
TRULICITY 26
TRUMENBA 30
TRUQAP 38
TUKYSA 38
TURALIO 38
TWINRIX (PF) 30
TYMLOS 54
TYPHIM VI 30
UPTRAVI 16
ursodiol 28
valacyclovir 10
VALCHLOR 20
valganciclovir 10
valproic acid 51
valproic acid (as sodium salt) 51
valsartan 16
valsartan-hydrochlorothiazide ... 16
VALTOCO 51
vancomycin 10
VANFLYTA 38
VAQTA (PF) 30
varenicline tartrate 21
VARIVAX (PF) 30
VAXCHORA VACCINE 30
VEMLIDY 10
VENCLEXTA 38
VENCLEXTA STARTING PACK 38
venlafaxine 51
VENTOLIN HFA 61
verapamil 16
VERQUVO 16
VERSACLOZ 51
VERZENIO 38
VESTURA (28) 56
VIENVA 56
vigabatrin 51
VIGADRONE 51
vilazodone 51
VIMKUNYA (PF) 30
VIRACEPT 10
VIREAD 10
VITRAKVI 38
VIVITROL 51
VIVJOA 10
VIVOTIF 31
VONJO 38
VORANIGO 38
voriconazole 10
VOSEVI 11
VOWST 28
VRAYLAR 51
VTAMA 20
VUMERITY 51
warfarin 16
WEGOVY 21
WELIREG 38
WINREVAIR 61
WYOST 39
XALKORI 39
XATMEP 39
XCOPRI 51
XCOPRI MAINTENANCE PACK 51
XCOPRI TITRATION PACK 51
XDEMVY 58
XERMELO 39
XIFAXAN 11
XIGDUO XR 26
XIIDRA 58
XOCOVA 11
XOFLUZA 11
XOLAIR 61
XOLREMDI 31
XOSPATA 39
XPOVIO 39
XTANDI 39
XTRENBO 39
XULTOPHY 100/3.6 26
YARGESA 26
YESINTEK 20
YF-VAX (PF) 31
YONSA 39
YORVIPATH 26
YULITHIRA 39
YUVAFEM 56
ZAFEMY 56
zafirlukast 61
ZARXIO 31
ZEJULA 39
ZELBORAF 39
ZELSUVMI 20
ZELVYSIA 26
ZENBEXUS 39
ZENPEP 28
ZEPOSIA 51
ZEPOSIA STARTER KIT (28-DAY) 51
ZEPOSIA STARTER PACK (7-DAY) 51
zidovudine 11
ziprasidone hcl 51
ziprasidone mesylate 51
ZIRGAN 58
ZOKINVY 21
ZOLINZA 39
zolpidem 52
ZONISADE 52
zonisamide 52
ZTALMY 52
ZUBSOLV 52
ZURZUVAE 52

ZYKADIA..... 39
ZYMFENTRA.....28

Sección:
Autorización previa

Acitretin

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Actimmune

Products Affected

- **ACTIMMUNE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Afinitor

Products Affected

- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- **YULITHIRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For everolimus only, documentation of advanced, hormone receptor-positive, HER2-negative breast cancer -AND- all of the following (1-3): 1) member is a postmenopausal woman 2) using in combination with exemestane 3) therapeutic failure or intolerance to prior treatment with letrozole or anastrozole. For everolimus only, documentation of non-functional neuroendocrine tumors -AND- all of the following (1-2): 1) disease is classified as progressive, well-differentiated, non-functional 2) disease is of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic. For everolimus only, documentation of advanced renal cell carcinoma -AND- therapeutic failure or intolerance to prior treatment with sunitinib or sorafenib. For everolimus only, documentation of renal angiomyolipoma and tuberous sclerosis complex (TSC), member does not require immediate surgery. For everolimus and everolimus tablets for oral suspension, documentation of TSC with Subependymal Giant Cell Astrocytoma -AND- member is not a candidate for curative surgical resection. For everolimus only, documentation of progressive neuroendocrine tumors of pancreatic origin -AND- disease is unresectable, locally advanced or metastatic. For everolimus tablets for oral suspension only, documentation of use for adjunctive treatment of TSC-associated partial-onset seizures.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Akeega

Products Affected

- **AKEEGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. -AND- Concomitant therapy with prednisone. -AND- Concomitant therapy with a gonadotropin-releasing hormone analog or a bilateral orchiectomy, -AND- For metastatic castration-sensitive prostate cancer, disease harbors a deleterious or suspected deleterious BRCA2 mutation based on an FDA-approved test. -AND- For metastatic castration-resistant prostate cancer, BRCA mutations.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Alecensa

Products Affected

- **ALECENSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test - AND- One of the following (1-2): 1) metastatic disease, 2) will be used as adjuvant treatment following tumor resection of node positive or greater than or equal to 4 cm tumor(s).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Alpha1-Proteinase Inhibitors

Products Affected

- **PROLASTIN-C INTRAVENOUS SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when furnished incident to a physician service and is not self-administered.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Alunbrig

Products Affected

- **ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG**
- **ALUNBRIG ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ambrisentan PAH

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ampyra

Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Amitriptyline

Products Affected

- *amitriptyline*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure or documentation of intolerance or contraindication to 2 non-high risk alternative drugs for the same indication is required (e.g. SSRIs and SNRIs). If safer alternatives for the same indication are not available, then no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Benztropine

Products Affected

- *benztropine oral*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Clomipramine

Products Affected

- *clomipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure or documentation of intolerance or contraindication to 2 non-high risk alternative drugs for the same indication is required (e.g. SSRIs and SNRIs). If safer alternatives for the same indication are not available, then no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Cyclobenzaprine

Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Cyproheptadine

Products Affected

- *cyproheptadine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Doxepin

Products Affected

- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events. When daily dose is less than or equal to 6mg, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure or documentation of intolerance or contraindication to 2 non-high risk alternative drugs for the same indication is required (e.g. SSRIs and SNRIs). If safer alternatives for the same indication are not available, then no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Hydroxyzine

Products Affected

- *hydroxyzine hcl oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Imipramine

Products Affected

- *imipramine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure or documentation of intolerance or contraindication to 2 non-high risk alternative drugs for the same indication is required (e.g. SSRIs and SNRIs). If safer alternatives for the same indication are not available, then no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Nortriptyline

Products Affected

- *nortriptyline*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure or documentation of intolerance or contraindication to 2 non-high risk alternative drugs for the same indication is required (e.g. SSRIs and SNRIs). If safer alternatives for the same indication are not available, then no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Paroxetine

Products Affected

- *paroxetine hcl oral suspension*
- *paroxetine hcl oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Attestation of counseling on risk-benefit profile and potential anticholinergic adverse effects -AND- Therapeutic failure, contraindication, or intolerance to 2 other antidepressants (i.e., SSRI, SNRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anticholinergic Promethazine

Products Affected

- *promethazine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The following information (1-3) is required: 1) Documentation of diagnosis, 2) Explanation of risk-benefit profile favoring use of the high-risk medication, 3) Attestation of an intent to monitor and address treatment-related adverse events.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anzupgo

Products Affected

- **ANZUPGO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Arikayce

Products Affected

- **ARIKAYCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aripiprazole

Products Affected

- *aripiprazole oral solution*
- *aripiprazole oral tablet,disintegrating*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For major depressive disorder, therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aubagio

Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Augtyro

Products Affected

- **AUGTYRO ORAL CAPSULE 160 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive. Documentation of solid tumors -AND- disease harbors a NTRK gene fusion -AND- one of the following (1-2): 1) disease is locally advanced or metastatic, or 2) surgical resection is likely to result in severe morbidity -AND- one of the following (3-4): 3) disease has progressed following treatment, or 4) the member has no satisfactory alternative therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Austedo

Products Affected

- **AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG**
- **AUSTEDO XR**
- **AUSTEDO XR TITRATION KT(WK1-4)**
- **ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Auvelity

Products Affected

- **AUVELITY ORAL TABLET, IR AND ER, BIPHASIC**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Avmapki-Fakzynja

Products Affected

- **AVMAPKI-FAKZYNJA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For recurrent low-grade serous ovarian cancer (LGSOC), disease is KRAS-mutated -AND- member has received at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Avonex

Products Affected

- **AVONEX INTRAMUSCULAR PEN INJECTOR KIT**
- **AVONEX INTRAMUSCULAR SYRINGE KIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ayvakit

Products Affected

- **AYVAKIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable or metastatic gastrointestinal stromal tumor -AND- tumors harbor a PDGFRA exon 18 mutation. Documentation of agressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia, or indolent systemic mastocytosis -AND- platelet count greater than or equal to 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bafiertam

Products Affected

- **BAFIERTAM**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	Therapeutic failure or intolerance to generic dimethyl fumarate is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Balversa

Products Affected

- **BALVERSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) FGFR3 mutation status as detected by an FDA approved test 2) disease progression on or after at least on prior line of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Banzel

Products Affected

- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	Patients with familial short QT syndrome
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benlysta

Products Affected

- **BENLYSTA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benzo Potentiator Alprazolam

Products Affected

- *alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benzo Potentiator Clonazepam

Products Affected

- *clonazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benzo Potentiator Clorazepate

Products Affected

- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benzo Potentiator Diazepam

Products Affected

- **DIAZEPAM INTENSOL**
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*
- *diazepam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benzo Potentiator Lorazepam

Products Affected

- **LORAZEPAM INTENSOL**
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Besremi

Products Affected

- **BESREMI**
- **BESREMI PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of polycythemia vera
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Betaseron

Products Affected

- **BETASERON SUBCUTANEOUS KIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bosulif

Products Affected

- **BOSULIF ORAL CAPSULE 100 MG, 50 MG**
- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy. For pediatric patients 1 year of age and older, one of the following (3, 4): 3) newly diagnosed PH-positive CML in the chronic phase 4) diagnosis of Ph-positive CML in the chronic phase and no longer responding to or intolerant to at least 1 prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For capsules and 18 years of age or older, intolerance to generic bosutinib tablets or inability to swallow tablets is required. For tablets and 18 years of age or older, intolerance to generic bosutinib tablets is required. For Bosutinib 100mg capsules and pediatric 1 year of age or older, inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bosutinib

Products Affected

- *bosutinib oral tablet 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Braftovi

Products Affected

- **BRAFTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	Use in wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.
Required Medical Information	Documentation of diagnosis. For metastatic colorectal cancer (mCRC) and using in combination with cetuximab, all of the following (1-3): 1) BRAF V600E mutation status as detected by an FDA-authorized test 2) using in combination with cetuximab 3) member has received prior therapy for CRC. For mCRC and using in combination with cetuximab and fluorouracil-based chemotherapy, all of the following (4-5): 4) BRAF V600E mutation status, as detected by an FDA-authorized test 5) using in combination with cetuximab and fluorouracil-based chemotherapy. For unresectable or metastatic melanoma, all of the following (6-7): 6) BRAF V600E or V600K mutation status, as detected by an FDA-authorized test 7) using in combination with binimetinib. For metastatic non-small cell lung cancer, all of the following (8-9): 8) BRAF V600E mutation status, as detected by an FDA-authorized test 9) using in combination with binimetinib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Brinsupri

Products Affected

- **BRINSUPRI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Brukinsa

Products Affected

- **BRUKINSA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma (MCL), previous treatment with at least 1 prior therapy. For marginal zone lymphoma (MZL), previous treatment with at least 1 anti-CD20-based regimen. For follicular lymphoma (FL), using in combination with obinutuzumab and previous treatment with at least 2 prior lines of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Buphenyl

Products Affected

- *sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cabometyx

Products Affected

- **CABOMETYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1-6): 1) diagnosis of advanced renal cell carcinoma (RCC), 2) diagnosis of advanced RCC and using as a first-line treatment in combination with nivolumab, 3) member has previously been treated with sorafenib for hepatocellular carcinoma, 4) member has experienced disease progression following prior VEGFR-targeted therapy and is either radioactive iodine-refractory or is ineligible for radioactive iodine therapy for locally advanced or metastatic differentiated thyroid cancer, 5) diagnosis of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET), 6) diagnosis of previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Calquence

Products Affected

- **CALQUENCE (ACALABRUTINIB MAL)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma, member has received at least one prior therapy -OR- all of the following (1-3): 1) member has not received prior therapy for MCL, 2) member is ineligible for autologous hematopoietic stem cell transplantation (HSCT), and 3) using in combination with bendamustine and rituximab.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Caplyta

Products Affected

- **CAPLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For major depressive disorder, therapeutic failure, contraindication or intolerance to Vraylar and one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For schizophrenia and bipolar I disorder, therapeutic failure, intolerance, or contraindication to Vraylar and one other generic atypical antipsychotic (e.g. quetiapine). For bipolar II disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Caprelsa

Products Affected

- **CAPRELSA ORAL TABLET 100 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Carbaglu

Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cayston

Products Affected

- **CAYSTON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Therapeutic failure, contraindication, intolerance, or resistance to generic inhaled tobramycin is required. For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CF drugs

Products Affected

- **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cialis

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of benign prostatic hyperplasia (BPH) and trial/failure of 2 of the following medications: dutasteride, doxazosin, tamsulosin, terazosin, finasteride, alfuzosin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cinryze

Products Affected

- **CINRYZE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cobenfy

Products Affected

- **COBENFY**
- **COBENFY STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Therapeutic failure, intolerance, or contraindication to Vraylar and one other generic atypical antipsychotic (e.g. quetiapine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cometriq

Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressive, metastatic medullary thyroid cancer
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Copiktra

Products Affected

- **COPIKTRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member is no longer responding or is intolerant to at least 2 prior therapies for chronic lymphocytic leukemia and small lymphocytic leukemia.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Corlanor

Products Affected

- *ivabradine oral tablet 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following: 1) Normal sinus rhythm, 2) Resting heart rate greater than or equal to 70 beats per minute, 3) For adults, left ventricular ejection fraction less than or equal to 35 percent, 4) For adults, concurrent use of 1 beta-blocker used for treatment of heart failure (i.e. bisoprolol, carvedilol, metoprolol succinate) or therapeutic failure, intolerance, or contraindication to the maximum tolerated dose of 2 beta-blockers used for treatment of heart failure.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cosentyx

Products Affected

- **COSENTYX (2 SYRINGES)**
- **COSENTYX PEN (2 PENS)**
- **COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML**
- **COSENTYX UNOREADY PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID) or all are contraindicated. For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs or all are contraindicated.
Age Restrictions	Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 12 years of age for hidradenitis suppurativa and ankylosing spondylitis -OR- less than 18 years of age for non-radiographic axial spondyloarthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. For hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Cotellic

Products Affected

- **COTELLIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following for unresectable or metastatic melanoma (1-2): 1) BRAF V600E or V600K mutation status 2) Concomitant therapy with vemurafenib. For cobimetinib monotherapy, documentation of histiocytic neoplasms.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cysteamine Ophthalmic Drops

Products Affected

- **CYSTARAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Danziten

Products Affected

- **DANZITEN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Daraprim

Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For primary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 100 cells/mm*3 -AND- Toxoplasma IgG positive -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For secondary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 200 cells/mm*3. For secondary prophylaxis of cystoisosporiasis with CD4 count less than 200 cells/mm*3 or acute cystoisosporiasis infection: failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For primary prophylaxis of Pneumocystis jirovecii pneumonia: diagnosis of HIV -AND- CD4 count less than 200 cells/mm*3 -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Daurismo

Products Affected

- **DAURISMO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Deferasirox

Products Affected

- *deferasirox oral tablet, dispersible*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dihydroergotamine

Products Affected

- *dihydroergotamine nasal*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Drizalma

Products Affected

- **DRIZALMA SPRINKLE ORAL**
  CAPSULE, DELAYED REL SPRINKLE
  20 MG, 30 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dulaglutide

Products Affected

- **TRULICITY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Duvyzat

Products Affected

- **DUVYZAT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy with pathogenic mutation in the dystrophin gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ensacove

Products Affected

- **ENSACOVE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally advanced or metastatic non-small cell lung cancer (NSCLC) -AND- Disease is ALK-positive, as detected by an FDA-approved test -AND- Not previously received an ALK inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Entresto Sprinkle

Products Affected

- **ENTRESTO SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of symptomatic heart failure with left ventricular systolic dysfunction -AND- weight less than 40kg, or weight greater than or equal to 40kg and less than 50kg and one of the following (1 or 2): 1) therapeutic failure or intolerance to generic sacubitril/valsartan tablets, or 2) inability to swallow tablets.
Age Restrictions	Deny if greater than 17 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, all of the following are required (1-3): 1) attestation of positive clinical response to therapy, 2) member is younger than 18 years of age, 3) weight less than 40kg, or weight greater than or equal to 40kg and less than 50kg and one of the following (4 or 5): 4) intolerance to generic sacubitril/valsartan tablets, or 5) inability to swallow tablets.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Entyvio

Products Affected

- **ENTYVIO PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation of receiving or currently undergoing at least 2 doses of IV Entyvio within 6 weeks of initiating therapy with Entyvio SC.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For moderate to severe ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq. For moderate to severe active Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Eohilia

Products Affected

- **EOHILIA**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 12 weeks
Required Medical Information	Diagnosis of eosinophilic esophagitis -AND- esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy -AND- clinical symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, gastroesophageal reflux)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Epclusa

Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Epidiolex

Products Affected

- **EPIDIOLEX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Eprontia

Products Affected

- *topiramate oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ergotamine-Caffeine

Products Affected

- *ergotamine-caffeine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use to abort a vascular headache -AND- therapeutic failure, intolerance, or contraindication to a generic triptan -OR- documentation of use to prevent a vascular headache -AND- therapeutic failure, intolerance, or contraindication to generic prophylactic migraine medication (e.g., topiramate, propanolol, timolol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Erivedge

Products Affected

- **ERIVEDGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Erleada

Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Escitalopram Capsule

Products Affected

- *escitalopram oxalate oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder or generalized anxiety -AND- Therapy has been initiated with escitalopram 10mg or member has been receiving and is experiencing unfavorable tolerability to escitalopram 20mg -AND- Intolerance to generic escitalopram tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g., SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Etanercept

Products Affected

- **ENBREL MINI**
- **ENBREL SUBCUTANEOUS SOLUTION**
- **ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)**
- **ENBREL SURECLICK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis and Ankylosing Spondylitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis or Less than 4 years of age for Plaque Psoriasis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Therapeutic failure or intolerance to 1 of the following preferred adalimumab products is required, when being utilized for the same medically accepted indication and age: Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Exxua

Products Affected

- **EXXUA ORAL TABLET EXTENDED RELEASE 24 HR**
- **EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fanapt

Products Affected

- **FANAPT**
- **FANAPT TITRATION PACK A**
- **FANAPT TITRATION PACK B**
- **FANAPT TITRATION PACK C**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of one of the following: olanzapine, quetiapine, or risperidone -AND- When utilized for the same medically accepted indication, trial and failure of Vraylar
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fasenra

Products Affected

- **FASENRA PEN**
- **FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fecal Microbiota Products

Products Affected

- **VOWST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a recent diagnosis of Clostridioides difficile infection (CDI) confirmed by a positive stool test -AND- Classified as recurrent (e.g., at least 2 CDI episodes) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder and trial and failure of two other generic antidepressants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Filspari

Products Affected

- **FILSPARI ORAL TABLET 200 MG, 400 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Filsuvez

Products Affected

- **FILSUVEZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) -AND- at least one open wound.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement in targeted wound(s) -AND- member requires additional courses of treatment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fintepla

Products Affected

- **FINTEPLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam).
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Firazyr

Products Affected

- *icatibant*
- **SAJAZIR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Firmagon

Products Affected

- **FIRMAGON KIT W DILUENT SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Forteo

Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fotivda

Products Affected

- **FOTIVDA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member has received at least two prior systemic therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fruzaqla

Products Affected

- **FRUZAQLA ORAL CAPSULE 1 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member has received previous threatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy -AND- member has received previous treatment with an anti-VEGF therapy -AND- one of the following, if member is RAS wild-type (1-2): 1) member has received previous therapy with an anti-EGFR therapy 2) prescriber attests that treatment with an anti-EGFR therapy would not be medically appropriate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gattex

Products Affected

- **GATTEX 30-VIAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gavreto

Products Affected

- **GAVRETO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, disease is RET fusion-positive as detected by an FDA approved test. For advanced or metastatic thyroid cancer, all of the following (1-2): 1) disease is RET fusion-positive 2) if radioactive iodine is appropriate, the member is radioactive iodine-refractory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gilenya

Products Affected

- *fingolimod*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gilotrif

Products Affected

- **GILOTRIF**

PA Criteria	Criteria Details
Exclusion Criteria	Tumors with resistant EGFR mutations.
Required Medical Information	Documentation of metastatic non-small cell lung cancer (NSCLC) -AND- one of the following, as detected by an FDA-approved test (1-3): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutation 3) disease harbors non-resistant EGFR mutation (i.e., S768I, L861Q, G719X) -OR- documentation of squamous metastatic NSCLC and member has experienced progression on platinum-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Glatiramer

Products Affected

- **COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**
- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- **GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gleevec

Products Affected

- *imatinib oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult agressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvent treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gleostine

Products Affected

- *lomustine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s). Documentation of Hodgkin's lymphoma -AND- all of the following (1-2): 1) using lomustine in combination with other chemotherapies 2) member has experienced disease progression with initial chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gomekli

Products Affected

- **GOMEKLI ORAL CAPSULE 1 MG, 2 MG**
- **GOMEKLI ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of neurofibromatosis type 1 (NF1) -AND- presence of symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Guanfacine ER ADHD

Products Affected

- *guanfacine oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hepcludex

Products Affected

- **HEPCLUDEX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hernexeos

Products Affected

- **HERNEXEOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For non-squamous non-small cell lung cancer (NSCLC), all of the following (1-2): 1) disease is unresectable or metastatic, 2) disease harbors HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Hypnotic Potentiator Zolpidem

Products Affected

- *zolpidem oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	When used concomitantly with an opioid agonist, both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of an opioid agonist, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Hyrnuo

Products Affected

- **HYRNUO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For non-squamous non-small cell lung cancer (NSCLC), all of the following (1-3): 1) disease is locally advanced or metastatic, 2) disease harbors HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and 3) member has received at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ibrance

Products Affected

- **IBRANCE ORAL CAPSULE 125 MG**
- **IBRANCE ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ibtrozi

Products Affected

- **IBTROZI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iclusig

Products Affected

- **ICLUSIG**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of newly-diagnosed chronic phase CML
Required Medical Information	Documentation of T3151+ chronic myeloid leukemia (CML) -OR- documentation of chronic phase CML and member has experienced resistance or intolerance to at least two prior kinase inhibitors -OR- documentation of accelerated phase or blast phase CML and no other kinase inhibitor is indicated -OR- member is using Iclusig as monotherapy and meets one of the following (1-2): 1) documentation of T3151+ acute lymphoblastic leukemia (ALL) 2) documentation of Ph+ ALL and no other tyrosine kinase inhibitor therapy is indicated -OR- member has newly diagnosed Ph+ ALL and is using Iclusig in combination with chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Idhifa

Products Affected

- **IDHIFA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic graft versus host disease, previous treatment with at least 1 prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For suspension, inability to swallow oral tablets or oral capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Imkeldi

Products Affected

- **IMKELDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult agressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvent treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documentation of an inability to swallow oral tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Immune Globulins

Products Affected

- **GAMMAGARD LIQUID**
- **GAMMAGARD LIQUID ERC**
- **GAMMAGARD S-D (IGA**
- **PRIVIGEN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Increlex

Products Affected

- **INCRELEX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inluriyo

Products Affected

- **INLURIYO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-3): 1) disease is ER-positive, HER2-negative, 2) disease harbors an ESR1 mutation, as detected by an FDA-approved test, 3) member has experienced disease progression following at least one line of endocrine therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inlyta

Products Affected

- **INLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced renal cell carcinoma -AND- one of the following (1-2): 1) if using axitinib as first line therapy, member is using axitinib in combination with avelumab or pembrolizumab 2) if using axitinib as a single-agent, member has been treated with at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inqovi

Products Affected

- **INQOVI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inrebic

Products Affected

- **INREBIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate-2 or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than or equal to 50x10*9/L
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Insulin Supplies

Products Affected

- **ALCOHOL PADS**
- **GAUZE PAD TOPICAL BANDAGE 2 X 2 "**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation the product is being used for the delivery of insulin into the body.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interferon Alfa

Products Affected

- **PEGASYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iressa

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
Required Medical Information	Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Itovebi

Products Affected

- **ITOVEBI ORAL TABLET 3 MG, 9 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endocrine-resistant, locally advanced or metastatic breast cancer -AND- all of the following (1-4): 1) disease is HR-positive, HER2-negative 2) disease is PIK3CA-mutated, as detected by an FDA-approved test 3) the member is using in combination with palbociclib and fulvestrant 4) the member has experienced recurrence on or after completing adjuvant endocrine therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Itraconazole

Products Affected

- *itraconazole oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Onychomycosis: 3 months. All other indications: 12 months
Other Criteria	Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ivermectin Oral

Products Affected

- *ivermectin oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iwilfin

Products Affected

- **IWILFIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of high-risk neuroblastoma (HRNB) -AND- partial response to anti-glycolipid disialoganglioside (GD2) immunotherapy (e.g., dinutuximab, naxitamab).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jakafi

Products Affected

- **JAKAFI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than or equal to 50x10*9/L -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jascayd

Products Affected

- **JASCAYD**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jaypirca

Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory mantle cell lymphoma, member has received at least two (2) previous lines of systemic therapy, at least one (1) of which was a BTK inhibitor. For relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, member has previously been treated with a covalent BTK inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jideytro

Products Affected

- **JIDEYTRO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Joenja

Products Affected

- **JOENJA ORAL TABLET 70 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Jynarque

Products Affected

- *tolvaptan (polycys kidney dis) oral tablet*
- *tolvaptan (polycys kidney dis) oral tablets, sequential*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kerendia

Products Affected

- **KERENDIA**

PA Criteria	Criteria Details
Exclusion Criteria	eGFR less than 25 mL/min/1.73 m*2, serum potassium greater than 5.5 mEq/L
Required Medical Information	Documentation of type 2 diabetes mellitus with chronic kidney disease (T2DM+CKD) or heart failure (HF) with left ventricular ejection fraction (LVEF) of greater than or equal to 40% -AND- one of the following (1. 2. or 3.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor 2) therapeutic failure to at least one SGLT2 inhibitor or 3) contraindication or intolerance to at least one SGLT2 inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For T2DM+CKD reauthorization, attestation that signs or symptoms of hyperkalemia are not present. For HF reauthorization, attestation of positive clinical response to therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kesimpta

Products Affected

- **KESIMPTA PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kineret

Products Affected

- **KINERET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kisqali

Products Affected

- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative -AND- one of the following (1-3): 1) member is using ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy 2) member is using ribociclib in combination with fulvestrant and member is using fulvestrant as initial endocrine-based therapy or member has experienced disease progression on endocrine therapy. 3) disease is classified as stage II or stage III early breast cancer at high risk of recurrence, ribociclib is being used in combination with an aromatase inhibitor as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Komzifti

Products Affected

- **KOMZIFTI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory acute myeloid leukemia, the member has a susceptible NPM1 mutation -AND- the member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Korlym

Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes, 2) Glucose intolerance
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG, 25 MG**
- **KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG, 7.5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Koselugo granules, 1 of the following is required (1-2): 1) inability to swallow oral capsules, 2) body surface area of less than 0.55 m*2
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Krazati

Products Affected

- **KRAZATI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy -AND- using as a single agent. Documentation of locally advanced or metastatic colorectal cancer -AND- disease is KRAS G12C-mutated as determined by an FDA-approved test -AND- using in combination with cetuximab -AND- prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kuvan

Products Affected

- **JAVYGTOR**
- *sapropterin*
- **ZELVYSIA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kygevvi

Products Affected

- **KYGEVVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Thymidine Kinase 2 Deficiency (TK2d) -AND- Pathogenic mutation in TK2 gene, as confirmed by genetic testing -AND- symptom onset on or before 12 years of age
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Latuda

Products Affected

- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lazcluze

Products Affected

- **LAZCLUZE ORAL TABLET 240 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) -AND- all of the following (1-4): 1) disease harbors EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution mutation, as detected by an FDA-approved test 2) disease is locally advanced or metastatic, 3) member is treatment naive for advanced disease, 4) using in combination with amivantinib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lenvima

Products Affected

- **LENVIMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of differentiated thyroid cancer -AND- meets all of the following (1-3): 1) disease is locally recurrent or metastatic 2) disease is progressive 3) disease is radioactive iodine refractory. Documentation of advanced renal cell carcinoma -AND- one of the following (4-5): 4) member is using lenvatinib in combination with pembrolizumab and is using lenvatinib and pembrolizumab as first-line treatment 5) member is using lenvatinib in combination with everolimus and has experienced therapeutic failure or intolerance to one prior anti-angiogenic therapy. Documentation of unresectable hepatocellular carcinoma -AND- member is using lenvatinib as first-line treatment. Documentation of endometrial cancer -AND- meets all of the following (6-10): 6) member is using lenvatinib in combination with pembrolizumab 7) disease is advanced 8) disease is not classified as microsatellite instability-high or disease is classified as mismatch repair proficient as determined by an FDA-approved test 9) member has experienced disease progression following prior systemic therapy 10) member is not a candidate for curative surgery or radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Leqembi Iqlik

Products Affected

- **LEQEMBI IQLIK SUBCUTANEOUS AUTO-INJECTOR 360 MG/1.8 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Leukine

Products Affected

- **LEUKINE INJECTION RECON SOLN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lidoderm

Products Affected

- *lidocaine topical adhesive patch,medicated 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) -AND- One of the following (1-3): 1) trial and failure of 1 other agent used to treat diagnosis (e.g. gabapentin for PHN, duloxetine for DPN), 2) inability to swallow oral medication, 3) unable to take an oral medication due to potential adverse events (e.g. sedation).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Diabetic peripheral neuropathy
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lifyorli

Products Affected

- **LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9), 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For epithelial ovarian, fallopian tube, or primary peritoneal cancer, all of the following (1-3): 1) disease is platinum-resistant, 2) member has received 1-3 prior systemic treatment regimens, at least 1 of which included bevacizumab, 3) using in combination with nab-paclitaxel.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Liraglutide

Products Affected

- *liraglutide*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Litfulo

Products Affected

- **LITFULO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Livtencity

Products Affected

- **LIVTENCITY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Loargys

Products Affected

- **LOARGYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Arginase 1 Deficiency (ARG1-D) -AND- Used in conjunction with dietary protein restriction -AND- Diagnosis is confirmed by 1 of the following (1-3): 1) genetic testing, 2) newborn screening, or 3) elevated arginine levels in plasma.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lonsurf

Products Affected

- **LONSURF**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer as a single agent or in combination with bevacizumab in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*

PA Criteria	Criteria Details
Exclusion Criteria	For irritable bowel syndrome (IBS): Exclude if male gender
Required Medical Information	Documentation of chronic severe diarrhea-predominant IBS -AND- trial and failure or intolerance to one anti-diarrheal (e.g. loperamide), anti-spasmodic, or tricyclic antidepressant, or contraindication to all
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lumakras

Products Affected

- **LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy -AND- using as a single agent. Documentation of metastatic colorectal cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- using in combination with panitumumab -AND- prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lybalvi

Products Affected

- **LYBALVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lynparza

Products Affected

- **LYNPARZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) in complete or partial response to first-line platinum-based chemotherapy 2) diagnosis of deleterious or suspected deleterious BRCA mutated disease or disease is associated with homologous recombination deficiency (HRD) positive status with a deleterious or suspected deleterious BRCA mutation or genomic instability and will be using in combination with bevacizumab. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) deleterious or suspected deleterious germline or somatic BRCA mutation 2) in complete or partial response to platinum-based chemotherapy. For deleterious or suspected deleterious gBRCAm, HER2-negative breast cancer, 1 of the following (1-2): 1) classified as high-risk, early breast cancer and has been treated with neoadjuvant or adjuvant chemotherapy 2) has been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting and if hormone receptor (HR)-positive, has been previously treated with or considered inappropriate for treatment with endocrine therapy. For metastatic pancreatic adenocarcinoma, all of the following (1-2): 1) a deleterious or suspected deleterious gBRCA mutation 2) did not progress on at least 16 weeks of a first-line platinum-based chemotherapy regimen. For deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation metastatic castration-resistant prostate cancer, all of the following (1-2): 1) progressed following prior treatment with enzalutamide or abiraterone 2) concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy. For deleterious or suspected deleterious BRCA mutation metastatic castration-resistant prostate cancer, using in combination with all of the following (1-2): 1) abiraterone 2) prednisone or prednisolone.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lyrica

Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When used concomitantly with an opioid agonist, attestation of intent to monitor & address concomitant drug-drug interaction adverse events is also required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lytgobi

Products Affected

- **LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-2): 1) disease harbors FGFR2 fusions or other rearrangements 2) member has experienced therapeutic failure or intolerance to at least one prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Macitentan PAH

Products Affected

- **OPSUMIT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Macitentan/Tadalafil PAH

Products Affected

- **OPSYNVI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mavyret

Products Affected

- **MAVYRET ORAL PELLETS IN PACKET**
- **MAVYRET ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mekinist

Products Affected

- **MEKINIST ORAL RECON SOLN**
- **MEKINIST ORAL TABLET 0.5 MG, 2 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For trametinib monotherapy, documentation of unresectable or metastatic melanoma -AND- meets all of the following (1-2): 1) member has a BRAF V600E or V600K mutation 2) member is BRAF inhibitor treatment naive. For use in combination with dabrafenib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with dabrafenib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation, as detected by an FDA approved test when FDA indicated. For use in combination with dabrafenib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Mekinist powder for oral solution, attestation of inability to swallow Mekinist (trametinib) tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Mektovi

Products Affected

- **MEKTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, all of the following (1-2): 1) BRAF V600E or V600K mutation status, as detected by an FDA-authorized test 2) using in combination with encorafenib. For metastatic non-small cell lung cancer, all of the following (1-2): 1) BRAF V600E mutation status, as detected by an FDA-authorized test 2) using in combination with encorafenib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Metyrosine

Products Affected

- *metyrosine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of pheochromocytoma defined by 1 of the following (1 or 2): 1) Elevated metanephrines in plasma or urine, or 2) Tumor evidence from CT scan or MRI -AND- Documentation of 1 of the following (3., 4., or 5.): 3) Planned resection surgery, 4) Resection surgery is contraindicated, or 5) malignant pheochromocytoma. -AND- therapeutic failure, contraindication, or intolerance to a selective alpha-blocker (e.g., doxazosin, prazosin, terazosin).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Miglustat2

Products Affected

- *miglustat*
- **YARGESA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Modeyso

Products Affected

- **MODEYSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of diffuse midline glioma -AND- disease harbors an H3 K27M mutation -AND- member has experienced progressive disease following prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mulpleta

Products Affected

- **MULPLETA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet -AND- Platelet count of less than 50x10*9/L
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Namzaric

Products Affected

- *memantine-donepezil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and intolerance to generic memantine and generic donepezil
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nayzilam

Products Affected

- **NAYZILAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nemluvio

Products Affected

- **NEMLUVIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prurigo nodularis -OR- Documentation of moderate to severe atopic dermatitis and one of the following (1-3): 1) trial and failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus), 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement, or 3) severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Prurigo nodularis: 6 months initial, 12 months reauth. Atopic Dermatitis: 12 months
Other Criteria	For prurigo nodularis, must follow recommended dosing guidelines based upon weight. For atopic dermatitis, must follow recommended dosing based on FDA approved dosing guidelines. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Nerlynx

Products Affected

- **NERLYNX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of early-stage, HER2-positive breast cancer -AND- meets all of the following: 1)member has received adjuvant trastuzumab-based therapy 2) member is using neratinib as a single agent. Documentation of advanced HER-2 positive, or metastatic HER2-positive breast cancer and meets all of the following 1) using neratinib in combination with capecitabine 2) member has received two or more prior anti-HER2 based regimens in the metastatic setting.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nexavar

Products Affected

- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nexletol

Products Affected

- **NEXLETOL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nexlizet

Products Affected

- **NEXLIZET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ninlaro

Products Affected

- **NINLARO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nitisinone

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hereditary tyrosinemia type 1 (HT-1) confirmed by biochemical or genetic testing -AND- dietary restriction of tyrosine and phenylalanine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Northera

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- Documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nubeqa

Products Affected

- **NUBEQA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer -AND- one of the following (1-2): 1) using in combination with a GnRH analog 2) member has had a bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nucala

Products Affected

- **NUCALA SUBCUTANEOUS AUTO-INJECTOR**
- **NUCALA SUBCUTANEOUS RECON SOLN**
- **NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nuedexta

Products Affected

- *dextromethorphan-quinidine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting improvement in symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nuplazid

Products Affected

- **NUPLAZID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hallucinations and delusions associated with Parkinson's disease psychosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nurtec

Products Affected

- **NURTEC ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nuvigil

Products Affected

- *armodafinil*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Octreotide

Products Affected

- *octreotide acetate injection solution*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Odomzo

Products Affected

- **ODOMZO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ofev

Products Affected

- *nintedanib*
- **OFEV**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ogsiveo

Products Affected

- **OGSIVEO ORAL TABLET 100 MG, 150 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressing desmoid tumor(s) requiring systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ojemda

Products Affected

- **OJEMDA ORAL SUSPENSION FOR RECONSTITUTION**
- **OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory pediatric low-grade glioma -AND- one of the following (1-2): 1) BRAF fusion or rearrangement, or 2) BRAF V600K mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ojjaara

Products Affected

- **OJJAARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of anemia.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Onureg

Products Affected

- **ONUREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Acetaminophen/Codeine

Products Affected

- *acetaminophen-codeine oral solution 120-12 mg/5 ml*
- *acetaminophen-codeine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Acetaminophen/Oxycodone

Products Affected

- *oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Buprenorphine (LA)

Products Affected

- *buprenorphine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	All the following are required (1-3): 1) pain requiring treatment is severe, requiring daily, around-the-clock, long-term opioid therapy, 2) member is not opioid naive, 3) attestations that non-opioid alternative therapies have been explored (e.g., NSAIDs), controlled substance history in the state Prescription Drug Monitoring Program (PDMP) has been reviewed, and counseling on the potential adverse effects of opioid analgesics, including the risks of misuse, abuse, and addiction, has been provided. A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Fentanyl (LA)

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	All the following are required (1-3): 1) pain requiring treatment is severe, requiring daily, around-the-clock, long-term opioid therapy, 2) member is not opioid naive, 3) attestations that non-opioid alternative therapies have been explored (e.g., NSAIDs), controlled substance history in the state Prescription Drug Monitoring Program (PDMP) has been reviewed, and counseling on the potential adverse effects of opioid analgesics, including the risks of misuse, abuse, and addiction, has been provided. A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Hydromorphone

Products Affected

- *hydromorphone oral liquid*
- *hydromorphone oral tablet 2 mg, 4 mg, 8 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Methadone (LA)

Products Affected

- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	All the following are required (1-3): 1) pain requiring treatment is severe, requiring daily, around-the-clock, long-term opioid therapy, 2) member is not opioid naive, 3) attestations that non-opioid alternative therapies have been explored (e.g., NSAIDs), controlled substance history in the state Prescription Drug Monitoring Program (PDMP) has been reviewed, and counseling on the potential adverse effects of opioid analgesics, including the risks of misuse, abuse, and addiction, has been provided. A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Morphine

Products Affected

- *morphine concentrate oral solution*
- *morphine oral solution 10 mg/5 ml (2 mg/ml), 20 mg/5 ml (4 mg/ml)*
- *morphine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Morphine (LA)

Products Affected

- *morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	All the following are required (1-3): 1) pain requiring treatment is severe, requiring daily, around-the-clock, long-term opioid therapy, 2) member is not opioid naive, 3) attestations that non-opioid alternative therapies have been explored (e.g., NSAIDs), controlled substance history in the state Prescription Drug Monitoring Program (PDMP) has been reviewed, and counseling on the potential adverse effects of opioid analgesics, including the risks of misuse, abuse, and addiction, has been provided. A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Oxycodone

Products Affected

- *oxycodone oral concentrate*
- *oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opioid Tramadol

Products Affected

- *tramadol oral tablet 50 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	A) When used concomitantly with substance abuse therapy, 1 of the following is required (1-2): 1) documentation of acute pain condition (e.g., acute traumatic injury) in which treatment with other agents would cause insufficient pain control, 2) pain requiring treatment is related to a terminal illness. In absence of substance abuse therapy, these criteria are not required. B) When used concomitantly with a benzodiazepine & centrally acting skeletal muscle relaxant (i.e., carisoprodol), all of the following are required (1-5): 1) documentation of diagnosis, 2) attestation that non-opioid therapies have been considered (e.g., NSAIDs), 3) attestation that non-benzodiazepine therapies have been considered (e.g., SSRIs, SNRIs), 4) trial/failure of 2 other skeletal muscle relaxants (e.g., methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, 5) attestation of intent to monitor & address concomitant drug-drug interaction adverse events. In absence of a benzodiazepine & centrally acting skeletal muscle relaxant, these criteria are not required. C) When used concomitantly with an opioid potentiator (e.g., gabapentinoid, sedative-hypnotic), both of the following are required (1-2): 1) documentation of diagnosis, 2) attestation of intent to monitor & address concomitant drug-drug interaction adverse events is required. In absence of an opioid potentiator, these criteria are not required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Concomitant Substance Abuse Therapy: 1 month. All other criteria: 12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opipza

Products Affected

- **OPIPZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- 1 of the following (1-2): 1) intolerance to generic aripiprazole tablets, 2) inability to swallow oral tablets. For major depressive disorder, documentation of adjunctive therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For major depressive disorder, therapeutic failure, contraindication or intolerance to Vraylar and one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). When utilized for the same medically accepted indication, trial and failure of Vraylar.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq. For psoriatic arthritis, patients 18 years of age and older must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, Skyrizi SC, Rinvoq/Rinvoq LQ. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq/Rinvoq LQ. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orgovyx

Products Affected

- **ORGOVYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orkambi

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET**
- **ORKAMBI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orserdu

Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Otezla

Products Affected

- **OTEZLA**
- **OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47)**
- **OTEZLA XR**
- **OTEZLA XR INITIATION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For plaque psoriasis, all of the following (1-2): 1) member is greater than or equal to 18 years of age with mild-to-severe disease -OR- if the member is greater than or equal to 6 years of age and less than 18 years, weight is greater than or equal to 20 kg for Otezla or 50 kg for Otelza XR, and member has moderate-to-severe disease -AND- 2) inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to one systemic therapy for prevention of recurrent oral ulcers. For psoriatic arthritis, if the member is greater than or equal to 6 years of age and less than 18 years and weight is greater than or equal to 20 kg for Otezla or 50 kg for Otelza XR.
Age Restrictions	Deny if less than 6 years of age for plaque psoriasis or psoriatic arthritis. Deny if less than 18 years of age for Behcet's Disease.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Ozempic Oral

Products Affected

- **OZEMPIC ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Panretin

Products Affected

- **PANRETIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pemazyre

Products Affected

- **PEMAZYRE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable locally advanced cholangiocarcinoma or metastatic cholangiocarcinoma -AND- all of the following (1-2): 1) disease harbors FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) member has experienced therapeutic failure or intolerance to at least on prior therapy. Documentation of relapsed or refractory myeloid/lymphoid neoplasms -AND- disease harbors an FGFR1 rearrangement.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pheburane

Products Affected

- **PHEBURANE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- intolerence to generic sodium phenylbutyrate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) HR-positive, HER2-negative tumor status, 2) PIK3CA mutation positive as detected by an FDA-approved test, 3) disease progression on or after an endocrine-based regimen, 4) Concomitant therapy with fulvestrant
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pirfenidone

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Plegridy

Products Affected

- **PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML**
- **PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pomalyst

Products Affected

- *pomalidomide*
- **POMALYST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Pomalyst, intolerance to generic pomalidomide is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Posaconazole Tablet

Products Affected

- *posaconazole oral tablet,delayed release (dr/ec)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy) -AND- weight greater than 40 kg. For invasive aspergillosis infection, trial/failure or contraindication to voriconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Adalimumab

Products Affected

- **HADLIMA**
- **HADLIMA PUSHTOUCH**
- **HADLIMA(CF)**
- **HADLIMA(CF) PUSHTOUCH**
- **SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML**
- **SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 1 immunosuppressant or corticosteroid, or all are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Uveitis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. These criteria are applicable to Hadlima with NDC starting with 78206, and Simlandi with NDC starting with 51759.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Denosumab (Onco)

Products Affected

- **BILPREVDA**
- **WYOST**
- **XTRENBO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity and 1 of the following (1-2): 1) member is 18 years old or older, or 2) member is a skeletally mature adolescent (e.g. has at least one mature long bone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Denosumab (Osteo)

Products Affected

- **BILDYOS**
- **ENOBY**
- **JUBBONTI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Ustekinumab

Products Affected

- **STEQEYMA SUBCUTANEOUS SOLUTION**
- **STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **YESINTEK SUBCUTANEOUS SOLUTION**
- **YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Prenatal Vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pretomanid

Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Criteria will be applied consistent with the current ATS/CDC/ERS/IDSA Clinical Practice Guideline for the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of disease improvement -AND- member requires additional antimicrobial therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Prevymis Oral Pellets

Products Affected

- **PREVYMIS ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 6 months of age with HSCT. Deny if less than 12 years of age with kidney transplant.
Prescriber Restrictions	
Coverage Duration	7 months
Other Criteria	One of the following is required (1-2): 1) inability to swallow tablets, 2) unable to use Prevymis (letermovir) tablets due to body weight dosing limitations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Provigil

Products Affected

- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pulmozyme

Products Affected

- **PULMOZYME**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Qinlock

Products Affected

- **QINLOCK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Qulipta

Products Affected

- **QULIPTA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ravicti

Products Affected

- *glycerol phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of a urea cycle disorders (UCDs)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Redemplo

Products Affected

- **REDEMPLO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Repatha

Products Affected

- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Retevmo

Products Affected

- **RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer -AND- disease is classified as RET gene fusion as detected by an FDA approved test. Documentation of advanced or metastatic medullary thyroid cancer -AND- disease is classified as RET mutation as detected by an FDA approved test. Documentation of advanced or metastatic thyroid cancer -AND- all of the following (1-2): 1) disease is classified as RET gene fusion as detected by an FDA approved test 2) if radioactive iodine is appropriate for the member, the member is radioactive iodine-refractory. Documentation of locally advanced or metastatic solid tumor(s) -AND- disease harbors a RET gene fusion, as detected by an FDA-approved test -AND- one of the following (1-2): 1) the member has no satisfactory alternative treatments 2) the member's tumors have progressed following prior systemic treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Revlimid

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial
Required Medical Information	Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product after previous treatment -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Revuforj

Products Affected

- **REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory acute leukemia, member has a lysine methyltransferase 2A gene (KMT2A) translocation, as determined by an FDA-authorized test. For relapsed or refractory acute myeloid leukemia, the member has a susceptible NPM1 mutation -AND- the member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rexulti

Products Affected

- **REXULTI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For major depressive disorder, therapeutic failure, contraindication or intolerance to Vraylar and one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For schizophrenia, therapeutic failure, intolerance, or contraindication to Vraylar and one other generic atypical antipsychotic (e.g. quetiapine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rezdiffra

Products Affected

- **REZDIFFRA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rezlidhia

Products Affected

- **REZLIDHIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rinvoq LQ

Products Affected

- **RINVOQ LQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or all non-biologic DMARDs are contraindicated or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	For PsA, deny if 18 years of age or older
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Riociguat PAH

Products Affected

- **ADEMPAS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rivfloza

Products Affected

- **RIVFLOZA SUBCUTANEOUS SOLUTION**
- **RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Romvimza

Products Affected

- **ROMVIMZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor -AND- attestation that surgical resection may cause one of the following (1-2): 1) worsening functional limitation, 2) severe morbidity
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**
- **ROZLYTREK ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rubraca

Products Affected

- **RUBRACA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) Disease harbors a deleterious BRCA mutation (germline or somatic) 2) member is in complete or partial response to platinum-based chemotherapy. For metastatic castration-resistant prostate cancer, all of the following (1-3): 1) disease harbors a deleterious BRCA mutation (germline and/or somatic) 2) member has been treated with androgen receptor-directed therapy 3) member is concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or member has had a bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rydapt

Products Affected

- **RYDAPT**

PA Criteria	Criteria Details
Exclusion Criteria	Use as single agent induction therapy for AML
Required Medical Information	Documentation of diagnosis. For a new diagnosis of acute myeloid leukemia, member is using in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy regimens and member is FLT3 mutation positive as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sabril

Products Affected

- *vigabatrin*
- **VIGADRONE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms
Age Restrictions	Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Samsca

Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Saphris

Products Affected

- *asenapine maleate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Scemblix

Products Affected

- **SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1-3): 1) the member is newly-diagnosed, 2) member has been previously treated for Ph+ CML in chronic phase, 3) disease is positive for the T3151 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Secuado

Products Affected

- **SECUADO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- intolerance to generic asenapine sublingual tablets -AND- trial/failure or intolerance to 1 of the following or all are contraindicated (1-3): 1) olanzapine, 2) quetiapine, 3) risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Semaglutide

Products Affected

- **OZEMPIC SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Signifor

Products Affected

- **SIGNIFOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, both of the following are required (1 and 2: 1) patient remains not a candidate for required surgery or the surgery has not been curative, and 2) attestation of decrease in urinary free cortisol levels from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sildenafil PAH

Products Affected

- *sildenafil (pulm.hypertension) oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Siliq

Products Affected

- **SILIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, and Skyrizi SC. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sirturo

Products Affected

- **SIRTURO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Criteria will be applied consistent with the current ATS/CDC/ERS/IDSA Clinical Practice Guideline for the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of disease improvement -AND- member requires additional antimicrobial therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Skyrizi

Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 55 MG/0.37 ML**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sohonos

Products Affected

- **SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	Deny if female and less than 8 years of age -OR- if male and less than 10 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in volume of new heterotopic ossification from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Somatropin

Products Affected

- **NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Somavert

Products Affected

- **SOMAVERT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sprycel

Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Stivarga

Products Affected

- **STIVARGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sutent

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For gastrointestinal stromal tumor (GIST), the member has experienced therapeutic failure, intolerance, or contraindication to imatinib. For a high risk of recurrent renal cell carcinoma, member has had a nephrectomy and sunitinib is to be used as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sympazan

Products Affected

- **SYMPAZAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Synarel

Products Affected

- **SYNAREL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For central precocious puberty (CPP), advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L. For female with endometriosis, attestation of not pregnant if of childbearing age -AND- Therapeutic failure, contraindication or intolerance to 2 of the following standard of care treatments: NSAIDs, combination hormonal contraceptive, progestin (i.e. medroxyprogesterone injection), GnRH agonist (i.e. Leuprolide) or danazol
Age Restrictions	Deny if onset of puberty after 8 years of age for females or after 9 years of age for males unless there is medical necessity for treatment of central precocious puberty. Deny if less than 18 years of age for endometriosis.
Prescriber Restrictions	
Coverage Duration	Endometriosis: 6 months, CPP: 6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization for CPP, attestation of pubertal development slowing from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tabrecta

Products Affected

- **TABRECTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tadalafil PAH

Products Affected

- *tadalafil (pulm. hypertension)*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tafinlar

Products Affected

- **TAFINLAR ORAL CAPSULE**
- **TAFINLAR ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For dabrafenib monotherapy, documentation of unresectable or metastatic melanoma -AND- documentation of a BRAF V600E mutation. For use in combination with trametinib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with trametinib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation, as detected by an FDA-approved test when FDA indicated. For use in combination with trametinib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar (dabrafenib) capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Tagrisso

Products Affected

- **TAGRISSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) and one of the following (1-5): 1) Adjuvant therapy after tumor resection -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test 2) Locally advanced disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used in combination with pemetrexed and platinum-based chemotherapy, 3) Metastatic disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used with or without combination therapy of pemetrexed and platinum-based chemotherapy, 4) Metastatic disease -AND- disease harbors EGFR T790M mutations, as detected by an FDA-approved test -AND- has progressed on or after EGFR TKI therapy, 5) Locally advanced, unresectable (stage III) disease -AND- disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy -AND- disease harbors EGFR exon 19 deletions or EGFR exon 21 L858R mutations, as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Talzenna

Products Affected

- **TALZENNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent - OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tarceva

Products Affected

- *erlotinib*

PA Criteria	Criteria Details
Exclusion Criteria	Use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy.
Required Medical Information	Documentation of metastatic non-small cell lung cancer (NSCLC) -AND- one of the following, as detected by an FDA-approved test (1-2): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutations -OR- documentation of locally advanced, unresectable or metastatic pancreatic cancer -AND- all of the following (1-2): 1) using erlotinib as first-line therapy 2) using in combination with gemcitabine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Targretin

Products Affected

- *bexarotene oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Targretin Gel

Products Affected

- *bexarotene topical*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions associated with one (1) of the following stages of cutaneous T-cell lymphoma (CTCL) (1. or 2.): 1) Stage IA or 2) Stage IB - AND- the member has experience therapeutic failure, contraindication, or intolerance to at least one other therapy for CTCL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tarpeyo

Products Affected

- **TARPEYO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tascenso ODT

Products Affected

- **TASCENSO ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Inability to swallow capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tasigna

Products Affected

- *nilotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For adult patients with Ph+ chronic myeloid leukemia (CML), member's CML is in the chronic or accelerated phase and the member is no longer responding to or is intolerant to imatinib -OR- member is newly diagnosed in the chronic phase. For pediatric patients, one of the following (1-2): 1) member has chronic phase or accelerated phase Ph+ CML and is is resistant or intolerant to prior tyrosine kinase inhibitor therapy 2) member is newly diagnosed with Ph+ CML in the chronic phase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tasimelteon

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tazorac

Products Affected

- *tazarotene topical cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tecfidera

Products Affected

- *dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tepmetko

Products Affected

- **TEPMETKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Testosterone

Products Affected

- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tezspire

Products Affected

- **TEZSPIRE SUBCUTANEOUS PEN INJECTOR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Thalomid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis
Required Medical Information	Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Thrombopoiesis Stimulating Agents

Products Affected

- *eltrombopag olamine oral powder in packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tibsovo

Products Affected

- **TIBSOVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is IDH1 mutation positive as detected by an FDA-approved test. For newly-diagnosed acute myeloid leukemia, member is using as monotherapy or in combination with azacitidine -AND- member meets one of the following (1-5): 1) age is greater than or equal to 75 years of age 2) severe cardiac or pulmonary comorbidity 3) reduced renal function 4) hepatic impairment 5) or prescriber attestation that member is not a candidate for intensive induction therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tirzepatide

Products Affected

- **MOUNJARO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tocilizumab

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tofacitinib

Products Affected

- *tofacitinib oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For immediate release formulation for polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
Age Restrictions	Deny if less than 18 years of age for rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis. Deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis and psoriatic arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. For rheumatoid arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq/Rinvoq LQ. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, Skyrizi SC, Rinvoq/Rinvoq LQ. For ulcerative colitis (UC), patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257. Doses greater than 10 mg per day will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day will not be approved for ulcerative colitis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tofacitinib ER

Products Affected

- *tofacitinib oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. For rheumatoid arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, Skyrizi SC, Rinvoq/Rinvoq LQ. For ulcerative colitis (UC), patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257. Doses greater than 11 mg per day will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 22mg per day will not be approved for ulcerative colitis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tofacitinib Solution

Products Affected

- *tofacitinib oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Documentation of polyarticular juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis and psoriatic arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to a preferred adalimumab product, and Rinvoq/Rinvoq LQ. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, Skyrizi SC, Rinvoq/Rinvoq LQ. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Topical Lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Topical Lidocaine-Prilocaine

Products Affected

- *lidocaine-prilocaine topical cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tretinoin Acne

Products Affected

- *tretinoin topical cream*
- *tretinoin topical gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two generic topical non-retinoid acne medications (e.g., clindamycin-benzoyl peroxide)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Trikafta

Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Trintellix

Products Affected

- **TRINTELLIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Truqap

Products Affected

- **TRUQAP**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tukysa

Products Affected

- **TUKYSA ORAL TABLET 150 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer, member will be using in combination with trastuzumab and capecitabine -AND- member has received one or more prior anti-HER2 based regimens in the metastatic setting. For RAS wild-type HER2-positive unresectable or metastatic colorectal cancer, member will be using in combination with trastuzumab -AND- member has experienced disease progression following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Turalio

Products Affected

- **TURALIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tykerb

Products Affected

- *lapatinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced HER2-positive, or metastatic HER2-positive breast cancer, the member has received prior therapy with an anthracycline, a taxane, and trastuzumab -AND- will be using in combination with capecitabine. For HR+, metastatic breast cancer, the member is post-menopausal -AND- the member's cancer over expresses the HER2 receptor -AND- the member will be using lapatinib in combination with letrozole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tymlos

Products Affected

- **TYMLOS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Uptravi

Products Affected

- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG PACK**
- **UPTRAVI ORAL TABLETS,DOSE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Valchlor

Products Affected

- **VALCHLOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received at least one prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Valtoco

Products Affected

- **VALTOCO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vanflyta

Products Affected

- **VANFLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is FLT3-ITD-positive as detected by an FDA-approved test -AND- one of the following (1-3): 1) member is receiving induction therapy and is using Vanflyta in combination with standard cytarabine and anthracycline induction therapy 2) member is receiving consolidation therapy and is using Vanflyta in combination with standard cytarabine consolidation therapy 3) member is receiving maintenance therapy and is using Vanflyta as monotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Venclexta

Products Affected

- **VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG**
- **VENCLEXTA STARTING PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For newly-diagnosed AML, member is using in combination with azacitidine, decitabine, or cytarabine -AND- age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Verquvo

Products Affected

- **VERQUVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Verzenio

Products Affected

- **VERZENIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative. For early breast cancer that is at high risk of recurrence and is node-positive, all of the following (1-2): 1) used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) 2) used as adjuvant treatment. For advanced or metastatic breast cancer, used as initial endocrine-based therapy and used in combination with an aromatase inhibitor -OR- used after documented disease progression following endocrine therapy and used in combination with fulvestrant -OR- used after documented disease progression and used following endocrine therapy and prior chemotherapy in the metastatic setting and will be used as monotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Viibryd

Products Affected

- *vilazodone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vitrakvi

Products Affected

- **VITRAKVI ORAL CAPSULE 100 MG, 25 MG**
- **VITRAKVI ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity -AND- There are no satisfactory alternative treatments or tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vivjoa

Products Affected

- **VIVJOA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy) -AND- the member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vonjo

Products Affected

- **VONJO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voranigo

Products Affected

- **VORANIGO ORAL TABLET 10 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-3): 1) grade 2 astrocytoma or grade 2 oligodendroglioma, 2) disease harbors a susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation, as detected by an FDA-approved test, 3) will be used following surgery including biopsy, sub-total resection, or gross total resection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voriconazole

Products Affected

- *voriconazole intravenous recon soln*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vosevi

Products Affected

- **VOSEVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Votrient

Products Affected

- *pazopanib oral tablet 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor
Required Medical Information	Documentation of diagnosis. For advanced soft-tissue sarcoma, trial/failure of at least one prior chemotherapy regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vraylar

Products Affected

- **VRAYLAR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For a diagnosis of schizophrenia and bipolar I disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vtama

Products Affected

- **VTAMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-2): 1) Documentation of plaque psoriasis -AND- 2) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol) -OR- the member has psoriasis on the face -OR- Documentation of all of the following (3-4): 3) Atopic dermatitis, 4) trial and failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vumerity

Products Affected

- **VUMERITY**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	Therapeutic failure or intolerance to generic dimethyl fumarate is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Wegovy

Products Affected

- **WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Wegovy Oral

Products Affected

- **WEGOVY ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Welireg

Products Affected

- **WELIREG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Winrevair

Products Affected

- **WINREVAIR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xalkori

Products Affected

- **XALKORI ORAL CAPSULE**
- **XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer (NSCLC), disease is ALK-positive as detected by an FDA-approved test or ROS1-positive as detected by an FDA-approved test. For relapsed or refractory anaplastic large cell lymphoma (ALCL), disease is ALK-positive. For unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT), disease is ALK-positive.
Age Restrictions	Deny if less than 1 year of age or greater than 21 years of age for ALCL.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For crizotinib oral pellets and NSCLC, inability to swallow capsules is required. For crizotinib oral pellets and ALCL / IMT, inability to swallow oral capsules -OR- body surface area less than 1.34 m2 is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xcopri

Products Affected

- **XCOPRI**
- **XCOPRI MAINTENANCE PACK**
- **XCOPRI TITRATION PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xdemvy

Products Affected

- **XDEMVY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary is not actively suicidal
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	In patients with comorbid depression, attestation of adequate treatment for depression is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xermelo

Products Affected

- **XERMELO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xifaxan

Products Affected

- **XIFAXAN ORAL TABLET 550 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolair

Products Affected

- **XOLAIR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolremdi

Products Affected

- **XOLREMDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in incidence of infections is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xospata

Products Affected

- **XOSPATA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member is FLT3 mutation-positive.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For castration-resistant prostate cancer and metastatic castration sensitive-prostate cancer, the member is using in combination with a GnRH analog or the member has had a bilateral orchiectomy. For non-metastatic castration-sensitive prostate cancer, the member has biochemical recurrence at high risk for metastasis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xyrem

Products Affected

- *sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Yonsa

Products Affected

- **YONSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with methylprednisolone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Yorvipath

Products Affected

- **YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of hypoparathyroidism -AND- albumin-corrected serum calcium greater than or equal to 7.8 mg/dL -AND- trial and failure of an active form of vitamin D (e.g. calcitriol, alfacalcidol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of normalization or improvement in total serum calcium from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zejula

Products Affected

- **ZEJULA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, member is in complete or partial response to first-line platinum-based therapy -AND- disease is associated with homologous recombination deficiency-positive status, defined by at least one of the following (1 or 2): 1) a deleterious or suspected deleterious BRCA mutation or 2) genomic instability. For recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, all of the following (1-2): 1) disease harbors a deleterious or suspected deleterious germline BRCA mutation 2) member is in a complete or partial response to platinum-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zelboraf

Products Affected

- **ZELBORAF**

PA Criteria	Criteria Details
Exclusion Criteria	Wild-type BRAF melanoma
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, member has a BRAF V600E mutation. For Erdheim-Chester Disease, member has a BRAF V600 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zelsuvmi

Products Affected

- **ZELSUVMI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of molluscum contagiosum
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	For reauthorization, attestation that the member has previously experienced complete or partial clearance of molluscum contagiosum lesions with Zelsuvmi -AND- additional course of therapy is required for recurrence of molluscum contagiosum
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zenbexus

Products Affected

- **ZENBEXUS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zeposia

Products Affected

- **ZEPOSIA**
- **ZEPOSIA STARTER KIT (28-DAY)**
- **ZEPOSIA STARTER PACK (7-DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying multiple sclerosis agents
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Ulcerative Colitis: Plan Year, Multiple Sclerosis: 24 months
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zokinvy

Products Affected

- **ZOKINVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- BSA of at least 0.39 m*2. For Hutchinson-Gilford Progeria Syndrome (HGPS), a mutation in the LMNA gene is required. For Processing-Deficient Progeroid Lamionpathy (PL), 1 of the following is required (1-3): 1) heterozygous LMNA mutation and progerin-like protein accumulation, 2) homozygous ZMPSTE24 mutations, or 3) compound heterozygous ZMPSTE24 mutations.
Age Restrictions	Deny if less than 12 months of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zolinza

Products Affected

- **ZOLINZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zonisade

Products Affected

- **ZONISADE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-6): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic gabapentin capsules/solution, 3) generic lacosamide solution, 4) generic levetiracetam solution, 5) generic oxcarbazepine suspension, 6) generic pregabalin capsules/solution.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ztalmy

Products Affected

- **ZTALMY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures associated with CDKL5 deficiency confirmed by genetic testing.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zurzuvae

Products Affected

- **ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of postpartum depression -AND- attestation of symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery -AND- less than or equal to 12 months postpartum.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	30 days
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zykadia

Products Affected

- **ZYKADIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zymfentra

Products Affected

- **ZYMFENTRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation of receiving or currently undergoing at least 3 doses of IV infliximab within 10 weeks of initiating therapy with Zymfentra.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq. For moderate to severe active Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206 and Simlandi with NDC starting with 51759. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ABIRTEGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with prednisone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For generic abiraterone (other than Abirtega), intolerance to Abirtega is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Index of Drugs

abiraterone oral tablet 250 mg, 500 mg 390
ABIRTEGA 390
acetaminophen-codeine oral solution 120-12 mg/5 ml 215
acetaminophen-codeine oral tablet 215
acitretin 1
ACTEMRA ACTPEN 324
ACTEMRA SUBCUTANEOUS 324
ACTIMMUNE 2
ADEMPAS 276
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML 5
AKEEGA 6
ALCOHOL PADS 134
ALECENSA 7
alosetron oral tablet 0.5 mg, 1 mg 172
alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg 37
ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG 9
ALUNBRIG ORAL TABLETS,DOSE PACK 9
ambrisentan 10
amitriptyline 12
ANZUPGO 23
ARIKAYCE 24
aripiprazole oral solution 25
aripiprazole oral tablet,disintegrating 25
armodafinil 206
asenapine maleate 284
AUGTYRO ORAL CAPSULE 160 MG, 40 MG 27
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 28
AUSTEDO XR 28
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG 28
AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 29
AVMAPKI-FAKZYNJA 30
AVONEX INTRAMUSCULAR PEN INJECTOR KIT 31
AVONEX INTRAMUSCULAR SYRINGE KIT 31
AYVAKIT 32
BAFIERTAM 33
BALVERSA 34
BENLYSTA SUBCUTANEOUS 36
benztropine oral 13
BESREMI 42
BESREMI PEN 42
BETASERON SUBCUTANEOUS KIT 43
bexarotene oral 309
bexarotene topical 310
BILDYOS 255
BILPREVDA 254
BOSULIF ORAL CAPSULE 100 MG, 50 MG 44
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG 44
bosutinib oral tablet 400 mg 45
BRAFTOVI 46
BRINSUPRI 48
BRUKINSA ORAL TABLET 49
buprenorphine 219
CABOMETYX 51
CALQUENCE (ACALABRUTINIB MAL) 52
CAPLYTA 53
CAPRELSA ORAL TABLET 100 MG, 300 MG 54
carglumic acid 55
CAYSTON 56
CINRYZE 59
clobazam oral suspension 213
clobazam oral tablet 213
clomipramine 14
clonazepam oral tablet 0.5 mg, 1 mg, 2 mg 38
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg 38
clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg 39
COBENFY 60
COBENFY STARTER PACK 60

COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) 61
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 111
COPIKTRA 62
COSENTYX (2 SYRINGES) 64
COSENTYX PEN (2 PENS) 64
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML 64
COSENTYX UNOREADY PEN 64
COTELLIC 66
cyclobenzaprine oral tablet 10 mg, 5 mg 15
cyproheptadine oral tablet 16
CYSTARAN 67
dalfampridine 11
DANZITEN 68
dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg 296
DAURISMO ORAL TABLET 100 MG, 25 MG 70
deferasirox oral tablet, dispersible 71
dextromethorphan-quinidine 203
DIACOMIT ORAL CAPSULE 250 MG, 500 MG 73
DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG 73
DIAZEPAM INTENSOL 40
diazepam oral solution 5 mg/5 ml (1 mg/ml) 40
diazepam oral tablet 40
dihydroergotamine nasal 74
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg 316
doxepin oral capsule 17
doxepin oral concentrate 17
doxepin oral tablet 17
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG 75
droxidopa oral capsule 100 mg, 200 mg, 300 mg 200
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML 77
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML 77
DUVYZAT 78
eltrombopag olamine oral powder in packet 12.5 mg, 25 mg 321
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg 321
EMGALITY PEN 79
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) 79
ENBREL MINI 92
ENBREL SUBCUTANEOUS SOLUTION 92
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) 92
ENBREL SURECLICK 92
ENOBY 255
ENSACOVE 80
ENTRESTO SPRINKLE 81
ENTYVIO PEN 82
EOHILIA 84
EPIDIOLEX 86
ergotamine-caffeine 88
ERIVEDGE 89
ERLEADA ORAL TABLET 240 MG, 60 MG 90
erlotinib 308
escitalopram oxalate oral capsule 91
everolimus (antineoplastic) oral tablet 3
everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg 3
EXXUA ORAL TABLET EXTENDED RELEASE 24 HR 94
EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK 94
FANAPT 95
FANAPT TITRATION PACK A 95
FANAPT TITRATION PACK B 95
FANAPT TITRATION PACK C 95
FASENRA PEN 96

FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML 96
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr 221
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) 98
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG 98
FILSPARI ORAL TABLET 200 MG, 400 MG 99
FILSUVEZ 100
fingolimod 109
FINTEPLA 101
FIRMAGON KIT W DILUENT SYRINGE 103
FOTIVDA 105
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG 106
GAMMAGARD LIQUID 128
GAMMAGARD LIQUID ERC 128
GAMMAGARD S-D (IGA < 1 MCG/ML) 128
GATTEX 30-VIAL 107
GAUZE PAD TOPICAL BANDAGE 2 X 2 " 134
GAVRETO 108
gefitinib 136
GILOTRIF 110
glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml 111
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 111
glycerol phenylbutyrate 264
GOMEKLI ORAL CAPSULE 1 MG, 2 MG 115
GOMEKLI ORAL TABLET FOR SUSPENSION 115
guanfacine oral tablet extended release 24 hr 116
HADLIMA 252
HADLIMA PUSHTOUCH 252
HADLIMA(CF) 252
HADLIMA(CF) PUSHTOUCH 252
HEPCLUDEX 117
HERNEXEOS 118
hydromorphone oral liquid 223
hydromorphone oral tablet 2 mg, 4 mg, 8 mg 223
hydroxyzine hcl oral tablet 18
HYRNUO 120
IBRANCE ORAL CAPSULE 125 MG 121
IBRANCE ORAL TABLET 121
IBTROZI 122
icatibant 102
ICLUSIG 123
IDHIFA 124
imatinib oral tablet 100 mg, 400 mg 112
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG 125
IMBRUVICA ORAL SUSPENSION 125
IMBRUVICA ORAL TABLET 125
imipramine hcl 19
IMKELDI 126
INCRELEX 129
INLURIYO 130
INLYTA 131
INQOVI 132
INREBIC 133
ITOVEBI ORAL TABLET 3 MG, 9 MG 137
itraconazole oral capsule 138
ivabradine oral tablet 5 mg, 7.5 mg 63
ivermectin oral 139
IWILFIN 140
JAKAFI 141
JASCAYD 142
JAVYGTOR 156
JAYPIRCA ORAL TABLET 100 MG, 50 MG 143
JIDEYTRO ORAL TABLET 100 MG, 25 MG 144
JOENJA ORAL TABLET 70 MG 145
JUBBONTI 255
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG 147
KALYDECO ORAL TABLET 147
KERENDIA 148
KESIMPTA PEN 149

KINERET.....150
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3).....151
KOMZIFTI.....152
KOSELUGO ORAL CAPSULE 10 MG, 25 MG.....154
KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG, 7.5 MG.....154
KRAZATI.....155
KYGEVVI.....157
lapatinib.....339
LAZCLUZE ORAL TABLET 240 MG, 80 MG.....159
lenalidomide.....269
LENVIMA.....160
LEQEMBI IQLIK SUBCUTANEOUS AUTO-INJECTOR 360 MG/1.8 ML.....162
LEUKINE INJECTION RECON SOLN.....163
lidocaine hcl mucous membrane solution 4 % (40 mg/ml).....331
lidocaine topical adhesive patch,medicated 5 %.....164
lidocaine topical ointment.....331
lidocaine-prilocaine topical cream.....332
LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9), 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9).....165
liraglutide.....166
LITFULO.....167
LIVTENCITY.....168
LOARGYS.....169
lomustine.....114
LONSURF.....170
LORAZEPAM INTENSOL.....41
lorazepam oral tablet 0.5 mg, 1 mg, 2 mg.....41
LORBRENA ORAL TABLET 100 MG, 25 MG.....171
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....173
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg.....158
LYBALVI.....174
LYNPARZA.....175
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5).....178
MAVYRET ORAL PELLETS IN PACKET.....181
MAVYRET ORAL TABLET.....181
megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml).....182
megestrol oral tablet.....182
MEKINIST ORAL RECON SOLN.....183
MEKINIST ORAL TABLET 0.5 MG, 2 MG.....183
MEKTOVI.....185
memantine-donepezil.....190
methadone oral solution 10 mg/5 ml, 5 mg/5 ml.....225
methadone oral tablet 10 mg, 5 mg.....225
metyrosine.....186
mifepristone oral tablet 300 mg.....153
miglustat.....187
modafinil.....260
MODEYSO.....188
morphine concentrate oral solution.....227
morphine oral solution 10 mg/5 ml (2 mg/ml), 20 mg/5 ml (4 mg/ml).....227
morphine oral tablet.....227
morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg.....229
MOUNJARO.....323
MULPLETA.....189
NAYZILAM.....191
NEMLUVIO.....192
NERLYNX.....194
NEXLETOL.....196
NEXLIZET.....197
nilotinib hcl.....313
NINLARO.....198
nintedanib.....209
nitisinone.....199

NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) 294
nortriptyline 20
NUBEQA 201
NUCALA SUBCUTANEOUS AUTO-INJECTOR 202
NUCALA SUBCUTANEOUS RECON SOLN 202
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML 202
NUPLAZID 204
NURTEC ODT 205
octreotide acetate injection solution 207
ODOMZO 208
OFEV 209
OGSIVEO ORAL TABLET 100 MG, 150 MG 210
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 211
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) 211
OJJAARA 212
ONUREG 214
OPIPZA 235
OPSUMIT 179
OPSYNVI 180
ORENCIA CLICKJECT 236
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML 236
ORGOVYX 238
ORKAMBI ORAL GRANULES IN PACKET 239
ORKAMBI ORAL TABLET 239
ORSERDU ORAL TABLET 345 MG, 86 MG 240
OTEZLA 241
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) 241
OTEZLA XR 241
OTEZLA XR INITIATION 241
oxycodone oral concentrate 231
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg 231
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg 217
OZEMPIC ORAL 243
OZEMPIC SUBCUTANEOUS 287
PANRETIN 244
paroxetine hcl oral suspension 21
paroxetine hcl oral tablet 21
pazopanib oral tablet 200 mg 355
PEGASYS 135
PEMAZYRE 245
PHEBURANE 246
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) 247
pirfenidone oral capsule 248
pirfenidone oral tablet 248
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML 249
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML 249
pomalidomide 250
POMALYST 250
posaconazole oral tablet,delayed release (dr/ec) 251
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg 177
pregabalin oral solution 177
PRENATAL VITAMIN PLUS LOW IRON 257
pretomanid 258
PREVYMIS ORAL PELLETS IN PACKET 259
PRIVIGEN 128
PROLASTIN-C INTRAVENOUS SOLUTION 8
promethazine oral tablet 22
PULMOZYME 261
pyrimethamine 69

QINLOCK 262
QULIPTA 263
REDEMPLO 265
REPATHA SURECLICK 266
REPATHA SYRINGE 266
RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 267
REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG 270
REXULTI ORAL TABLET 271
REZDIFFRA 272
REZLIDHIA 273
RINVOQ LQ 275
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG 274
RIVFLOZA SUBCUTANEOUS SOLUTION 277
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML 277
ROMVIMZA 278
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG 279
ROZLYTREK ORAL PELLETS IN PACKET 279
RUBRACA 280
rufinamide 35
RYDAPT 281
SAJAZIR 102
sapropterin 156
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG 285
SECUADO 286
SIGNIFOR 288
sildenafil (pulm.hypertension) oral tablet 289
SILIQ 290
SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML 252
SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML 252
SIRTURO 291
SKYRIZI SUBCUTANEOUS PEN INJECTOR 292
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 55 MG/0.37 ML 292
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) 292
sodium oxybate 374
sodium phenylbutyrate 50
sofosbuvir-velpatasvir 85
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 5 MG 293
SOMAVERT 295
sorafenib 195
STEQEYMA SUBCUTANEOUS SOLUTION 256
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML 256
STIVARGA 297
sunitinib malate 298
SYMPAZAN 299
SYNAREL 300
TABRECTA 301
tadalafil (pulm. hypertension) 302
tadalafil oral tablet 2.5 mg, 5 mg 58
TAFINLAR ORAL CAPSULE 303
TAFINLAR ORAL TABLET FOR SUSPENSION 303
TAGRISSO 305
TALZENNA 307
TARPEYO 311
TASCENSO ODT 312
tasimelteon 314
tazarotene topical cream 315
TEPMETKO 317
teriflunomide 26
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml) 104
testosterone cypionate 318
testosterone enanthate 318
testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %) 318
tetrabenazine oral tablet 12.5 mg, 25 mg 366
TEZSPIRE SUBCUTANEOUS PEN INJECTOR 319

THALOMID ORAL CAPSULE 100 MG, 50 MG 320
TIBSOVO 322
TOBI PODHALER 57
tobramycin in 0.225 % nacl 57
tobramycin inhalation 57
tofacitinib oral solution 329
tofacitinib oral tablet 325
tofacitinib oral tablet extended release 24 hr 327
tolvaptan 283
tolvaptan (polycys kidney dis) oral tablet 146
tolvaptan (polycys kidney dis) oral tablets, sequential 146
topiramate oral solution 87
tramadol oral tablet 50 mg 233
tretinoin topical cream 333
tretinoin topical gel 0.01 %, 0.025 % 333
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 334
TRIKAFTA ORAL TABLETS, SEQUENTIAL 334
TRINTELLIX 335
TRULICITY 76
TRUQAP 336
TUKYSA ORAL TABLET 150 MG, 50 MG 337
TURALIO 338
TYMLOS 340
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG 341
UPTRAVI ORAL TABLETS,DOSE PACK 341
VALCHLOR 342
VALTOCO 343
VANFLYTA 344
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG 345
VENCLEXTA STARTING PACK 345
VERQUVO 346
VERZENIO 347
vigabatrin 282
VIGADRONE 282
vilazodone 348
VITRAKVI ORAL CAPSULE 100 MG, 25 MG 349
VITRAKVI ORAL SOLUTION 349
VIVJOA 350
VONJO 351
VORANIGO ORAL TABLET 10 MG, 40 MG 352
voriconazole intravenous recon soln 353
VOSEVI 354
VOWST 97
VRAYLAR 356
VTAMA 357
VUMERITY 358
WEGOVY ORAL 360
WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML 359
WELIREG 361
WINREVAIR 362
WYOST 254
XALKORI ORAL CAPSULE 363
XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG 363
XCOPRI 364
XCOPRI MAINTENANCE PACK 364
XCOPRI TITRATION PACK 364
XDEMVY 365
XERMELO 367
XIFAXAN ORAL TABLET 550 MG 368
XOLAIR 369
XOLREMDI 370
XOSPATA 371
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK) 372
XTANDI ORAL CAPSULE 373
XTANDI ORAL TABLET 40 MG, 80 MG 373
XTRENBO 254

YARGESA.....187
YESINTEK SUBCUTANEOUS SOLUTION.....256
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML..256
YONSA.....375
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML.....376
YULITHIRA.....3
ZEJULA.....377
ZELBORAF.....378
ZELSUVMI.....379
ZELVYSIA.....156
ZENBEXUS.....380
ZEPOSIA.....381
ZEPOSIA STARTER KIT (28-DAY).....381
ZEPOSIA STARTER PACK (7-DAY)...381
ZOKINVY.....382
ZOLINZA.....383
zolpidem oral tablet.....119
ZONISADE.....384
ZTALMY.....385
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....386
ZYKADIA.....387
ZYMFENTRA.....388

Sección: Terapia por pasos

DPP4 Agents

Products Affected

- **JANUMET 50 MG-1,000 MG TABLET**
- **JANUMET 50 MG-500 MG TABLET**
- **JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE**
- **JANUVIA 100 MG TABLET**
- **JANUVIA 25 MG TABLET**
- **JANUVIA 50 MG TABLET**
- **JENTADUETO 2.5 MG-1,000 MG TABLET**
- **JENTADUETO 2.5 MG-500 MG TABLET**
- **JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE**
- **JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE**
- **TRADJENTA 5 MG TABLET**

Details

Criteria	Require a 1 month trial of saxagliptin, saxagliptin-metformin ER, sitagliptin, sitagliptin-metformin, or sitagliptin-metformin ER in the last 90 days.

Herpetic Keratitis

Products Affected

- **ZIRGAN 0.15 % EYE GEL**

Details

Criteria	Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days when utilized for the same medically accepted indication and age

Pulmonary Antiinflammatory

Products Affected

- *fluticasone propionate 100 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 250 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 50 mcg/actuation blister powder for inhalation*

Details

Criteria	Require a 1 month trial of Qvar and Asmanex/Asmanex HFA (Step 1 drugs) in the last 180 days

Rho Kinase Inhibitors

Products Affected

- **RHOPRESSA 0.02 % EYE DROPS DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE**

Details

Criteria	Require a 1 month trial of one preferred glaucoma drug (Step 1 drug) in the last 120 days

Rytary

Products Affected

- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

Details

Criteria	Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days

SGLT2 Agents

Products Affected

- **FARXIGA 10 MG TABLET**
- **FARXIGA 5 MG TABLET**
- **JARDIANCE 10 MG TABLET**
- **JARDIANCE 25 MG TABLET**

Details

Criteria	Pending CMS Review

Index of Drugs

FARXIGA 10 MG TABLET 6
FARXIGA 5 MG TABLET 6
fluticasone propionate 100 mcg/actuation blister powder for inhalation 3
fluticasone propionate 110 mcg/actuation hfa aerosol inhaler 3
fluticasone propionate 220 mcg/actuation hfa aerosol inhaler 3
fluticasone propionate 250 mcg/actuation blister powder for inhalation 3
fluticasone propionate 44 mcg/actuation hfa aerosol inhaler 3
fluticasone propionate 50 mcg/actuation blister powder for inhalation 3
JANUMET 50 MG-1,000 MG TABLET 1
JANUMET 50 MG-500 MG TABLET 1
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE 1
JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE 1
JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE 1
JANUVIA 100 MG TABLET 1
JANUVIA 25 MG TABLET 1
JANUVIA 50 MG TABLET 1
JARDIANCE 10 MG TABLET 6
JARDIANCE 25 MG TABLET 6
JENTADUETO 2.5 MG-1,000 MG TABLET 1
JENTADUETO 2.5 MG-500 MG TABLET 1
JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE 1
JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE 1
RHOPRESSA 0.02 % EYE DROPS 4
ROCKLATAN 0.02 %-0.005 % EYE DROPS 4
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE 5
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE 5
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE 5
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE 5
TRADJENTA 5 MG TABLET 1
ZIRGAN 0.15 % EYE GEL 2